
<html lang="en"     class="pb-page"  data-request-id="7ea135f7-e6c9-42cc-baf1-7b085aca87a0"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2015.58.issue-4;article:article:10.1021/jm501921k"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Highly Potent, Selective, and Efficacious Small Molecule Inhibitors of ERK1/2" /></meta><meta name="dc.Creator" content="Li  Ren" /></meta><meta name="dc.Creator" content="Jonas  Grina" /></meta><meta name="dc.Creator" content="David  Moreno" /></meta><meta name="dc.Creator" content="James F.  Blake" /></meta><meta name="dc.Creator" content="John J.  Gaudino" /></meta><meta name="dc.Creator" content="Rustam  Garrey" /></meta><meta name="dc.Creator" content="Andrew T.  Metcalf" /></meta><meta name="dc.Creator" content="Michael  Burkard" /></meta><meta name="dc.Creator" content="Matthew  Martinson" /></meta><meta name="dc.Creator" content="Kevin  Rasor" /></meta><meta name="dc.Creator" content="Huifen  Chen" /></meta><meta name="dc.Creator" content="Brian  Dean" /></meta><meta name="dc.Creator" content="Stephen E.  Gould" /></meta><meta name="dc.Creator" content="Patricia  Pacheco" /></meta><meta name="dc.Creator" content="Sheerin  Shahidi-Latham" /></meta><meta name="dc.Creator" content="Jianping  Yin" /></meta><meta name="dc.Creator" content="Kristina  West" /></meta><meta name="dc.Creator" content="Weiru  Wang" /></meta><meta name="dc.Creator" content="John G.  Moffat" /></meta><meta name="dc.Creator" content="Jacob B.  Schwarz" /></meta><meta name="dc.Description" content="Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of (S)-14k, a potent, selective, and orally bioavailable agent that ..." /></meta><meta name="Description" content="Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of (S)-14k, a potent, selective, and orally bioavailable agent that ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 11, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm501921k" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm501921k" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm501921k" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm501921k" /></link>
        
    
    

<title>Discovery of Highly Potent, Selective, and Efficacious Small Molecule Inhibitors of ERK1/2 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm501921k" /></meta><meta property="og:title" content="Discovery of Highly Potent, Selective, and Efficacious Small Molecule Inhibitors of ERK1/2" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0019.jpeg" /></meta><meta property="og:description" content="Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of (S)-14k, a potent, selective, and orally bioavailable agent that inhibited tumor growth in mouse xenograft models. On the basis of its in vivo efficacy and preliminary safety profiles, (S)-14k was selected for further preclinical evaluation." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm501921k"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm501921k">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm501921k&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm501921k&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm501921k&amp;href=/doi/10.1021/jm501921k" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1976-1991</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm501900s" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm5019274" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Highly Potent, Selective, and Efficacious Small Molecule Inhibitors of ERK1/2</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li++Ren">Li Ren</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jonas++Grina">Jonas Grina</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Moreno">David Moreno</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+F.++Blake">James F. Blake</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+J.++Gaudino">John J. Gaudino</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rustam++Garrey">Rustam Garrey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+T.++Metcalf">Andrew T. Metcalf</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Burkard">Michael Burkard</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Martinson">Matthew Martinson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Rasor">Kevin Rasor</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Huifen++Chen">Huifen Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian++Dean">Brian Dean</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+E.++Gould">Stephen E. Gould</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patricia++Pacheco">Patricia Pacheco</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sheerin++Shahidi-Latham">Sheerin Shahidi-Latham</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jianping++Yin">Jianping Yin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kristina++West">Kristina West</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Weiru++Wang">Weiru Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+G.++Moffat">John G. Moffat</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jacob+B.++Schwarz">Jacob B. Schwarz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States</span></div><div class="corresp-info"><strong>*</strong> Phone: 1-303-386-1448. Email: <a href="/cdn-cgi/l/email-protection#b2dedb9cc0d7dcf2d3c0c0d3cbd0dbddc2dad3c0dfd39cd1dddf"><span class="__cf_email__" data-cfemail="2f4346015d4a416f4e5d5d4e564d46405f474e5d424e014c4042">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm501921k&amp;href=/doi/10.1021%2Fjm501921k" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1976–1991</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 20, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 December 2014</li><li><span class="item_label"><b>Published</b> online</span>11 February 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 February 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm501921k" title="DOI URL">https://doi.org/10.1021/jm501921k</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1976%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLi%2BRen%252C%2BJonas%2BGrina%252C%2BDavid%2BMoreno%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D4%26contentID%3Djm501921k%26title%3DDiscovery%2Bof%2BHighly%2BPotent%252C%2BSelective%252C%2Band%2BEfficacious%2BSmall%2BMolecule%2BInhibitors%2Bof%2BERK1%252F2%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1991%26publicationDate%3DFebruary%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm501921k"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2650</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">23</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm501921k" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Highly Potent, Selective, and Efficacious Small Molecule Inhibitors of ERK1/2&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Jonas&quot;,&quot;last_name&quot;:&quot;Grina&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Moreno&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;F. Blake&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;J. Gaudino&quot;},{&quot;first_name&quot;:&quot;Rustam&quot;,&quot;last_name&quot;:&quot;Garrey&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;T. Metcalf&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Burkard&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Martinson&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Rasor&quot;},{&quot;first_name&quot;:&quot;Huifen&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;Dean&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;E. Gould&quot;},{&quot;first_name&quot;:&quot;Patricia&quot;,&quot;last_name&quot;:&quot;Pacheco&quot;},{&quot;first_name&quot;:&quot;Sheerin&quot;,&quot;last_name&quot;:&quot;Shahidi-Latham&quot;},{&quot;first_name&quot;:&quot;Jianping&quot;,&quot;last_name&quot;:&quot;Yin&quot;},{&quot;first_name&quot;:&quot;Kristina&quot;,&quot;last_name&quot;:&quot;West&quot;},{&quot;first_name&quot;:&quot;Weiru&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;G. Moffat&quot;},{&quot;first_name&quot;:&quot;Jacob&quot;,&quot;last_name&quot;:&quot;B. Schwarz&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;1976-1991&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm501921k&quot;},&quot;abstract&quot;:&quot;Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of (S)-14k, a potent, selective, and orally bioavailable agent that inhibited tumor growth in mouse xenograft models. On the basis of its in vivo efficacy and preliminary safety profiles, (S)-14k was selected for further preclinical evaluation.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501921k&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501921k" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501921k&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501921k" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501921k&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501921k" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm501921k&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501921k&amp;href=/doi/10.1021/jm501921k" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm501921k" /></input><a href="/doi/pdf/10.1021/jm501921k" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm501921k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm501921k%26sid%3Dliteratum%253Aachs%26pmid%3D25603482%26genre%3Darticle%26aulast%3DRen%26date%3D2015%26atitle%3DDiscovery%2Bof%2BHighly%2BPotent%252C%2BSelective%252C%2Band%2BEfficacious%2BSmall%2BMolecule%2BInhibitors%2Bof%2BERK1%252F2%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D4%26spage%3D1976%26epage%3D1991%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292271" title="Urea">Urea</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jmcmar.2015.58.issue-4/20150226/jmcmar.2015.58.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0019.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of (<i>S</i>)-<b>14k</b>, a potent, selective, and orally bioavailable agent that inhibited tumor growth in mouse xenograft models. On the basis of its in vivo efficacy and preliminary safety profiles, (<i>S</i>)-<b>14k</b> was selected for further preclinical evaluation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Ras/Raf/MEK/ERK (MAPK) signal transduction pathway is widely activated in a large subset of human cancers and thus has attracted significant interest as a therapeutic target for cancer.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Constitutive activation of the MAPK pathway by overexpression of growth factors, as well as oncogenic Ras and Raf mutations, are frequently observed in tumor types such as colon, lung, pancreatic, ovary, and kidney.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The downstream consequence of disregulation of this pathway is over and/or constitutive production of phosphorylated ERK1/2 (pERK). Activity of this pathway has been linked to disease progression and clinical outcome in several malignancies.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p last">Small molecule inhibitors of B-Raf and MEK have shown promising activities in the clinic for a variety of solid tumors. The approval of Zelboraf<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> (vemurafenib), Telfinlar<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> (Dabrafenib), and Mekinist<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> (trametinib) as treatments for metastatic melanoma validate the approach of targeting the MAPK pathway as an effective way of treating cancer. In comparison to B-Raf and MEK inhibitors, the development of small molecule inhibitors of ERK1/2 has lagged behind with only few reports of preclinical development.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> ERK1 and 2, which show 89% sequence identity within the kinase domain, are pivotal in the pathway downstream of Ras, Raf, and MEK, acting as a central node where multiple signaling pathways converge to drive transcription. ERK1/2 are activated by MEK1/2 through phosphorylation of both a threonine and a tyrosine residue, namely Thr202 and Tyr204 of ERK1 and Thr173 and Tyr185 of ERK2. Once activated, ERK1/2 phosphorylates serine/threonine residues of more than 50 downstream substrates and activates both cytosolic and nuclear proteins that are responsible for cell growth, proliferation, survival, angiogenesis, and differentiation, all hallmarks of the cancer phenotype.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Thus, it may be beneficial to target the ERK proteins directly as a more effective way to block the MAPK signaling pathway. Furthermore, an ERK inhibitor may have utility in combination with other MAPK inhibitors. Recently, researchers at Genentech and Merck independently reported that dual inhibition of MEK and ERK by small molecule inhibitors acted to overcome acquired resistance to MEK inhibitors, providing further rationale for developing selective ERK1/2 inhibitors.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Herein, we describe the medicinal chemistry efforts leading to the discovery of (<i>S</i>)-<b>14k</b>, a potent, selective, and efficacious inhibitor of ERK1/2.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Structure-Based Design</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04624" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04624" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Previously, we disclosed a novel series of ATP competitive ERK1/2 inhibitors, exemplified by <b>1a</b> and <b>1b</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) built upon a piperidinopyrimidine urea template.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> On the basis of excellent potency and good in vitro ADME properties (medium predicted CL in hepatocytes and moderate plasma protein binding),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> the pharmacokinetics of <b>1a</b> was evaluated in mice, rats, beagle dogs, and cynomolgous monkeys. Unfortunately, compound <b>1a</b> showed high clearance and low oral bioavailability in multiple species, a profile shared with most analogues from the series.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Stuctures of <b>1a</b> and <b>1b</b> from the piperidinopyrimidine urea series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To understand the underlying reason for the poor PK across the series, in vitro metabolic profilings were performed on representative analogues. Consistently, major metabolites were identified that resulted from oxidation of the benzylic C-5 and C-8 positions on the core (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). In addition to high clearance, <b>1a</b> exhibited low permeability (<i>P</i><sub>app</sub> AB (10<sup>–6</sup> cm/s) = 1.3) and efflux (efflux ratio BA/AB = 7.8), limiting its oral absorption. These inherent PK liabilities of the piperidinopyrimidine urea template prompted us to search for an alternative core.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Structure-Based Design: From Piperidinopyrimidine Ureas to Pyridones</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In designing a new template, it was highly desirable to maintain all the critical interactions between <b>1a</b> and the ERK2 protein while removing the metabolic liability inherent in the piperidinopyrimidine core. As can be seen in the X-ray cocrystal structure of <b>1b</b> bound to ERK2 (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A), the pyrimidine ring accepts a hydrogen bond from the backbone NH of Met108 while the amino group at the 2-position donates a H-bond to the carbonyl oxygen of the same residue. The oxygen of the tetrahydro-2<i>H</i>-pyran is hydrogen-bonded to the side chain of Lys114, although it appears that the bulk of the potency realized from this group is derived via hydrophobic interactions near the hinge region. Additionally, the urea oxygen accepts two hydrogen bonds: one from the side chain of Lys54 and another from a bound water molecule that is complexed to Gln105, Glu71, and Asp167 (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B). The latter H-bond is believed to be critical to ERK1/2 and a key feature of our strategy to achieve selectivity against other members of the closely related CMGC family of kinases. The (<i>S</i>)-CH<sub>2</sub>OH group is in the vicinity of Asp167 and Asn154 and can make a hydrogen bond interaction to either the side chain carboxylate of Asp167 or the amide carbonyl of Asn154. It is important to note that the stereochemistry of this chiral center is critical for potency, as observed by us<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and others.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The 3-Cl-4-F phenyl moiety points toward the glycine-rich loop, making largely hydrophobic contacts. The metabolically labile piperidine acts mainly as a spacer and a conformational control and could potentially be replaced. It was hypothesized that a 4-pyridone could serve as effective replacement for the piperidine urea linker, as shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, based on the following considerations.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Pyridone <b>6a</b> (orange) docked into the X-ray structure of <b>1b</b> (green) with ERK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O6E">4O6E</a>, solved at 1.95 Å resolution). Hydrogen-bonding interactions are illustrated with red dashed lines. (B) Same model as in (A), rotated to illustrate key water mediated H-bond interactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">First of all, modeling studies (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) suggested that the pyridone carbonyl mimics the urea oxygen and should make the same hydrogen bond interactions to both Lys54 and the bound water molecule that is complexed to Gln105, Glu71, and Asp167. Second, an overlap of the pyridone and the piperidinopyrimidine urea templates revealed that the left-hand-side pyrimidine and right-hand-side benzyl moieties occupy similar space and should maintain critical contacts with the hinge and the glycine-rich loop. It was reasoned that the pyridone series could have improved metabolic stability due to removal of the two metabolic soft spots present in the piperidinopyrimidine scaffold (C-5 and C-8). Another salient feature of the pyridone design is elimination of the urea linker. Although the urea oxygen is necessary for activity, the urea NH does not make any specific interaction with the protein and removal of the unnecessary hydrogen bond donor could positively impact permeability and absorption.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24522" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24522" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pyrimidine pyridones <b>6</b> were prepared in a four-step procedure as described in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Suzuki coupling of commercially available 2,4-dichloropyrimidine and 2-fluoropyridin-4-ylboronic acid produced <b>3</b>. Replacing the 2-Cl with tetrahydro-2<i>H</i>-pyran-4-amine (THP amine) gave aminopyrimidine <b>4</b>, which was converted to pyridone <b>5</b> under acidic conditions. Chemoselective <i>N</i>-alkylation with various benzyl bromides afforded <b>6a</b>–<b>6f</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>6a</b>–<b>6f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reaction conditions: (a) 5% Pd(dppf)Cl<sub>2</sub>(DCM), Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O (4:1), 80 °C, 3 h, 96%; (b) tetrahydro-2<i>H</i>-pyran-4-amine, <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine, 2-butanol, 100 °C, 16 h, 49%; (c) 2 N HCl, 100 °C, 16 h, 94%; (d) benzyl bromide, K<sub>2</sub>CO<sub>3</sub>, DMF, 25 °C, 65%.</p></p></figure><div class="NLM_p">Hydroxylated analogues such as <b>14</b> required a slightly different synthesis as illustrated in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Suzuki coupling of commercially available 4-bromo-2-(methylthio)pyrimidine and 2-fluoropyridin-4-ylboronic acid produced <b>7</b>, which was converted to the key pyridone intermediate <b>8</b> via acidic hydrolysis. Chemoselective N-alkylation with mesylate <b>10</b> (prepared via aryl Grignard addition to commercially available TBS protected glycolaldehyde) gave racemic methyl sulfide <b>11</b>, which was oxidized to sulfone <b>12</b>. Installation of the THP amine followed by TBS deprotection afforded <b>14a</b>–<b>14o</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Compounds <b>14a</b>–<b>14o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reaction conditions: (a) 5% Pd(dppf)Cl<sub>2</sub>(DCM), Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O (4:1), 80 °C, 2 h, 90%; (b) 2 N HCl, 100 °C, 2 h, 50%; (c) THF, 0 °C, 1 h, 93%; (d) MsCl, NEt<sub>3</sub>, DCM, 0 °C, 1 h, 96%; (e) KHMDS, THF, 65 °C, 30 h, 65%; (f) <i>m</i>CPBA, DCM, 0 °C, 2 h, 89%; (g) tetrahydro-2<i>H</i>-pyran-4-amine, 2-butanol, 120 °C, 4 h, 90%; (h) TBAF, THF, 25 °C, 16 h, 90%.</p></p></figure><div class="NLM_p">The synthetic route shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a> to produce racemic compounds was modified to obtain the desired (<i>S</i>)-enantiomers with high ee (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> It was hypothesized that the key pyridone N-alkylation between <b>18</b> and <b>8</b> would occur via a SN2 mechanism with complete inversion at the newly created chiral center (<b>19</b>) and thus would require a precursor such as <b>16</b>. The absolute (<i>R</i>)-stereochemistry of the chiral center in diol <b>16</b> could be set via the well-known Sharpless dihydroxylation by using AD-mix-β.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Indeed, treatment of styrene <b>15</b> with AD-mix-β afforded <b>16</b> with 95% ee (determined from <b>17</b> by chiral chromatography). TBS protection of the primary alcohol (<b>17</b>) followed by mesylation of the benzylic hydroxyl group gave <b>18</b>. With KHMDS as a base, displacement of mesylate by intermediate <b>8</b> occurred predominantly on nitrogen to afford <b>19</b>. Although the enantiomeric excess of <b>19</b> was not measured, it was inferred to be >95% because no ee loss was observed during the transformation from <b>17</b> (95% ee) to (<i>S</i>)-<b>14k</b> (96% ee, determined by chiral chromatography). The absolute stereochemistry of (<i>S</i>)-<b>14k</b> was confirmed by X-ray crystallography (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), indicating that the N-alkylation to produce <b>19</b> occurred with clean inversion.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0011.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Compounds (<i>S</i>)-<b>14k</b> and <b>22a</b>–<b>22i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reaction conditions: (a) NaH, methyltriphenylphosphonium bromide, THF, 25 °C, 16 h, 47%; (b) AD-mix-β, <i>t</i>-BuOH/H<sub>2</sub>O (1:1), 25 °C, 16 h, 64%; (c) TBSCl, imidazole, DCM, 0 °C, 1 h, 58%; (d) MsCl, NEt<sub>3</sub>, DCM, 0 °C, 1 h, 96%; (e) KHMDS, THF, 65 °C, 30 h, 65%; (f) <i>m</i>CPBA, DCM, 0 °C, 2 h, 89%; (g) R<sub>4</sub>NH<sub>2</sub>, 120 °C, 4 h, 90%; (h) TBAF, THF, 25 °C, 16 h, 90%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compounds were screened for potency against ERK2 enzymatic activity, Cdk2/Cyclin A binding, and inhibition of ERK-dependent p90RSK Serine 380 phosphorylation in HepG2 cells. To enable determination of subnanomolar enzyme potencies, ERK2 kinase activity was assayed in the presence of 2 mM ATP (80× the ATP <i>K</i><sub>m</sub><sup>(apparent)</sup> of 25 μM) and <i>K</i><sub>i</sub> values derived by the Cheng–Prusoff formula.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Given that the residues in the ATP site are conserved between ERK1 and ERK2, compounds were not routinely tested against ERK1, however, follow-up testing of several compounds confirmed that the ERK1 activity (<i>K</i><sub>i</sub> or IC<sub>50</sub> values) were consistently within 3-fold of ERK2.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Cyclin-dependent kinase 2 (CDK2) was employed as a representative kinase selectivity assay due to its relatively similar sequence homology with ERK2 in the ATP binding pocket and previous experience that this kinase was a frequent and biologically significant off-target.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Pyridone <b>6a</b>, with an unsubstituted benzyl group, showed promising activity with an enzyme <i>K</i><sub>i</sub> = 0.6 nM and cellular IC<sub>50</sub> = 120 nM. This encouraging result confirmed the validity of our docking experiments and gave us further confidence in using this model to drive SAR. We first proceeded to introduce small, mostly lipophilic substituents onto the phenyl ring to optimize interaction with the glycine-rich loop (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In general, halogens at the 3- and/or 4-position afforded a modest increase in potency and selectivity over CDK2. 3-Chlorophenyl (<b>6b</b>) was favored over 4-chlorophenyl (<b>6c</b>), affording a 4-fold improvement in cellular activity over <b>6a</b>. While 3,4-disubstituted analogues such as <b>6d</b> and <b>6e</b> remained similarly active, extending the pyridone side chain from benzyl to phenylethyl (<b>6f</b>) resulted in substantial lost in cellular potency.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of the Right-Hand-Side Phenyl Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0012.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center" char="±">ERK2 enzyme <i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">CDK2 enzyme <i>K</i><sub>d</sub> (nM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="±">phospho-p90RSK IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">CDK2 <i>K</i><sub>d</sub>/ERK2 <i>K</i><sub>i</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="left">–CH<sub>2</sub>Ph</td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 11</td><td class="colsep0 rowsep0" align="char" char="±">120 ± 26</td><td class="colsep0 rowsep0" align="char" char=".">35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="left">–CH<sub>2</sub>-3-Cl-Ph</td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">20 ± 13</td><td class="colsep0 rowsep0" align="char" char="±">30 ± 12</td><td class="colsep0 rowsep0" align="char" char=".">67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6c</b></td><td class="colsep0 rowsep0" align="left">–CH<sub>2</sub>-4-Cl-Ph</td><td class="colsep0 rowsep0" align="char" char="±">0.8 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">49 ± 22</td><td class="colsep0 rowsep0" align="char" char="±">85 ± 6</td><td class="colsep0 rowsep0" align="char" char=".">61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6d</b></td><td class="colsep0 rowsep0" align="left">–CH<sub>2</sub>-3-Cl-4-F-Ph</td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">37 ± 12</td><td class="colsep0 rowsep0" align="char" char="±">29 ± 6</td><td class="colsep0 rowsep0" align="char" char=".">93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6e</b></td><td class="colsep0 rowsep0" align="left">–CH<sub>2</sub>-3-F-4-Cl-Ph</td><td class="colsep0 rowsep0" align="char" char="±">0.3 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 9</td><td class="colsep0 rowsep0" align="char" char="±">34 ± 10</td><td class="colsep0 rowsep0" align="char" char=".">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6f</b></td><td class="colsep0 rowsep0" align="left">–CH<sub>2</sub> CH<sub>2</sub>-3-F-4-Cl-Ph</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">103 ± 32</td><td class="colsep0 rowsep0" align="char" char="±">615 ± 9</td><td class="colsep0 rowsep0" align="char" char=".">69</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last"><i>K</i><sub>i</sub> values were determined by carrying out ERK2 enzymatic assays in the presence of ATP at 80× <i>K</i><sub>m</sub><sup>(app)</sup> and applying Cheng–Prusoff correction to convert IC<sub>50</sub> to <i>K</i><sub>i</sub>.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">All assay results represent the mean of at least three independent determinations.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last"><i>K</i><sub>d</sub> values were determined by competitive displacement of an ATP-analogue probe.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Cellular assay in PMA-stimulated HepG2 cells. See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for details.</p></div></div></div><div class="NLM_p">Because preliminary SAR on the phenyl ring tracked well with the piperidinopyrimidine ureas,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> we decided to focus on the hydroxymethyl substituent at the benzylic position as we<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and others<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> have shown that this group is near optimal in terms of both potency and kinase selectivity (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Although the cellular IC<sub>50</sub> of racemic <b>14a</b> remained unchanged in comparison to <b>6a</b> at first glance, it was important to realize that potency should improve by 2-fold if only the active (<i>S</i>)-enantiomer was obtained.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Expanded SAR of the Right-Hand-Side Phenyl Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0013.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center" char="±">ERK2 enzyme <i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">CDK2 enzyme <i>K</i><sub>d</sub> (nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="±">phospho-p90RSK IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">CDK2 <i>K</i><sub>d</sub>/ERK2 <i>K</i><sub>i</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">36 ± 19</td><td class="colsep0 rowsep0" align="char" char="±">148 ± 18</td><td class="colsep0 rowsep0" align="char" char=".">51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14b</b></td><td class="colsep0 rowsep0" align="left">2-Cl</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">108 ± 15</td><td class="colsep0 rowsep0" align="char" char="±">249 ± 43</td><td class="colsep0 rowsep0" align="char" char=".">98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14c</b></td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">69 ± 15</td><td class="colsep0 rowsep0" align="char" char="±">98 ± 43</td><td class="colsep0 rowsep0" align="char" char=".">46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14d</b></td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">43 ± 15</td><td class="colsep0 rowsep0" align="char" char="±">39 ± 16</td><td class="colsep0 rowsep0" align="char" char=".">108</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14e</b></td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="char" char="±">0.1 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">19 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">79 ± 23</td><td class="colsep0 rowsep0" align="char" char=".">190</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14f</b></td><td class="colsep0 rowsep0" align="left">3-Me</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">155 ± 129</td><td class="colsep0 rowsep0" align="char" char="±">100 ± 31</td><td class="colsep0 rowsep0" align="char" char=".">119</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14g</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">177 ± 116</td><td class="colsep0 rowsep0" align="char" char="±">82 ± 31</td><td class="colsep0 rowsep0" align="char" char=".">136</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14h</b></td><td class="colsep0 rowsep0" align="left">3-OMe</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">179 ± 124</td><td class="colsep0 rowsep0" align="char" char="±">227 ± 62</td><td class="colsep0 rowsep0" align="char" char=".">112</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14i</b></td><td class="colsep0 rowsep0" align="left">3-CN</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">219 ± 127</td><td class="colsep0 rowsep0" align="char" char="±">484 ± 149</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14j</b></td><td class="colsep0 rowsep0" align="left">3,4-diF</td><td class="colsep0 rowsep0" align="char" char="±">0.1 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 8</td><td class="colsep0 rowsep0" align="char" char="±">58 ± 31</td><td class="colsep0 rowsep0" align="char" char=".">160</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14k</b></td><td class="colsep0 rowsep0" align="left">3-F-4-Cl</td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">57 ± 29</td><td class="colsep0 rowsep0" align="char" char="±">49 ± 15</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14l</b></td><td class="colsep0 rowsep0" align="left">3-Cl-4-F</td><td class="colsep0 rowsep0" align="char" char="±">0.5 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">70 ± 28</td><td class="colsep0 rowsep0" align="char" char="±">37 ± 21</td><td class="colsep0 rowsep0" align="char" char=".">140</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14m</b></td><td class="colsep0 rowsep0" align="left">3,5-diF</td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">83 ± 34</td><td class="colsep0 rowsep0" align="char" char=".">55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14n</b></td><td class="colsep0 rowsep0" align="left">3,5-diCl</td><td class="colsep0 rowsep0" align="char" char="±">0.3 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">40 ± 16</td><td class="colsep0 rowsep0" align="char" char="±">27 ± 9</td><td class="colsep0 rowsep0" align="char" char=".">133</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14o</b></td><td class="colsep0 rowsep0" align="left">3-F-5-Cl</td><td class="colsep0 rowsep0" align="char" char="±">0.5 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">37 ± 13</td><td class="colsep0 rowsep0" align="char" char="±">41 ± 19</td><td class="colsep0 rowsep0" align="char" char=".">74</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last"><i>K</i><sub>i</sub> values were determined by carrying out ERK2 enzymatic assays in the presence of ATP at 80× <i>K</i><sub>m</sub><sup>(app)</sup> and applying Cheng–Prusoff correction to convert IC<sub>50</sub> to <i>K</i><sub>i</sub>.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">All assay results represent the mean of at least three independent determinations.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last"><i>K</i><sub>d</sub> values were determined by competitive displacement of an ATP-analogue probe.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">Cellular assay in PMA-stimulated HepG2 cells. See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for details.</p></div></div></div><div class="NLM_p">To expedite the SAR exploration of other regions of the molecule, we elected to proceed with testing racemic material due to ease of synthesis. Once an optimal racemic compound was identified, the more active (<i>S</i>)-enantiomer was prepared and profiled. Using this strategy, SAR of the terminal phenyl group was further expanded (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Again, exploring chlorine substitution on the aryl ring quickly revealed that 3-Cl (<b>14d</b> vs <b>14b</b> and <b>14c</b>) was favored in both biochemical and cellular assays. Further SAR exploration at this position showed 3-F (<b>14e</b>), 3-Me (<b>14f</b>), and 3-CF<sub>3</sub> (<b>14g</b>) were less potent in the cellular assay and polar substituents were not tolerated (<b>14h</b> and <b>14i</b>), likely due to unfavorable interaction with the largely lipophilic P-loop. On the basis of these results, we prepared dihalo analogues <b>14j</b>–<b>14o</b>. Most of these compounds retained cellular activity in comparison to <b>14d</b>, with the exception of <b>14m</b>, which is 2× less potent in the cellular assay.</div><div class="NLM_p">Because of the combination of good cellular potency and CDK2 selectivity, the active (<i>S</i>)-enantiomer of <b>14d</b>, <b>14e</b>, <b>14k</b>, and <b>14l</b> were obtained by asymmetric synthesis as described in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. As expected, all of the (<i>S</i>)-enantiomers were potent and selective (>70× over CDK2). These compounds showed reasonable in vitro ADME properties, such as medium metabolic stability as predicted by mouse liver microsomes and medium to high permeability as measured in the MDCK cell line, and were advanced to mouse (CD-1 strain) pharmacokinetic studies (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Among these compounds, the one bearing the 3-F-4-Cl substitution pattern ((<i>S</i>)-<b>14k</b>) showed the best overall mouse PK profile with low clearance and high bioavailability and was chosen as the preferred piece on the right-hand-side of the molecule.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro ADME Properties and Mouse PK Parameters of (<i>S</i>)-<b>14d</b>, (<i>S</i>)-<b>14e</b>, (<i>S</i>)-<b>14k</b> and (<i>S</i>)-<b>14l</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center" char="±">ERK2 enzyme <i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">CDK2 enzyme <i>K</i><sub>d</sub> (nM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="±">phospho-p90RSK IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">CDK2 <i>K</i><sub>d</sub>/ERK2 <i>K</i><sub>i</sub></th><th class="colsep0 rowsep0" align="center" char=".">in vitro predicted CL (mL/min/kg)<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char=".">permeability <i>P</i><sub>app</sub> AB<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center" char=".">in vivo CL (mL/min/kg) IV<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a></th><th class="colsep0 rowsep0" align="center" char=".">AUC (μM·h)<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>14d</b></td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">27 ± 7</td><td class="colsep0 rowsep0" align="char" char=".">80</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="char" char=".">114</td><td class="colsep0 rowsep0" align="char" char=".">0.59</td><td class="colsep0 rowsep0" align="char" char=".">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>14e</b></td><td class="colsep0 rowsep0" align="char" char="±">0.1 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">23 ± 19</td><td class="colsep0 rowsep0" align="char" char="±">42 ± 24</td><td class="colsep0 rowsep0" align="char" char=".">230</td><td class="colsep0 rowsep0" align="char" char=".">59</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">1.72</td><td class="colsep0 rowsep0" align="char" char=".">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>14k</b></td><td class="colsep0 rowsep0" align="char" char="±">0.3 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 8</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 4</td><td class="colsep0 rowsep0" align="char" char=".">70</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">11.3</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="char" char=".">3.05</td><td class="colsep0 rowsep0" align="char" char=".">66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>14l</b></td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">31 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">38 ± 8</td><td class="colsep0 rowsep0" align="char" char=".">165</td><td class="colsep0 rowsep0" align="char" char=".">66</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="char" char=".">63</td><td class="colsep0 rowsep0" align="char" char=".">2.18</td><td class="colsep0 rowsep0" align="char" char=".">76</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last"><i>K</i><sub>i</sub> values were determined by carrying out ERK2 enzymatic assays in the presence of ATP at 80× <i>K</i><sub>m</sub><sup>(app)</sup> and applying Cheng–Prusoff correction to convert IC<sub>50</sub> to <i>K</i><sub>i</sub>.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">All assay results represent the mean of at least three independent determinations.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last"><i>K</i><sub>d</sub> values were determined by competitive displacement of an ATP-analogue probe.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">Cellular assay in PMA-stimulated HepG2 cells. See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for details.</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">Mouse hepatic CL predicted from liver microsomes.</p></div><div class="footnote" id="t3fn6"><sup>f</sup><p class="last">Permeability measurement determined in MDCK cell line, in units of 10<sup>–6</sup> cm/s.</p></div><div class="footnote" id="t3fn7"><sup>g</sup><p class="last">IV clearance measured at 1 mg/kg for CD-1 mouse, dosed as a solution in 40% PEG400/60% H<sub>2</sub>O.</p></div><div class="footnote" id="t3fn8"><sup>h</sup><p class="last">CD-1 mouse PO PK at 5 mg/kg, dosed as a solution in 40% PEG400/60% of 10% HP-<i>b</i>-CD in H<sub>2</sub>O.</p></div></div></div><div class="NLM_p">Having chosen the 3-F-4-Cl-Ph as the preferred right-hand-side substituent, central pyridone ring SAR was investigated next (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Again, we elected to proceed with testing racemic material due to ease of synthesis. Only small substitutions, especially at the 3- and 5-position of the pyridone were considered, as conformational analysis suggested that the pyrimidine and the pyridone core would prefer to be coplanar when bound. 3-F substitution (<b>23a</b>) retained potency, albeit with a loss of selectivity over CDK2. Substitutions at other positions were not well tolerated, and 5-F (<b>23b</b>), 5-Me (<b>23c</b>), and 6-Me (<b>23d</b>) were substantially less active. Changing the pyridone template to either the pyrimidinone (<b>23e</b>) or the pyridazinone (<b>23f</b>) resulted in a drop in potency. The decrease in activity of <b>23e</b> and <b>23f</b> was likely due to the increased polarity (decreased lipophilicity) of the linker.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR of the Central Pyridone Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0014.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center" char="±">ERK2 enzyme <i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">CDK2 enzyme <i>K</i><sub>d</sub> (nM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">phospho-p90RSK IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">CDK2 <i>K</i><sub>d</sub>/ERK2 <i>K</i><sub>i</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14k</b></td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">57 ± 29</td><td class="colsep0 rowsep0" align="center">49 ± 15</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b></td><td class="colsep0 rowsep0" align="left">C–F</td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="char" char="±">0.3 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 4</td><td class="colsep0 rowsep0" align="center">82 ± 35</td><td class="colsep0 rowsep0" align="char" char=".">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23b</b></td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="left">C–F</td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="char" char="±">41 ± 7</td><td class="colsep0 rowsep0" align="char" char="±">723 ± 179</td><td class="colsep0 rowsep0" align="center">>5000</td><td class="colsep0 rowsep0" align="char" char=".">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23c</b></td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="left">C-Me</td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">643 ± 229</td><td class="colsep0 rowsep0" align="center">687 ± 122</td><td class="colsep0 rowsep0" align="char" char=".">195</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23d</b></td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="left">C-Me</td><td class="colsep0 rowsep0" align="char" char="±">6.8 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">758 ± 262</td><td class="colsep0 rowsep0" align="center">1619 ± 213</td><td class="colsep0 rowsep0" align="char" char=".">111</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23e</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="char" char="±">2.4 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">202 ± 38</td><td class="colsep0 rowsep0" align="center">697 ± 156</td><td class="colsep0 rowsep0" align="char" char=".">84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23f</b></td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">92 ± 42</td><td class="colsep0 rowsep0" align="center">230 ± 58</td><td class="colsep0 rowsep0" align="char" char=".">54</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last"><i>K</i><sub>i</sub> values were determined by carrying out ERK2 enzymatic assays in the presence of ATP at 80× <i>K</i><sub>m</sub><sup>(app)</sup> and applying Cheng–Prusoff correction to convert IC<sub>50</sub> to <i>K</i><sub>i</sub>.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">All assay results represent the mean of at least three independent determinations.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last"><i>K</i><sub>d</sub> values were determined by competitive displacement of an ATP-analogue probe.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">Cellular assay in PMA-stimulated HepG2 cells. See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for details.</p></div></div></div><div class="NLM_p">SAR of the pyrimidine ring was examined next (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Other hinge binding templates such as pyridine (<b>24a</b>) as well as an isomeric pyrimidine (<b>24b</b>) were both less effective. Substitution at the 5-position of the pyrimidine ring with fluorine (<b>24e</b>) or chlorine (<b>24d</b>) largely retained cellular potency, albeit with a loss of selectivity over CDK2. The loss of activity with a larger methyl group (<b>24c</b>) was attributed to an unfavorable change in the dihedral angle between the pyrimidine and pyridone rings, resulting in increased strain energy upon binding.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SAR of the Pyrimidine Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0015.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center">A</th><th class="colsep0 rowsep0" align="center">B</th><th class="colsep0 rowsep0" align="center" char="±">ERK2 enzyme <i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">CDK2 enzyme <i>K</i><sub>d</sub> (nM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="±">phospho-p90RSK IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">CDK2 <i>K</i><sub>d</sub>/ERK2 <i>K</i><sub>i</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14k</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">57 ± 29</td><td class="colsep0 rowsep0" align="char" char="±">49 ± 15</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24a</b></td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">567 ± 274</td><td class="colsep0 rowsep0" align="char" char="±">385 ± 119</td><td class="colsep0 rowsep0" align="char" char=".">315</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24b</b></td><td class="colsep0 rowsep0" align="left">C–H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">763 ± 209</td><td class="colsep0 rowsep0" align="char" char="±">4428 ± 990</td><td class="colsep0 rowsep0" align="char" char=".">55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24c</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">C-Me</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">136 ± 63</td><td class="colsep0 rowsep0" align="char" char="±">801 ± 116</td><td class="colsep0 rowsep0" align="char" char=".">62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24d</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">C–Cl</td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">116 ± 60</td><td class="colsep0 rowsep0" align="char" char=".">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24e</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">C–F</td><td class="colsep0 rowsep0" align="char" char="±">0.1 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">30 ± 15</td><td class="colsep0 rowsep0" align="char" char=".">18</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last"><i>K</i><sub>i</sub> values were determined by carrying out ERK2 enzymatic assays in the presence of ATP at 80× <i>K</i><sub>m</sub><sup>(app)</sup> and applying Cheng–Prusoff correction to convert IC<sub>50</sub> to <i>K</i><sub>i</sub>.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">All assay results represent the mean of at least three independent determinations.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last"><i>K</i><sub>d</sub> values were determined by competitive displacement of an ATP-analogue probe.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Cellular assay in PMA-stimulated HepG2 cells. See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for details.</p></div></div></div><div class="NLM_p">Final areas of SAR investigation focused on exploring other amino groups at the 2-position of the pyrimidine. This area is solvent exposed and can potentially be used to design inhibitors with improved physiochemical properties (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). To maintain potency, substituents capable of interacting with the side chain of Lys114 (as the oxygen of the THP moiety) were evaluated. In this exercise, we proceeded with enantiomerically enriched material because large quantities of intermediate <b>20</b> had become available at this stage of the project. A variety of structural changes were explored, such as varying the ring size (<b>22a</b>, <b>22b</b>, <b>22c</b>), ring substitution (<b>22e</b>), THP oxygen atom replacement (<b>22d</b>, <b>22f</b>) as well as ring opening (<b>22g</b>, <b>22h</b>, <b>22i</b>), without improving upon the potency of (<i>S</i>)-<b>14k</b>. Although the activity of oxetane <b>22c</b> looked promising initially, it was chemically unstable toward acid (pH = 1) and was not advanced.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. SAR of the Amino-pyrimidine</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0016.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0017.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last"><i>K</i><sub>i</sub> values were determined by carrying out ERK2 enzymatic assays in the presence of ATP at 80× <i>K</i><sub>m</sub><sup>(app)</sup> and applying Cheng–Prusoff correction to convert IC<sub>50</sub> to <i>K</i><sub>i</sub>.</p></div><div class="footnote" id="t6fn2"><sup>Table b</sup><p class="last">All assay results represent the mean of at least three independent determinations.</p></div><div class="footnote" id="t6fn3"><sup>Table c</sup><p class="last"><i>K</i><sub>d</sub> values were determined by competitive displacement of an ATP-analogue probe.</p></div><div class="footnote" id="t6fn4"><sup>Table d</sup><p class="last">Cellular assay in PMA-stimulated HepG2 cells. See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for details.</p></div></div><div></div></div><div class="NLM_p">To confirm our earlier hypothesis that the (<i>S</i>)-enantiomer was critical for potency, the opposite epitope (<i>R</i>)-<b>14k</b> was obtained (by chiral separation) and profiled (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). As anticipated, (<i>R</i>)-<b>14k</b> was 25-fold less active in the cellular assay in comparison to (<i>S</i>)-<b>14k</b>. Importantly, the more active enantiomer also maintained CDK2 selectivity. When compared to our previous lead <b>1a</b>, (<i>S</i>)-<b>14k</b> has equivalent cellular potency with improved CDK2 selectivity. With an optimal combination of activity, selectivity, and mouse pharmacokinetics, (<i>S</i>)-<b>14k</b> emerged as a promising lead. The kinase selectivity profile of compound (<i>S</i>)-<b>14k</b> was determined by screening against a panel of 170 kinases. No kinase showed >70% inhibition other than ERK1 and ERK2 at a test concentration of 100 nM (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Furthermore, (<i>S</i>)-<b>14k</b> showed no significant inhibition when screened against a panel of 40 receptors at a concentration of 10 μM except for mild adenosine (64% inhibition) A1 agonism (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Activities of (<i>R</i>)-<b>14k</b>, (<i>S</i>)-<b>14k</b>, and <b>1a</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0018.gif" alt="" id="fx7" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center" char="±">ERK2 enzyme <i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">CDK2 enzyme <i>K</i><sub>d</sub> (nM)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="±">phospho-p90RSK IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">CDK2 <i>K</i><sub>d</sub>/ERK2 <i>K</i><sub>i</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>rac</i>)-<b>14k</b></td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">57 ± 29</td><td class="colsep0 rowsep0" align="char" char="±">49 ± 15</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<b>14k</b></td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">267 ± 57</td><td class="colsep0 rowsep0" align="char" char="±">433 ± 159</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>14k</b></td><td class="colsep0 rowsep0" align="char" char="±">0.3 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 8</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 4</td><td class="colsep0 rowsep0" align="char" char=".">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1a</b></td><td class="colsep0 rowsep0" align="char" char="±">0.1 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">20 ± 3</td><td class="colsep0 rowsep0" align="char" char=".">41</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last"><i>K</i><sub>i</sub> values were determined by carrying out ERK2 enzymatic assays in the presence of ATP at 80× <i>K</i><sub>m</sub><sup>(app)</sup> and applying Cheng–Prusoff correction to convert IC<sub>50</sub> to <i>K</i><sub>i</sub>.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">All assay results represent the mean of at least three independent determinations.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last"><i>K</i><sub>d</sub> values were determined by competitive displacement of an ATP-analogue probe.</p></div><div class="footnote" id="t7fn4"><sup>d</sup><p class="last">Cellular assay in PMA-stimulated HepG2 cells. See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for details.</p></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> X-ray Crystal Structure</h3><div class="NLM_p">An X-ray structure of (<i>S</i>)-<b>14k</b> bound to ERK2 at 2.58 Å resolution was obtained (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). The crystal structure confirms earlier modeling conclusions that the 2-aminopyrimidine interacts via a pair of H-bonds with the hinge region of ERK2 at Met108. The 4-THP interacts with Lys114 via the ether oxygen, although it appears that the bulk of the potency is derived from hydrophobic interactions in this region. As we hypothesized above, a key water molecule (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B) forms a H-bond to the pyridone carbonyl (2.85 Å), which also interacts with the side chain of Lys54 (3.01 Å). The methyl hydroxyl substituent interacts with the carboxylate side chain of Asp167 (2.70 Å). The 3-F-4-Cl phenyl group occupies a small hydrophobic pocket under the P-loop that is formed when Tyr36 is displaced toward the C-helix.</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) X-ray structure of (<i>S</i>)-<b>14k</b> (green) bound to ERK2, solved at 2.58 Å resolution (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XJ0">4XJ0</a>). Hydrogen-bonding interactions are illustrated with red dashed lines. (B) X-ray structure rotated to illustrate key water mediated H-bond interactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> In Vitro ADME and Pharmacokinetics</h3><div class="NLM_p">The in vitro ADME properties of (<i>S</i>)-<b>14k</b> were determined (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). Liver hepatocytes predicted low to medium stability across species, similar to what was observed with our pervious lead <b>1a</b>. Permeability measurement in the MDCK cell line showed high permeability without efflux, a significant improvement over <b>1a</b>, suggesting better absorption potential. Other properties such as solubility (45 μg/mL @ pH 7.4) and human plasma protein binding (95.8%) were deemed sufficient although less desirable than <b>1a</b>. Compound (<i>S</i>)-<b>14k</b> displayed no inhibition of cytochrome P450 enzymes (IC<sub>50</sub> > 10 μM for CYP3A4, CYP1A2, CYP2C9, CYP2C19, CYP2D6) and was negative in the time-dependent CYP inhibition (TDI) assay for major CYP isoforms (CYP3A4, CYP1A2, CYP2C9, CYP2C19, and CYP2D6). In addition, minimal hERG channel inhibition was observed with an IC<sub>50</sub> = 14.5 μM.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. In Vitro ADME Properties of (<i>S</i>)-<b>14k</b> and <b>1a</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">in vitro predicted CL (mL/min/kg)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">PPB % bound</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center" char=".">rat</th><th class="colsep0 rowsep0" align="center" char=".">mouse</th><th class="colsep0 rowsep0" align="center" char=".">permeability <i>P</i><sub>app</sub> AB<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">efflux ratio BA/AB</th><th class="colsep0 rowsep0" align="center" char=".">solubility (μg/mL)<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a> @ pH 7.4</th><th class="colsep0 rowsep0" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center" char=".">rat</th><th class="colsep0 rowsep0" align="center" char=".">mouse</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>14k</b></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="char" char=".">11.3</td><td class="colsep0 rowsep0" align="char" char=".">0.84</td><td class="colsep0 rowsep0" align="char" char=".">45</td><td class="colsep0 rowsep0" align="char" char=".">95.8</td><td class="colsep0 rowsep0" align="char" char=".">96.7</td><td class="colsep0 rowsep0" align="char" char=".">98.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1a</b></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">7.8</td><td class="colsep0 rowsep0" align="char" char=".">526</td><td class="colsep0 rowsep0" align="char" char=".">82.4</td><td class="colsep0 rowsep0" align="char" char=".">82.8</td><td class="colsep0 rowsep0" align="char" char=".">89.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Hepatic CL predicted from liver hepatocytes.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Permeability measurement determined in MDCK cell line, in units of 10<sup>–6</sup> cm/s.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Thermodynamic solubility.</p></div></div></div><div class="NLM_p">On the basis of the combination of good potency, selectivity, and in vitro ADME profile, the PK of (<i>S</i>)-<b>14k</b> was evaluated in nude mice (Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>). The clearance was modest (CL = 40 mL/min/kg) at 1 mg/kg IV, and oral bioavailability was excellent at 5 mg/kg (<i>F</i> = 139%). More extensive PK evaluations were performed in rats, dogs, and cynomolgous monkeys. The results of these experiments were summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Key Pharmacokinetic Parameters for (<i>S</i>)-<b>14k</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" align="center">species</th><th class="rowsep1 colsep0" colspan="4" align="center">mouse<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" align="center">rat<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" align="center">dog<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" align="center">cyno<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose PO (mg/kg)</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">30</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">150</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μM)</td><td class="colsep0 rowsep0" align="center">3.12</td><td class="colsep0 rowsep0" align="center">20.2</td><td class="colsep0 rowsep0" align="center">38.9</td><td class="colsep0 rowsep0" align="center">67.7</td><td class="colsep0 rowsep0" align="center">1.49</td><td class="colsep0 rowsep0" align="center">2.91</td><td class="colsep0 rowsep0" align="center">0.98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="center">3.52</td><td class="colsep0 rowsep0" align="center">2.33</td><td class="colsep0 rowsep0" align="center">1.71</td><td class="colsep0 rowsep0" align="center">1.97</td><td class="colsep0 rowsep0" align="center">1.16</td><td class="colsep0 rowsep0" align="center">1.55</td><td class="colsep0 rowsep0" align="center">2.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (μM·h)</td><td class="colsep0 rowsep0" align="center">5.40</td><td class="colsep0 rowsep0" align="center">46.8</td><td class="colsep0 rowsep0" align="center">129</td><td class="colsep0 rowsep0" align="center">175</td><td class="colsep0 rowsep0" align="center">2.15</td><td class="colsep0 rowsep0" align="center">4.87</td><td class="colsep0 rowsep0" align="center">3.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="center">139</td><td class="colsep0 rowsep0" align="center">169</td><td class="colsep0 rowsep0" align="center">139</td><td class="colsep0 rowsep0" align="center">127</td><td class="colsep0 rowsep0" align="center">44</td><td class="colsep0 rowsep0" align="center">46</td><td class="colsep0 rowsep0" align="center">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/min/kg) IV<a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" colspan="4" align="center">40</td><td class="colsep0 rowsep0" align="center">39</td><td class="colsep0 rowsep0" align="center">18</td><td class="colsep0 rowsep0" align="center">12</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">Dosed as a suspension in 40% PEG400/60% of 10% HP-<i>b</i>-CD in H<sub>2</sub>O in nude mouse.</p></div><div class="footnote" id="t9fn2"><sup>b</sup><p class="last">Dosed as a solution in 40% PEG400/60% of 10% HP-<i>b</i>-CD in H<sub>2</sub>O.</p></div><div class="footnote" id="t9fn3"><sup>c</sup><p class="last">IV clearance measured at 1 mg/kg for nude mouse and rat, at 2 mg/kg for dog and cyno dosed as a solution in 40% PEG400/60% H<sub>2</sub>O.</p></div></div></div><div class="NLM_p">The overall PK profiles of (<i>S</i>)-<b>14k</b> looked quite promising across species. For example, the IV clearances were modest in all three species, an improvement over the previous lead <b>1a</b> (near hepatic blood flow CL in rat, dog, and cyno).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> These observations confirmed our hypothesis that by removing metabolic soft spots in the previous template, the pyridones should have improved metabolic stability over the piperidinopyrimidine ureas. Furthermore, oral bioavailability of (<i>S</i>)-<b>14k</b> in rat (<i>F</i> = 44%) and dog (<i>F</i> = 46%) at 5 mg/kg were superior to <b>1a</b> (11% F in rat and 26% in dog),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> partly due to improved absorption. In vitro ADME profiling revealed that while <b>1a</b> was an efflux substrate (efflux ratio BA/AB = 7.8) with low intrinsic permeability (<i>P</i><sub>app</sub> AB (10<sup>–6</sup> cm/s) = 1.3), (<i>S</i>)-<b>14k</b> was a highly permeable compound without efflux. This was attributed to replacing the urea linker with a pyridone template, eliminating an unnecessary hydrogen bond donor in the process. Importantly, our new lead also performed well in dose-escalation PK studies in nude mice. When dosed orally at 30, 100, and 150 mg/kg, a proportional increase in AUC was observed (Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>). At the lower dose of 30 mg/kg, the drug level in the plasma covered the free fraction adjusted cellular IC<sub>50</sub> (pRSK IC<sub>50</sub>/<i>F</i><sub>u</sub> = 944 nM) for more than 8 h (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Upon the basis of these results, (<i>S</i>)-<b>14k</b> was progressed into a PK/PD study (75 mg/kg, QD) in nude mice bearing subcutaneous human HCT116 colorectal cancer cell xenografts.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Dose-escalation of (<i>S</i>)-<b>14k</b> in nude mice. Three nude mice were dosed orally with (<i>S</i>)-<b>14k</b> at doses of 30, 100, and 150 mg/kg in 10%HP-<i>b</i>-CD/PEG400 suspension. At different time intervals, a blood sample was taken from each animal and plasma concentration was determined. Reported values were the average of three animals. The free fraction adjusted cellular IC<sub>50</sub> was calculated by dividing the cellular IC<sub>50</sub> by the unbound fraction in mouse.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Significant pRSK activity was observed at the 75 mg/kg dose, with the corresponding pRSK knockdown at the 2 h time point observed to be ∼70% (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Interestingly, at the 12 h time point, there was an apparent rebound in hyperphosphorylation of RSK, probably as a result of compensational feedback. Similar results were observed from other cell lines (A375 and Colo205, data not shown). On the basis of these results, (<i>S</i>)-<b>14k</b> was evaluated in a proof-of-concept tumor growth inhibition (TGI) study.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PK/PD in HCT116 xenograft tumors for compound (<i>S</i>)-<b>14k</b> at 2, 4, 8, and 12 h time points dosed orally at 75 mg/kg QD. Mean and sd for <i>n</i> = 3 animals are plotted. Green triangles represent total plasma concentration, red squares represent total tumor concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">(<i>S</i>)-<b>14k</b> was administered twice daily (BID) orally in nude mice bearing HCT116 colorectal cancer xenografts for 21 days (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). At the 75 mg/kg dose, significant tumor growth inhibition (70%) was obtained and the treatment was well tolerated. Body weight losses were within an acceptable range (<5%) throughout the study (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). In comparison, our prior lead <b>1a</b> was not as active at the 75 mg/kg dose in this model and only showed 69% TGI with 150 mg/kg dose after 28 days of BID dosing.</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. HCT116 colorectal tumor xenograft treated with compound (<i>S</i>)-<b>14k</b> orally at 75 mg/kg BID for 21 days. Cubic spline fitted tumor volume curves are shown for each group in red. Individual tumor volume traces are shown in gray, traces terminating in an X indicate animals sacrificed when tumors reached maximum permissible volume. The cubic spline fit for the vehicle group is shown in the (<i>S</i>)-<b>14k</b> treated group for comparison (green dashed line).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23604" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23604" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, a series of potent and selective ERK1/2 inhibitors were developed. These inhibitors are based on a novel pyridone template, which evolved through structure-based design from a piperidinopyrimidine urea lead <b>1a</b>. Comprehensive and systematic SAR investigation led to the identification of (<i>S</i>)-<b>14k</b>, a highly potent, selective, and efficacious ERK1/2 inhibitor. In comparison to our previous lead <b>1a</b>, (<i>S</i>)-<b>14k</b> showed much improved PK across species, which translated into better TGI in xenograft studies, especially at lower doses. These improvements were attributed to the design of a superior template by replacing the piperidine urea linker with a pyridone core, which led to the elimination of PK liabilities (metabolic soft spots and an unnecessary hydrogen bond donor) associated with the previous scaffold. On the basis of its in vivo efficacy and preliminary safety profile, (<i>S</i>)-<b>14k</b> was selected for further preclinical evaluation. The results from these studies will be reported in due course.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30534" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30534" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The reactions described herein were generally conducted under a positive pressure of nitrogen or argon or with a drying tube in commercial anhydrous solvents unless otherwise stated, and the reaction flasks were typically fitted with rubber septa during the introduction of reagents via a syringe or cannula. Glasswares were oven and/or heat dried. All reagents and solvents were used without further purification unless otherwise stated. Reaction progress was monitored by analytical TLC, HPLC, and LCMS. Analytical TLC was performed using glass plates precoated with silica gel from EMD (60 F<sub>254</sub>, 250 μm). TLC visualization was performed with UV light or by staining with Hanessian’s stain<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> or basic KMnO<sub>4</sub> solution. Flash column chromatography was performed on a Biotage model SP1 purification system running SPX software with prepacked silica gel or C18 columns and UV detection at 220 and 254 nm. Analytical HPLC was performed on an Agilent 1200 (column YMC ODS-AQ, 3 μm, 120 Å, 3.0 mm × 50 mm; run gradient 5–95% 0.01% HFBA/1% IPA/water/acetonitrile; UV detection 220 and 254 nm). Analytical LCMS was performed on an Agilent 1200 HPLC coupled with an Agilent 6120 quadruple LC/MS spectrometer using ESI or APCI ionization sources (column YMC ODS-AQ, 4.6 mm × 50 mm, 3 μm, 120 Å; run gradient 5–95% B over 4.5 min, holding 95% B for 1 min, followed by equilibration for 1 min; flow rate 2 mL/min; solvent A water/10 mM ammonium acetate/1% IPA; solvent B acetonitrile/10 mM ammonium acetate/1% IPA). Melting points were recorded on an electrothermal melting point apparatus, model 9100. <sup>1</sup>H NMR spectra were recorded in CDCl<sub>3</sub>, MeOH-<i>d</i><sub>4</sub> or DMSO-<i>d</i><sub>6</sub> solvents on a Varian Mercury (400 MHz) NMR spectrometer or on a Bruker AV III (400 or 500 MHz) spectrometer. Chemical shifts are expressed in parts per million (ppm, δ scale) using tetramethylsilane as the reference standard. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), dt (doublet of triplet), br (broad). Coupling constants are reported in hertz (Hz). The purity of each compound that was synthesized and tested for biological activity was ≥95% via HPLC analysis.</div><div class="NLM_p">For experiments involving the use of aminals, all procedures were carried out in compliance with the guidelines on animal studies outlined in the ACS Ethical Guidelines.</div><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 2-Chloro-4-(2-fluoropyridin-4-yl)pyrimidine (<b>3</b>)</h3><div class="NLM_p last">Sodium carbonate (4.91 g, 46.3 mmol) was added to 2-fluoropyridin-4-ylboronic acid (2.61 g, 18.5 mmol) and 2,4-dichloropyrimidine (2.30 g, 15.4 mmol) in dioxane/water (77 mL, 4:1), and the suspension was purged with argon. To this was added PdCl<sub>2</sub>(dppf)·DCM (0.630 g, 0.772 mmol), and the mixture was heated at 80 °C under argon. After 3 h, the reaction mixture was diluted with water (100 mL), and the resulting solid was collected by vacuum filtration to yield 2-chloro-4-(2-fluoropyridin-4-yl)pyrimidine (3.12 g, 96% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.80 (d, <i>J</i> = 5.2 Hz, 1H), 8.42 (d, <i>J</i> = 5.0 Hz, 1H), 7.87–7.78 (m, 1H), 7.71 (d, <i>J</i> = 5.4 Hz, 1H), 7.65–7.60 (m, 1H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 210.0, 212.1</div></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 4-(2-Fluoropyridin-4-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-yl)pyrimidin-2-amine (<b>4</b>)</h3><div class="NLM_p last"><i>N</i>-Ethyl-<i>N</i>-isopropylpropan-2-amine (0.496 mL, 2.86 mmol) was added to tetrahydro-2<i>H</i>-pyran-4-amine (0.265 g, 2.62 mmol) and 2-chloro-4-(2-fluoropyridin-4-yl)pyrimidine (0.50 g, 2.39 mmol) in 2-butanol (2 mL) in a sealed tube (microwave vial). The vial was sealed and heated at 100 °C in an oil bath overnight. The reaction mixture was evaporated, and the dark residue was treated with EtOAc (50 mL) and water (50 mL) and filtered through Celite, and the layers were separated. The EtOAc layer was washed with brine, dried over MgSO<sub>4</sub>, filtered, and evaporated. The crude product was purified by chromatography, eluting with 2:1 EtOAc/hexanes to give 4-(2-fluoropyridin-4-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-yl)pyrimidin-2-amine (0.32 g, 49% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.44 (d, <i>J</i> = 5.1 Hz, 1H), 8.34 (d, <i>J</i> = 6.0 Hz, 1H), 7.76–7.72 (m, 1H), 7.55–7.53 (m, 1H), 6.99 (d, <i>J</i> = 5.1 Hz, 1H), 5.38 (br, s, 1H), 4.21–4.11 (m, 1H), 4.07–3.98 (m, 2H), 3.64–3.54 (m, 2H), 2.16–2.06 (m, 2H), 1.68–1.53 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 275.1.</div></div><div id="sec8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 4-(2-((Tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>5</b>)</h3><div class="NLM_p last">HCl (1.0 M, 35 mL, 35 mmol) was added to 4-(2-fluoropyridin-4-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-yl)pyrimidin-2-amine (0.32 g, 1.2 mmol), and the mixture was heated at reflux overnight. The cooled reaction mixture was neutralized with solid NaHCO<sub>3</sub>. The resulting solid was collected by vacuum filtration, washed into a flask with EtOAc/MeOH, evaporated, and dried to afford 4-(2-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (0.30 g, 94% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.74 (br s, 1H), 8.40 (d, <i>J</i> = 5.0 Hz, 1H), 7.48 (d, <i>J</i> = 6.5 Hz, 1H), 7.33 (d, <i>J</i> = 7.5 Hz, 1H), 7.11 (d, <i>J</i> = 5.0 Hz, 1H), 6.99 (s, 1H), 6.85–6.76 (m, 1H), 4.04–3.92 (m, 1H), 3.92–3.85 (m, 2H), 3.45–3.36 (m, 2H), 1.90–1.81 (m, 2H), 1.59–1.48 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 273.1.</div></div><div id="sec8_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 1-Benzyl-4-(2-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>6a</b>)</h3><div class="NLM_p last">A mixture of 4-(2-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (0.030 g, 0.110 mmol), (bromomethyl)benzene (0.0144 mL, 0.121 mmol), and K<sub>2</sub>CO<sub>3</sub> (0.0305 g, 0.220 mmol) in DMF (1.10 mL) was stirred at room temperature for 12 h. The mixture was worked up with DCM (50 mL) and water (50 mL). The organics were extracted with DCM twice, washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The crude product was purified on reverse phase HPLC to give 1-benzyl-4-(2-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (0.0332 g, 66% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.85 (br s, 1H), 8.18 (s, 1H), 7.46 (d, <i>J</i> = 7.2 Hz, 1H), 7.39–7.31 (m, 6H), 7.04 (d, <i>J</i> = 6.0 Hz, 1H), 6.75 (d, <i>J</i> = 7.0 Hz, 1H), 5.21 (s, 2H), 4.22–4.18 (m, 1H), 4.06–4.00 (m, 2H), 3.58–3.50 (m, 2H), 2.04–2.00 (m, 2H), 1.82–1.78 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) = 363.2.</div></div><div id="sec8_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 1-(3-Chlorobenzyl)-4-(2-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>6b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.85 (br s, 1H), 8.24 (s, 1H), 7.42 (d, <i>J</i> = 7.0 Hz, 1H), 7.34–7.22 (m, 5H), 6.99 (d, <i>J</i> = 5.3 Hz, 1H), 6.78 (d, <i>J</i> = 7.0 Hz, 1H), 5.16 (s, 2H), 4.20–4.16 (m, 1H), 4.06–3.98 (m, 2H), 3.59–3.51 (m, 2H), 2.08–2.00 (m, 2H), 1.78–1.70 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) = 397.2, 399.2.</div></div><div id="sec8_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 1-(4-Chlorobenzyl)-4-(2-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>6c</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.82 (br s, 1H), 8.18 (s, 1H), 7.46 (d, <i>J</i> = 7.02 Hz, 1H), 7.36–7.26 (m, 5H), 7.04 (d, <i>J</i> = 6.0 Hz, 1H), 6.76 (d, <i>J</i> = 7.0 Hz, 1H), 5.16 (s, 2H), 4.22–4.18 (m, 1H), 4.06–3.98 (m, 2H), 3.58–3.50 (m, 2H), 2.06–1.98 (m, 2H), 1.84–1.76 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) = 397.2, 399.2.</div></div><div id="sec8_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 1-(3-Chloro-4-fluorobenzyl)-4-(2-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>6d</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.38 (br s, 1H), 8.21 (s, 1H), 7.46–7.38 (m, 2H), 7.28–7.20 (m, 2H), 7.16–7.12 (m, 1H), 7.01 (d, <i>J</i> = 5.2 Hz, 1H), 6.80–6.76 (m, 1H), 5.13 (s, 2H), 4.20–4.16 (m, 1H), 4.06–4.00 (m, 2H), 3.58–3.50 (m, 2H), 2.06–2.00 (m, 2H), 1.80–1.72 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) = 415.2, 417.2.</div></div><div id="sec8_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 1-(4-Chloro-3-fluorobenzyl)-4-(2-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>6e</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.32 (br s, 1H), 8.22 (s, 1H), 7.44–7.38 (m, 2H), 7.28–7.20 (m, 1H), 7.14–7.08 (m, 2H), 7.01 (d, <i>J</i> = 5.6 Hz, 1H), 6.80–6.76 (m, 1H), 5.15 (s, 2H), 4.21–4.17 (m, 1H), 4.07–4.01 (m, 2H), 3.58–3.50 (m, 2H), 2.06–2.00 (m, 2H), 1.82–1.76 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) = 415.2, 417.2.</div></div><div id="sec8_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 4-(2-Fluoropyridin-4-yl)-2-(methylthio)pyrimidine (<b>7</b>)</h3><div class="NLM_p last">A suspension of 4-bromo-2-(methylthio)pyrimidine (7.00 g, 34.1 mmol), 2-fluoropyridin-4-ylboronic acid (5.05 g, 35.8 mmol), Na<sub>2</sub>CO<sub>3</sub> (10.9 g, 102 mmol), and PdCl<sub>2</sub>(dppf)·DCM (1.40 g, 1.71 mmol) in dioxane/H<sub>2</sub>O (100 mL; 1:1) was heated to 85 °C under an Ar balloon for 2 h. The reaction mixture was cooled to room temperature and concentrated. The residue was diluted with EtOAc (200 mL) and water (100 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (1×). The organics were dried, filtered, and concentrated. The crude product was purified via column chromatography, eluting with hexanes/EtOAc (3:1) to give 4-(2-fluoropyridin-4-yl)-2-(methylthio)pyrimidine (6.83 g, 90%) as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.85 (d, <i>J</i> = 5.2 Hz, 1H), 8.46 (d, <i>J</i> = 5.2 Hz, 1H), 8.13–8.09 (m, 1H), 7.96 (d, <i>J</i> = 5.2 Hz, 1H), 7.92 (s, 1H), 2.62 (s, 3H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 222.1.</div></div><div id="sec8_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 4-(2-(Methylthio)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>8</b>)</h3><div class="NLM_p last">A suspension of 4-(2-fluoropyridin-4-yl)-2-(methylthio)pyrimidine (6.83 g, 30.9 mmol) in 2 N HCl (100 mL) was heated to reflux for 2 h. The reaction mixture was cooled to room temperature and placed in an ice bath. The pH was adjusted to about 7 with 2N NaOH (about 100 mL). The resulting solids were collected by filtration, washed with water, and dried to give 4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (5.07 g) as a solid. This material was placed in the thimble of a Soxhlet apparatus and was attached to a 1 L flask charged with EtOAc (500 mL). The material was continuously extracted for 3 days. The resulting white precipitate from the EtOAc layer was collected by filtration to give 4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (3.3 g, 49% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.85 (br, s, 1H), 8.75 (d, <i>J</i> = 5.0 Hz, 1H), 7.79 (d, <i>J</i> = 5.0 Hz, 1H), 7.54 (d, <i>J</i> = 7.0 Hz, 1H), 7.13 (s, 1H), 6.86 (d, <i>J</i> = 7.0 Hz, 1H), 2.58 (s, 3H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 220.0.</div></div><div id="sec8_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 2-(<i>tert</i>-Butyldimethylsilyloxy)-1-(3-chlorophenyl)ethanol (<b>9d</b>, R<sub>3</sub> = 3-Cl)</h3><div class="NLM_p last">A solution of 2-(<i>tert</i>-butyldimethylsilyloxy)acetaldehyde (2.00 g, 10.3 mmol) in dry THF (40 mL) was placed in an ice bath and to this was added 0.5 M (3-chlorophenyl)magnesium bromide (24.8 mL, 12.4 mmol) in THF dropwise via a syringe. The reaction mixture was stirred at 0 °C for 1 h and then carefully quenched by dropwise addition of water (5 mL). The reaction mixture was concentrated, and the residue was partitioned between EtOAc (100 mL) and saturated NH<sub>4</sub>Cl (50 mL). The layers were separated, and the organics were dried, filtered, and concentrated. The crude product was purified by column chromatography, eluting with hexanes/EtOAc (20:1) to give 2-(<i>tert</i>-butyldimethylsilyloxy)-1-(3-chlorophenyl)ethanol (2.55 g, 86%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39 (s, 1H), 7.29–7.21 (m, 3H), 4.75–4.69 (m, 1H), 3.79–3.73 (m, 1H), 3.55–3.48 (m, 1H), 2.95 (d, <i>J</i> = 1.8 Hz, 1H), 0.90 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H).</div></div><div id="sec8_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 2-(<i>tert</i>-Butyldimethylsilyloxy)-1-(3-chlorophenyl)ethylmethanesulfonate (<b>10d</b>, R<sub>3</sub> = 3-Cl)</h3><div class="NLM_p last">To a cold (0 °C) solution of 2-(<i>tert</i>-butyldimethylsilyloxy)-1-(3-chlorophenyl)ethanol (1.40 g, 4.88 mmol) in DCM (30 mL) was added triethylamine (1.02 mL, 7.32 mmol), followed by methanesulfonyl chloride (0.453 mL, 5.86 mmol). The reaction mixture was stirred at 0 °C for 1 h and then queched with water (5 mL). The layers were separated, and the organics were, dried, filtered, and concentrated to give 2-(<i>tert</i>-butyldimethylsilyloxy)-1-(3-chlorophenyl)ethylmethanesulfonate (1.70 g, 95%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38 (s, 1H), 7.37–7.26 (m, 3H), 5.54–5.49 (m, 1H), 3.96–3.89 (m, 1H), 3.83–3.77 (m, 1H), 2.95 (s, 3H), 0.88 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H).</div></div><div id="sec8_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 1-(2-(<i>tert</i>-Butyldimethylsilyloxy)-1-(3-chlorophenyl)ethyl)-4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>11d</b>, R<sub>3</sub> = 3-Cl)</h3><div class="NLM_p last">To a cooled (0 °C) suspension of 4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (0.556 g, 2.54 mmol) in THF (25 mL) was added 1.0 M of KHMDS (3.30 mL, 3.30 mmol) in THF. The reaction mixture was left at 0 °C for 10 min before 2-(<i>tert</i>-butyldimethylsilyloxy)-1-(3-chlorophenyl)ethylmethanesulfonate (1.76 g, 4.82 mmol) was added as a solution in THF (10 mL). The cold bath was removed, and the reaction mixture was heated to 55 °C for 40 h. The reaction mixture was cooled to room temperature and concentrated. The residue was taken up in EtOAc (100 mL) and washed with water (2 × 50 mL). The organics were dried, filtered, and concentrated. The crude product was purified via column chromatography, eluting with hexanes/EtOAc (3:1) to give 1-(2-(<i>tert</i>-butyldimethylsilyloxy)-1-(3-chlorophenyl)ethyl)-4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (0.79 g, 64%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.65 (d, <i>J</i> = 5.0 Hz, 1H), 7.52–7.45 (m, 2H), 7.37–7.27 (m, 4H), 6.87–6.82 (m, 1H), 6.28–6.24 (m, 1H), 4.41–4.33 (m, 1H), 4.26–4.21 (m, 1H), 2.64 (s, 3H), 0.88 (s, 9H), 0.06 (s, 3H), 0.01 (s, 3H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 488.1, 490.1.</div></div><div id="sec8_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 1-(2-(<i>tert</i>-Butyldimethylsilyloxy)-1-(3-chlorophenyl)ethyl)-4-(2-(methylsulfonyl)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>12d</b>, R<sub>3</sub> = 3-Cl)</h3><div class="NLM_p last">To a solution of 1-(2-(<i>tert</i>-butyldimethylsilyloxy)-1-(3-chlorophenyl)ethyl)-4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (0.79 g, 1.6 mmol) in 20 mL of DCM was added mCPBA (1.00 g, 4.0 mmol). The mixture was stirred at room temperature for 2 h and then quenched with saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (20 mL). The organics were washed with NaHCO<sub>3</sub> (1×), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The crude product was purified via column chromatography, eluting with hexanes/EtOAc (1:1) to give 1-(2-(<i>tert</i>-butyldimethylsilyloxy)-1-(3-chlorophenyl)ethyl)-4-(2-(methylsulfonyl)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (0.73 g, 87%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.06 (d, <i>J</i> = 5.4 Hz, 1H), 7.91 (d, <i>J</i> = 5.4 Hz, 1H), 7.57 (d, <i>J</i> = 7.5 Hz, 1H), 7.46 (s, 1H), 7.36–7.29 (m, 3H), 6.94–6.89 (m, 1H), 6.27–6.21 (m, 1H), 4.40–4.34 (m, 1H), 4.27–4.20 (m, 1H), 3.45 (s, 3H), 0.88 (s, 9H), 0.06 (s, 3H), 0.01 (s, 3H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 519.1, 521.1.</div></div><div id="sec8_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 1-(1-(3-Chlorophenyl)-2-hydroxyethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>14d</b>)</h3><div id="sec8_15_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Step 1</h4><div class="NLM_p last">A solution of 1-(2-(<i>tert</i>-butyldimethylsilyloxy)-1-(3-chlorophenyl)ethyl)-4-(2-(methylsulfonyl)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (0.73 g, 1.4 mmol) and tetrahydro-2<i>H</i>-pyran-4-amine (0.21 g, 2.1 mmol) in <i>sec</i>-BuOH (4 mL) was heated to 120 °C for 4 h in a sealed tube. The reaction mixture was cooled to room temperature and concentrated. The crude 1-(2-(<i>tert</i>-butyldimethylsilyloxy)-1-(3-chlorophenyl)ethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>13d</b>, R<sub>3</sub> = 3-Cl) was used without purification in Step 2. <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 541.2, 542.2.</div></div><div id="sec8_15_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Step 2</h4><div class="NLM_p last">A solution of 1-(2-(<i>tert</i>-butyldimethylsilyloxy)-1-(3-chlorophenyl)ethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (0.76 g, 1.40 mmol) in THF (20 mL) was treated with 1.0 M of TBAF (1.69 mL, 1.69 mmol) in THF at room temperature for 30 min. The reaction mixture was concentrated, and the residue was taken up with EtOAc (50 mL) and water (20 mL). The layers were separated, and the organic layer was washed with water (1×). The combined organics were dried, filtered, and concentrated. The crude product was purified via column chromatography, eluting with EtOAc to give 1-(1-(3-Chlorophenyl)-2-hydroxyethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (0.40 g, 67%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (d, <i>J</i> = 5.0 Hz, 1H), 7.42–7.35 (m, 2H), 7.35–7.30 (m, 2H), 7.27–7.23 (m, 1H), 7.19 (s, 1H), 6.89 (d, <i>J</i> = 5.0 Hz, 1H), 6.81–6.73 (m, 1H), 6.29–6.18 (m, 1H), 5.15 (d, <i>J</i> = 8.0 Hz, 1H), 4.38–4.27 (m, 2H), 4.16–4.04 (m, 1H), 4.03–3.96 (m, 2H), 3.61–3.50 (m, 2H), 2.65–2.55 (m, 1H), 2.13–2.00 (m, 2H), 1.66–1.50 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 427.1, 429.1.</div></div></div><div id="sec8_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 1-(2-Hydroxy-1-phenylethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>14a</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (d, <i>J</i> = 5.1 Hz, 1H), 7.46–7.30 (m, 6H), 7.19 (s, 1H), 6.87 (d, <i>J</i> = 5.2 Hz, 1H), 6.78–6.71 (m, 1H), 6.35–6.27 (m, 1H), 4.39–4.30 (m, 2H), 4.15–4.04 (m, 1H), 4.04–3.95 (m, 2H), 3.60–3.50 (m, 2H), 2.84 (br, s, 1H), 2.09–2.01 (m, 2H), 1.65–1.51 (m, 3H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 393.2.</div></div><div id="sec8_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 1-(1-(2-Chlorophenyl)-2-hydroxyethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>14b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.41 (d, <i>J</i> = 5.0 Hz, 1H), 7.64–7.63 (m, 1H), 7.51–7.48 (m, 2H), 7.41–7.33 (m, 3H), 7.14 (d, <i>J</i> = 5.2 Hz, 1H), 7.09 (s, 1H), 6.84 (d, <i>J</i> = 7.2 Hz, 1H), 6.17–6.14 (m, 1H), 5.40–5.37 (m, 1H), 4.08–3.97 (m, 3H), 3.89–3.86 (m, 2H), 3.43–3.37 (m, 2H), 1.87–1.83 (m, 2H), 1.58–1.48 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 427.1, 429.1.</div></div><div id="sec8_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 1-(1-(4-Chlorophenyl)-2-hydroxyethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>14c</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (d, <i>J</i> = 4.6 Hz, 1H), 7.41–7.28 (m, 5H), 7.17 (s, 1H), 6.87 (d, <i>J</i> = 5.2 Hz, 1H), 6.79–6.71 (m, 1H), 6.27–6.19 (m, 1H), 5.18 (d, <i>J</i> = 6.8 Hz, 1H), 4.35–4.26 (m, 2H), 4.14–4.04 (m, 1H), 4.04–3.94 (m, 2H), 3.61–3.50 (m, 2H), 2.89 (br, s, 1H), 2.10–2.01 (m, 2H), 1.64–1.50 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 427.1, 429.1.</div></div><div id="sec8_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 1-(1-(3-Fluorophenyl)-2-hydroxyethyl)-4-(2-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>14e</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (d, <i>J</i> = 5.0 Hz, 1H), 7.40–7.33 (m, 2H), 7.17–7.01 (m, 4H), 6.87 (d, <i>J</i> = 5.2 Hz, 1H), 6.78–6.76 (m, 1H), 6.28–6.25 (m, 1H), 5.20 (d, <i>J</i> = 8.2 Hz, 1H), 4.32–4.31 (m, 2H), 4.13–4.06 (m, 1H), 4.02–3.98 (m, 2H), 3.59–3.52 (m, 2H), 3.11–3.08 (m, 1H), 2.07–2.04 (m, 2H), 1.63–1.53 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 411.1.</div></div><div id="sec8_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 1-(2-Hydroxy-1-<i>m</i>-tolylethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>14f</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.41 (d, <i>J</i> = 5.0 Hz, 1H), 7.85 (d, <i>J</i> = 7.0 Hz, 1H), 7.34 (d, <i>J</i> = 7.2 Hz, 1H), 7.26–7.22 (m, 1H), 7.15–7.09 (m, 5H), 6.86–6.84 (m, 1H), 6.03–5.99 (m, 1H), 5.22–5.20 (m, 1H), 4.17–4.11 (m, 1H), 4.03–3.97 (m, 2H), 3.89–3.86 (m, 2H), 3.43–3.37 (m, 2H), 2.28 (s, 3H), 1.87–1.84 (m, 2H), 1.57–1.49 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 407.1.</div></div><div id="sec8_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 1-(2-Hydroxy-1-(3-(trifluoromethyl)phenyl)ethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>14g</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42 (d, <i>J</i> = 5.0 Hz, 1H), 7.93 (d, <i>J</i> = 7.2 Hz, 1H), 7.70–7.68 (m, 2H), 7.62–7.61 (m, 2H), 7.35 (d, <i>J</i> = 8.0 Hz, 1H), 7.16 (d, <i>J</i> = 5.2 Hz, 1H), 7.11 (s, 1H), 6.89 (d, <i>J</i> = 8.2 Hz, 1H), 6.07–6.03 (m, 1H), 5.35–5.33 (m, 1H), 4.25–4.19 (m, 1H), 4.12–4.06 (m, 1H), 4.02–3.95 (m, 1H), 3.89–3.86 (m, 2H), 3.43–3.37 (m, 2H), 1.87–1.84 (m, 2H), 1.58–1.49 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 461.1.</div></div><div id="sec8_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 1-(2-Hydroxy-1-(3-methoxyphenyl)ethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>14h</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.41 (d, <i>J</i> = 5.0 Hz, 1H), 7.87 (d, <i>J</i> = 8.0 Hz, 1H), 7.34 (d, <i>J</i> = 8.2 Hz, 1H), 7.29–7.25 (m, 1H), 7.14 (d, <i>J</i> = 6.0 Hz, 1H), 7.09 (s, 1H), 6.89–6.84 (m, 4H), 6.03–6.01 (m, 1H), 5.23–5.20 (m, 1H), 4.18–4.11 (m, 1H), 4.04–3.96 (m, 2H), 3.89–3.86 (m, 2H), 3.73 (s, 3H), 3.43–3.37 (m, 2H), 1.87–1.84 (m, 2H), 1.58–1.48 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 423.1.</div></div><div id="sec8_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 3-(2-Hydroxy-1-(2-oxo-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-1(2<i>H</i>)-yl)ethyl)benzonitrile (<b>14i</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42 (d, <i>J</i> = 5.0 Hz, 1H), 7.92 (d, <i>J</i> = 7.0 Hz, 1H), 7.84 (s, 1H), 7.79 (d, <i>J</i> = 8.0 Hz, 1H), 7.64 (d, <i>J</i> = 7.2 Hz, 1H), 7.60–7.56 (m, 1H), 7.36–7.34 (m, 1H), 7.16 (d, <i>J</i> = 5.0 Hz, 1H), 7.10 (s, 1H), 6.89 (d, <i>J</i> = 7.0 Hz, 1H), 6.02–5.99 (m, 1H), 5.35–5.33 (m, 1H), 4.22–4.16 (m, 1H), 4.10–4.04 (m, 1H), 4.02–3.95 (m, 1H), 3.89–3.86 (m, 2H), 3.43–3.37 (m, 2H), 1.87–1.84 (m, 2H), 1.57–1.49 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 418.1.</div></div><div id="sec8_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 1-(1-(3,4-Difluorophenyl)-2-hydroxyethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>14j</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42 (d, <i>J</i> = 5.0 Hz, 1H), 7.88 (d, <i>J</i> = 7.3 Hz, 1H), 7.50–7.34 (m, 3H), 7.18–7.14 (m, 2H), 7.10 (s, 1H), 6.87 (d, <i>J</i> = 8.7 Hz, 1H), 5.99–5.96 (m, 1H), 5.31–5.29 (m, 1H), 4.18–4.12 (m, 1H), 4.05–3.96 (m, 2H), 3.89–3.87 (m, 2H), 3.43–3.37 (m, 2H), 1.87–1.84 (m, 2H), 1.58–1.49 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 429.1.</div></div><div id="sec8_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((tetrahydro-2<i>H</i>-pyran-4-ylamino))pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>14k</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (d, <i>J</i> = 5.0 Hz, 1H), 7.42–7.38 (m, 2H), 7.22–7.18 (m, 2H), 7.10 (d, <i>J</i> = 8.2 Hz, 1H), 6.88 (d, <i>J</i> = 5.0 Hz, 1H), 6.80–6.76 (m, 1H), 6.22–6.18 (m, 1H), 5.16 (d, <i>J</i> = 8.0 Hz, 1H), 4.34–4.28 (m, 2H), 4.12–4.08 (m, 1H), 4.04–3.96 (m, 2H), 3.58–3.52 (m, 2H), 2.74 (br, s, 1H), 2.09–2.03 (m, 2H), 1.62–1.56 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 445.1, 447.0.</div></div><div id="sec8_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 1-(1-(3-Chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(2-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>14l</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (d, <i>J</i> = 5.0 Hz, 1H), 7.47–7.44 (m, 1H), 7.38 (d, <i>J</i> = 7.8 Hz, 1H), 7.29–7.24 (m, 1H), 7.18–7.14 (m, 2H), 6.88 (d, <i>J</i> = 8.7 Hz, 1H), 6.80–6.77 (m, 1H), 6.21–6.17 (m, 1H), 5.17–5.14 (m, 1H), 4.32–4.29 (m, 2H), 4.15–4.08 (m, 1H), 4.03–3.98 (m, 2H), 3.60–3.52 (m, 2H), 2.70–2.66 (m, 1H), 2.09–2.03 (m, 2H), 1.63–1.53 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 445.1, 447.0.</div></div><div id="sec8_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 1-(1-(3,5-Difluorophenyl)-2-hydroxyethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>14m</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42 (d, <i>J</i> = 6.2 Hz, 1H), 7.91(d, <i>J</i> = 7.0 Hz, 1H), 7.35 (d, <i>J</i> = 8.0 Hz, 1H), 7.23–7.15 (m, 2H), 7.11 (s, 1H), 7.09–7.04 (m, 2H), 6.89 (d, <i>J</i> = 7.2 Hz, 1H), 5.99–5.96 (m, 1H), 5.34–5.31 (m, 1H), 4.19–4.13 (m, 1H), 4.08–3.95 (m, 2H), 3.89–3.87 (m, 2H), 3.43–3.37 (m, 2H), 1.87–1.84 (m, 2H), 1.59–1.49 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 429.1.</div></div><div id="sec8_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 1-(1-(3,5-Dichlorophenyl)-2-hydroxyethyl)-4-(2-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>14n</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42 (d, <i>J</i> = 5.1 Hz, 1H), 7.95 (d, <i>J</i> = 7.5 Hz, 1H), 7.57 (s, 1H), 7.39 (d, <i>J</i> = 1.7 Hz, 2H), 7.35 (d, <i>J</i> = 7.5 Hz, 1H), 7.16 (d, <i>J</i> = 5.1 Hz, 1H), 7.11 (d, <i>J</i> = 1.5 Hz, 1H), 6.90 (d, <i>J</i> = 6.0 Hz, 1H), 5.94–5.91 (m, 1H), 5.36–5.33 (m, 1H), 4.21–4.14 (m, 1H), 4.09–3.95 (m, 2H), 3.89–3.86 (m, 2H), 3.43–3.37 (m, 2H), 1.88–1.84 (m, 2H), 1.58–1.49 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 461.1, 463.1.</div></div><div id="sec8_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 1-(1-(3-Chloro-5-fluorophenyl)-2-hydroxyethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>14o</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42 (d, <i>J</i> = 5.2 Hz, 1H), 7.93 (d, <i>J</i> = 7.1 Hz, 1H), 7.42–7.34 (m, 2H), 7.25 (s, 1H), 7.20 (d, <i>J</i> = 9.4 Hz, 1H), 7.16 (d, <i>J</i> = 5.1 Hz, 1H), 7.11 (d, <i>J</i> = 1.9 Hz, 1H), 6.89 (d, <i>J</i> = 7.4 Hz, 1H), 5.97–5.94 (m, 1H), 5.35–5.32 (m, 1H), 4.20–4.14 (m, 1H), 4.07–3.97 (m, 2H), 3.90–3.86 (m, 2H), 3.43–3.37 (m, 2H), 1.87–1.85 (m, 2H), 1.58–1.49 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 445.1, 447.1.</div></div><div id="sec8_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 1-Chloro-2-fluoro-4-vinylbenzene (<b>15</b>)</h3><div class="NLM_p last">Sodium hydride (8.549 g, 213.7 mmol, 60% suspension in mineral oil) was added portionwise to a cold (0 °C) solution of 4-chloro-3-fluorobenzaldehyde (26.07 g, 164.4 mmol) and methyltriphenylphosphonium bromide (70.48 g, 197.3 mmol) in THF (400 mL). The reaction mixture was allowed to warm up to room temperature overnight. The solids were removed by filtration, and the filter cake was washed with ether (400 mL). The filtrate was concentrated (water bath about 20 °C), and the residue was suspended in hexanes (200 mL) and stirred for 30 min. The solids (mostly PPh<sub>3</sub>O) were removed by filtration, and the filter cake was washed with hexanes (200 mL). The filtrate was concentrated, and the crude product was purified by column chromatography, eluting with hexanes/EtOAc (25:1) to give 1-chloro-2-fluoro-4-vinylbenzene (12.1 g, 47%) as an oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.35–7.27 (m, 1H), 7.22–7.14 (m, 1H), 7.12–7.06 (m, 1H), 6.67–6.57 (m, 1H), 5.74 (d, <i>J</i> = 17.4 Hz, 1H), 5.32 (d, <i>J</i> = 10.8 Hz, 1H).</div></div><div id="sec8_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (<i>R</i>)-1-(4-Chloro-3-fluorophenyl)ethane-1,2-diol (<b>16</b>)</h3><div class="NLM_p last">1-Chloro-2-fluoro-4-vinylbenzene (9.40 g, 60.0 mmol) was added to a cold (0 °C) solution of AD-mix-β (84.2 g, 108 mmol) in <i>t</i>-BuOH/H<sub>2</sub>O (700 mL; 1:1), and the mixture was allowed to warm up to room temperature overnight. The next day, the reaction was placed in an ice bath and quenched with 10% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (200 mL). The mixture was stirred for 1 h and then extracted with EtOAc (3 × 500 mL). The combined organics were dried, filtered, and concentrated. The crude product was purified via column chromatography, eluting with DCM/EtOA (1:1) to give give (<i>R</i>)-1-(4-chloro-3-fluorophenyl)ethane-1,2-diol as an oil. (7.35 g, 64%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.59–7.42 (m, 1H), 7.38–7.29 (m, 1H), 7.23–7.18 (m, 1H), 5.45 (d, <i>J</i> = 4.8 Hz, 1H), 4.79–4.72 (m, 1H), 4.59–4.51 (m, 1H), 3.49–3.36 (m, 2H).</div></div><div id="sec8_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (<i>R</i>)-2-(<i>tert</i>-Butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethanol (<b>17</b>)</h3><div class="NLM_p last">Imidazole (0.911 g, 13.4 mmol) was added to a cold (0 °C) solution of (<i>R</i>)-1-(4-chloro-3-fluorophenyl)ethane-1,2-diol (1.02 g, 5.35 mmol) in DCM (20 mL), followed by TBSCl (0.968 g, 6.42 mmol). The reaction mixture was stirred at 0 °C for 1 h and then quenched with water (50 mL). The layers were separated, and the organics were dried, filtered, and concentrated. The crude product was purified via column chromatography, eluting with hexanes/EtOAc (100:1) to give (<i>R</i>)-2-(<i>tert</i>-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethanol (0.95 g, 58%; 95% enantiomeric excess (“ee”) by chiral HPLC (Chiral Tech, column IA, 4.6 mm × 250 mm, 5 μ, 10% ethanol/90% hexanes, 1 mL/min, retention time for (<i>S</i>)-<b>17</b>, 7.5 min; retention time for (<i>R</i>)-<b>17</b>, 8.4 min). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38–7.34 (m, 1H), 7.22–7.18 (m, 1H), 7.10–7.06 (m, 1H), 4.73–4.69 (m, 1H), 3.77–3.73 (m, 1H), 3.51–3.47 (m, 1H), 2.96 (d, <i>J</i> = 2.6 Hz, 1H), 0.90 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H).</div></div><div id="sec8_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (<i>R</i>)-2-(<i>tert</i>-Butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethylmethanesulfonate (<b>18</b>)</h3><div class="NLM_p last">Triethylamine (2.09 mL, 15.0 mmol) was added to a cold (0 °C) solution of (<i>R</i>)-2-(<i>tert</i>-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethanol (3.05 g, 10.0 mmol) in DCM (100 mL), followed by methanesulfonyl chloride (0.929 mL, 12.0 mmol). The reaction mixture was stirred at 0 °C for 30 min and then quenched with water (50 mL). The layers were separated, and the organic layer was washed with saturated NaHCO<sub>3</sub>, dried, filtered, and concentrated. The crude product was purified via column chromatography, eluting with hexanes/EtOAc (25:1) to give (<i>R</i>)-2-(<i>tert</i>-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethylmethanesulfonate (3.80 g, 99%) as an oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.44–7.40 (m, 1H), 7.22–7.18 (m, 1H), 7.14–7.10 (m, 1H), 5.52–5.48 (m, 1H), 3.93–3.90 (m, 1H), 3.82–3.78 (m, 1H), 2.98 (s, 3H), 0.88 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H).</div></div><div id="sec8_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (<i>S</i>)-1-(2-(<i>tert</i>-Butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>19</b>)</h3><div class="NLM_p last">KHMDS (1.0 M, 5.09 mL, 5.09 mmol) in THF was added to a cold (0 °C) suspension of 4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (0.93 g, 4.24 mmol) in THF (20 mL). The reaction mixture was stirred at 0 °C for 10 min before (<i>R</i>)-2-(<i>tert</i>-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethylmethanesulfonate (2.44 g, 6.36 mmol) was added as a solution in THF (5 mL). The reaction was heated to reflux for 30 h and then cooled to room temperature and concentrated. The residue was taken up in EtOAc (200 mL) and washed with water (100 mL). The organics were dried, filtered, and concentrated. The crude product was purified via column chromatography, eluting with hexanes/EtOAc (4:1) to give (<i>S</i>)-1-(2-(<i>tert</i>-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (1.35 g, 63%) as a solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.66 (d, <i>J</i> = 5.0 Hz, 1H), 7.47–7.41 (m, 2H), 7.34 (d, <i>J</i> = 5.0 Hz, 1H), 7.32–7.28 (m, 2H), 7.18–7.14 (m, 1H), 6.87–6.83 (m, 1H), 6.26–6.22 (m, 1H), 4.37–4.33 (m, 1H), 4.25–4.21 (m, 1H), 2.65 (s, 3H), 0.88 (s, 9H), 0.03 (s, 3H), −0.03 (s, 3H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 506.1, 508.1.</div></div><div id="sec8_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (<i>S</i>)-1-(2-(<i>tert</i>-Butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-(methylsulfonyl)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>20</b>)</h3><div class="NLM_p last"><i>m</i>CPBA (7.1 g, 29 mmol) was added to a cold (0 °C) solution of (<i>S</i>)-1-(2-(<i>tert</i>-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-(methylthio) pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (5.8 g, 11 mmol) in DCM (100 mL), and the mixture was stirred for 2 h. The reaction mixture was washed with saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (1×), saturated NaHCO<sub>3</sub> (1×), dried, filtered, and evaporated. The crude product was purified via column chromatography, eluting with hexanes/EtOAc (1:1) to give (<i>S</i>)-1-(2-(<i>tert</i>-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-(methylsulfonyl)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (5.5 g, 89%) as a solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.06 (d, <i>J</i> = 5.2 Hz, 1H), 7.91 (d, <i>J</i> = 5.4 Hz, 1H), 7.55 (d, <i>J</i> = 7.4 Hz, 1H), 7.45–7.41 (m, 1H), 7.32 (d, <i>J</i> = 2.4 Hz, 1H), 7.29–7.25 (m, 1H), 7.17–7.13 (m, 1H), 6.95–6.91 (m, 1H), 6.24–6.20 (m, 1H), 4.37–4.33 (m, 1H), 4.26–4.22 (m, 1H), 3.45 (s, 3H), 0.88 (s, 9H), 0.03 (s, 3H), −0.03 (s, 3H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 538.1, 540.0.</div></div><div id="sec8_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((tetrahydro-2<i>H</i>-pyran-4-ylamino))pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one ((<i>S</i>)-<b>14k</b>)</h3><div id="sec8_36_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Step 1</h4><div class="NLM_p last">A suspension of (<i>S</i>)-1-(2-(<i>tert</i>-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-(methylsulfonyl)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (5.77 g, 10.7 mmol) and tetrahydro-2<i>H</i>-pyran-4-amine (2.17 g, 21.4 mmol) in <i>sec</i>-BuOH (30 mL) was heated to 120 °C for 4 h in a sealed tube. The reaction mixture was cooled to room temperature and concentrated. The crude (<i>S</i>)-1-(2-(<i>tert</i>-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one was used without purification in Step 2. <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 559.2, 560.2.</div></div><div id="sec8_36_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Step 2</h4><div class="NLM_p last">A solution of (<i>S</i>)-1-(2-(<i>tert</i>-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (6.00 g, 10.7 mmol) in THF (20 mL) was treated with 1.0 M TBAF in THF (12.9 mL, 12.9 mmol) at room temperature for 30 min. The reaction mixture was concentrated, and the residue was taken up with EtOAc (50 mL) and water (50 mL). The organic layer was washed with water (1×). The combined organics were dried, filtered, and concentrated. The crude product was purified via column chromatography, eluting with EtOAc to give (<i>S</i>)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((tetrahydro-2<i>H</i>-pyran-4-ylamino))pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one as a solid (4.14 g, 87% over 2 steps; 96% enantiomeric excess (“ee”) by chiral HPLC (Chiral Tech, column OJ-H, 4.6 mm × 250 mm, 5 μ, 30% ethanol/70% hexanes, 1 mL/min, retention time for (<i>S</i>)-<b>14k</b>, 11.1 min; retention time for (<i>R</i>)-<b>14k</b>, 14.9 min). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (d, <i>J</i> = 5.0 Hz, 1H), 7.42–7.38 (m, 2H), 7.22–7.18 (m, 2H), 7.10 (d, <i>J</i> = 8.2 Hz, 1H), 6.88 (d, <i>J</i> = 5.0 Hz, 1H), 6.80–6.76 (m, 1H), 6.22–6.18 (m, 1H), 5.16 (d, <i>J</i> = 8.0 Hz, 1H), 4.34–4.28 (m, 2H), 4.12–4.08 (m, 1H), 4.04–3.96 (m, 2H), 3.58–3.52 (m, 2H), 2.74 (br, s, 1H), 2.09–2.03 (m, 2H), 1.62–1.56 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 445.1, 447.0.</div></div></div><div id="sec8_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> (<i>S</i>)-1-(1-(3-Chlorophenyl)-2-hydroxyethyl)-4-(2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one ((<i>S</i>)-<b>14d</b>)</h3><div class="NLM_p last">Enantiomeric excess (“ee”) 88% by chiral HPLC (Chiral Tech, column OD-H, 4.6 mm × 250 mm, 5 μ, 20% ethanol/80% hexanes, 1 mL/min, retention time for (<i>S</i>)-<b>14d</b>, 20.0 min; retention time for (<i>R</i>)-<b>14d</b>, 25.1 min) <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (d, <i>J</i> = 5.0 Hz, 1H), 7.42–7.35 (m, 2H), 7.35–7.30 (m, 2H), 7.27–7.23 (m, 1H), 7.19 (s, 1H), 6.89 (d, <i>J</i> = 5.0 Hz, 1H), 6.81–6.73 (m, 1H), 6.29–6.18 (m, 1H), 5.15 (d, <i>J</i> = 8.0 Hz, 1H), 4.38–4.27 (m, 2H), 4.16–4.04 (m, 1H), 4.03–3.96 (m, 2H), 3.61–3.50 (m, 2H), 2.65–2.55 (m, 1H), 2.13–2.00 (m, 2H), 1.66–1.50 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 427.1, 429.1.</div></div><div id="sec8_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> (<i>S</i>)-1-(1-(3-Fluorophenyl)-2-hydroxyethyl)-4-(2-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one ((<i>S</i>)-<b>14e</b>)</h3><div class="NLM_p last">Enantiomeric excess (“ee”) 86% by chiral HPLC (Chiral Tech, column OD-H, 4.6 mm × 250 mm, 5 μ, 20% ethanol/80% hexanes, 1 mL/min, retention time for (<i>S</i>)-<b>14e</b>, 10.3 min; retention time for (<i>R</i>)-<b>14e</b>, 13.1 min). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (d, <i>J</i> = 5.0 Hz, 1H), 7.40–7.33 (m, 2H), 7.17–7.01 (m, 4H), 6.87 (d, <i>J</i> = 5.2 Hz, 1H), 6.78–6.76 (m, 1H), 6.28–6.25 (m, 1H), 5.20 (d, <i>J</i> = 8.2 Hz, 1H), 4.32–4.31 (m, 2H), 4.13–4.06 (m, 1H), 4.02–3.98 (m, 2H), 3.59–3.52 (m, 2H), 3.11–3.08 (m, 1H), 2.07–2.04 (m, 2H), 1.63–1.53 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 411.1.</div></div><div id="sec8_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> (<i>S</i>)-1-(1-(3-Chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(2-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one ((<i>S</i>)-<b>14l</b>)</h3><div class="NLM_p last">Enantiomeric excess (“ee”) 82% by chiral HPLC (Chiral Tech, column OJ-H, 4.6 mm × 250 mm, 5 μ, 15% ethanol/85% hexanes, 1 mL/min, retention time for (<i>S</i>)-<b>14l</b>, 18.8 min; retention time for (<i>R</i>)-<b>14l</b>, 22.6 min). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (d, <i>J</i> = 5.0 Hz, 1H), 7.47–7.44 (m, 1H), 7.38 (d, <i>J</i> = 7.8 Hz, 1H), 7.29–7.24 (m, 1H), 7.18–7.14 (m, 2H), 6.88 (d, <i>J</i> = 8.7 Hz, 1H), 6.80–6.77 (m, 1H), 6.21–6.17 (m, 1H), 5.17–5.14 (m, 1H), 4.32–4.29 (m, 2H), 4.15–4.08 (m, 1H), 4.03–3.98 (m, 2H), 3.60–3.52 (m, 2H), 2.70–2.66 (m, 1H), 2.09–2.03 (m, 2H), 1.63–1.53 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 445.1, 447.0.</div></div><div id="sec8_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 1-((<i>S</i>)-1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((<i>R</i>)-tetrahydrofuran-3-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>22a</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (d, <i>J</i> = 5.2 Hz, 1H), 7.42–7.38 (m, 2H), 7.21–7.09 (m, 3H), 6.88 (d, <i>J</i> = 5.0 Hz, 1H), 6.80 (d, <i>J</i> = 9.0 Hz, 1H), 6.21–6.19 (m, 1H), 5.48 (d, <i>J</i> = 7.2 Hz, 1H), 4.64–4.58 (m, 1H), 4.30 (s, 2H), 4.03–3.97 (m, 2H), 3.90–3.84 (m, 1H), 3.78–3.74 (m, 1H), 3.26 (s, 1H), 2.39–2.30 (m, 1H), 1.94–1.87 (m, 1H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 431.1, 433.1.</div></div><div id="sec8_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 1-(<i>S</i>)-1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((<i>S</i>)-tetrahydrofuran-3-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>22b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (d, <i>J</i> = 5.2 Hz, 1H), 7.42–7.36 (m, 2H), 7.22–7.09 (m, 3H), 6.88 (d, <i>J</i> = 5.0 Hz, 1H), 6.80–6.79 (m, 1H), 6.22–6.19 (m, 1H), 5.51 (d, <i>J</i> = 7.2 Hz, 1H), 4.64–4.58 (m, 1H), 4.30–4.29 (m, 2H), 4.02–3.96 (m, 2H), 3.90–3.84 (m, 1H), 3.76–3.73 (m, 1H), 3.34 (s, 1H), 2.38–2.30 (m, 1H), 1.94–1.87 (m, 1H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 431.1, 433.1.</div></div><div id="sec8_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(oxetan-3-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>22c</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.45 (d, <i>J</i> = 5.1 Hz, 1H), 8.10 (d, <i>J</i> = 5.9 Hz, 1H), 7.89 (d, <i>J</i> = 7.4 Hz, 1H), 7.60–7.56 (m, 1H), 7.44 (d, <i>J</i> = 12.4 Hz, 1H), 7.24 (d, <i>J</i> = 5.1 Hz, 1H), 7.16 (d, <i>J</i> = 8.6 Hz, 1H), 7.12 (s, 1H), 6.88 (d, <i>J</i> = 9.1 Hz, 1H), 5.99–5.96 (m, 1H), 5.33–5.31 (m, 1H), 4.99–4.94 (m, 1H), 4.81–4.77 (m, 2H), 4.57–4.54 (m, 2H), 4.19–4.13 (m, 1H), 4.07–4.02 (m, 1H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 417.1, 419.1.</div></div><div id="sec8_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(3,3-difluorocyclobutylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>22d</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.47 (d, <i>J</i> = 5.2 Hz, 1H), 7.90–7.87 (m, 2H), 7.60–7.56 (m, 1H), 7.45–7.43 (m, 1H), 7.25 (d, <i>J</i> = 5.0 Hz, 1H), 7.17–7.13 (m, 2H), 6.90–6.89 (m, 1H), 6.00–5.96 (m, 1H), 5.33–5.31 (m, 1H), 4.28–4.12 (m, 2H), 4.07–4.02 (m, 1H), 3.02–2.92 (m, 2H), 2.74–2.61 (m, 2H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 451.1, 453.1.</div></div><div id="sec8_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-2-(((<i>R</i>,<i>S</i>)-2-methyl-tetrahydro-2<i>H</i>-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>22e</b>)</h3><div class="NLM_p last">Isolated as a mixture of two diastereomers (formate salt). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (br s, 1H), 7.45–7.32 (m, 2H), 7.24–7.04 (m, 3H), 6.94–6.73 (m, 2H), 6.22–6.18 (m, 1H), 5.57 (br s, 1H), 4.33 (d, <i>J</i> = 4.5 Hz, 3H), 3.91–3.87 (m, 1H), 3.78–3.74 (m, 2H), 2.03–1.52 (m, 4H), 1.21 (d, <i>J</i> = 6.1 Hz, 3H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 459.1, 460.1.</div></div><div id="sec8_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 1-((<i>S</i>)-1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-2-(((<i>R,S</i>)-1,1-dioxidotetrahydrothiophen-3-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>22f</b>)</h3><div class="NLM_p last">Isolated as a mixture of two diastereomers. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.48–8.24 (m, 1H), 7.50–7.32 (m, 2H), 7.22–7.15 (m, 1H), 7.13–7.02 (m, 2H), 6.99–6.87 (m, 1H), 6.81–6.72 (m, 1H), 6.24–6.15 (m, 1H), 5.99–5.89 (m, 0.5H), 5.73–5.66 (m, 0.5H), 4.94–4.79 (m, 1H), 4.38–4.24 (m, 2H), 3.63–3.51 (m, 1H), 3.48–3.27 (m, 2H), 3.26–3.08 (m, 2H), 2.72–2.58 (m, 1H), 2.47–2.34 (m, 1H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 479.0, 480.1.</div></div><div id="sec8_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(((<i>S</i>)-4-methoxybutan-2-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>22g</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.35 (br s, 1H), 7.45–7.32 (m, 2H), 7.22–7.18 (m, 2H), 7.12–7.08 (m, 1H), 6.83 (d, <i>J</i> = 5.4 Hz, 2H), 6.20 (t, <i>J</i> = 5.3 Hz, 1H), 5.51 (br s, 1H), 4.28 (d, <i>J</i> = 6.0 Hz, 3H), 3.62–3.40 (m, 2H), 1.96–1.67 (m, 2H), 1.28 (d, <i>J</i> = 6.6 Hz, 1H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 447.1, 449.1.</div></div><div id="sec8_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(1,3-difluoropropan-2-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>22h</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.41 (d, <i>J</i> = 4.7 Hz, 1H), 7.46–7.35 (m, 2H), 7.23–7.14 (m, 2H), 7.10 (d, <i>J</i> = 8.5 Hz, 1H), 6.97 (d, <i>J</i> = 4.8 Hz, 1H), 6.80 (d, <i>J</i> = 7.0 Hz, 1H), 6.22–6.15 (m, 1H), 5.50 (br, s, 1H), 4.78–4.71 (m, 1H), 4.69–4.59 (m, 3H), 4.57–4.49 (m, 1H), 4.33–4.28 (m, 2H), 2.67 (br, s, 1H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 439.1, 441.1.</div></div><div id="sec8_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 1-((<i>S</i>)-1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((<i>R</i>)-1-hydroxy-3-methoxypropan-2-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>22i</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.38 (d, <i>J</i> = 4.3 Hz, 1H), 7.81 (d, <i>J</i> = 7.2 Hz, 1H), 7.51–7.43 (m, 1H), 7.34–7.27 (m, 1H), 7.24 (s, 1H), 7.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.11–7.07 (m, 1H), 7.03 (d, <i>J</i> = 7.0 Hz, 1H), 6.15–6.07 (m, 1H), 4.36–4.22 (m, 2H), 4.21–4.14 (m, 1H), 3.73–3.65 (m, 2H), 3.64–3.52 (m, 2H), 3.37 (s, 3H); <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 449.1, 451.1.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i75"><a href="/doi/suppl/10.1021/jm501921k">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70104" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70104" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Experimental procedures for the synthesis of <b>6f</b>, <b>23a</b>–<b>23f</b>, and <b>24a</b>–<b>24e</b>, biological assay information, kinase selectivity of (<i>S</i>)-<b>14k</b>, Cerep panel of receptor selectivity of (<i>S</i>)-<b>14k</b>, protein expression and purification of ERK2 protein constructs for crystallography, crystal structure determination of ERK2 complex with (<i>S</i>)-<b>14k</b>.  This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm501921k/suppl_file/jm501921k_si_001.pdf">jm501921k_si_001.pdf (647.12 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm501921k" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35654" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35654" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Ren</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4c2025623e29220c2d3e3e2d352e25233c242d3e212d622f2321"><span class="__cf_email__" data-cfemail="1e7277306c7b705e7f6c6c7f677c77716e767f6c737f307d7173">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonas Grina</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Moreno</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James F. Blake</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John J. Gaudino</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rustam Garrey</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew T. Metcalf</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Burkard</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Martinson</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Rasor</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huifen Chen</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian Dean</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen E. Gould</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patricia Pacheco</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheerin Shahidi-Latham</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianping Yin</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kristina West</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weiru Wang</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John G. Moffat</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacob B. Schwarz</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i76" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i76"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i77" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i77"> Abbreviations Used</h2><tr><td class="NLM_term">Ac</td><td class="NLM_def"><p class="first last">acetyl</p></td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">aq</td><td class="NLM_def"><p class="first last">aqueous</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under curve</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">twice daily</p></td></tr><tr><td class="NLM_term">BOC</td><td class="NLM_def"><p class="first last"><i>tert</i>-butoxycarbonyl</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximal concentration</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P-450</p></td></tr><tr><td class="NLM_term">d</td><td class="NLM_def"><p class="first last">day</p></td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">dichloroethane</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">efflux</td><td class="NLM_def"><p class="first last">efflux ratio is the (B to A)/(A to B) value derived from MDCK cells transfected with human MDR1 (p-GP)</p></td></tr><tr><td class="NLM_term">ER%</td><td class="NLM_def"><p class="first last">extraction ratio %</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylacetamide</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMPK</td><td class="NLM_def"><p class="first last">drug metabolism and pharmacokinetics</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal effective concentration</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">ER%</td><td class="NLM_def"><p class="first last">extraction ratio %</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">Et</td><td class="NLM_def"><p class="first last">ethyl</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">%<i>F</i></td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr><tr><td class="NLM_term">equiv</td><td class="NLM_def"><p class="first last">equivalent</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FRET</td><td class="NLM_def"><p class="first last">Förster resonance energy transfer</p></td></tr><tr><td class="NLM_term">mp</td><td class="NLM_def"><p class="first last">melting point</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go related gene</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high performance liquid chromatography</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hour</p></td></tr><tr><td class="NLM_term">IPA</td><td class="NLM_def"><p class="first last">2-propanol</p></td></tr><tr><td class="NLM_term">KHMDS</td><td class="NLM_def"><p class="first last">potassium bis(trimethylsilyl)amide</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term"><i>m</i>CPBA</td><td class="NLM_def"><p class="first last">3-chlorobenzoperoxoic acid</p></td></tr><tr><td class="NLM_term">MsCl</td><td class="NLM_def"><p class="first last">methanesulfonyl chloride</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methylpyrrolidone</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub> AB</td><td class="NLM_def"><p class="first last">apparent cell permeability in the apical to basolateral direction</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term">Ph</td><td class="NLM_def"><p class="first last">phenyl</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once daily</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetrabutylammonium fluoride</p></td></tr><tr><td class="NLM_term">TBSCl</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylchlorosilane</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">THP amine</td><td class="NLM_def"><p class="first last">tetrahydro-2<i>H</i>-pyran-4-amine</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">steady-state volume of distribution</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00072" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00072" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 14 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Robert, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3291</span><span class="NLM_x">–</span> <span class="NLM_lpage">3310</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1038%2Fsj.onc.1210422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=17496923" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3291-3310&author=P.+J.+Robertauthor=C.+J.+Der&title=Targeting+the+Raf-MEK-ERK+mitogen-activated+protein+kinase+cascade+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210422%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DP.%2BJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520the%2520Raf-MEK-ERK%2520mitogen-activated%2520protein%2520kinase%2520cascade%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3291%26epage%3D3310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hoshino, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ari-i, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohno, M.</span><span> </span><span class="NLM_article-title">Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">–</span> <span class="NLM_lpage">822</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1038%2Fsj.onc.1202367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=9989833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADyaK1MXht1eht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=813-822&author=R.+Hoshinoauthor=Y.+Chataniauthor=T.+Yamoriauthor=T.+Tsuruoauthor=H.+Okaauthor=O.+Yoshidaauthor=Y.+Shimadaauthor=S.+Ari-iauthor=H.+Wadaauthor=J.+Fujimotoauthor=M.+Kohno&title=Constitutive+activation+of+the+41-%2F43-kDa+mitogen-activated+protein+kinase+signaling+pathway+in+human+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors</span></div><div class="casAuthors">Hoshino, Rika; Chatani, Yuji; Yamori, Takao; Tsuruo, Takashi; Oka, Hiroya; Yoshida, Osamu; Shimada, Yutaka; Ari-i, Shigeki; Wada, Hiromi; Fujimoto, Jiro; Kohno, Michiaki</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">813-822</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">The 41-kDa and 43-kDa mitogen-activated protein (MAP) kinases play a pivotal role in the mitogenic signal transduction pathway and are essential components of the MAP kinase cascade, which includes MAP kinase kinase (MEK) and Raf-1.  As aberrant activation of signal transducing mols. such as Ras and Raf-1 has been linked with cancer, the authors examd. whether constitutive activation of the 41-/43-kDa MAP kinases is assocd. with the neoplastic phenotype of 138 tumor cell lines and 102 primary tumors derived from various human organs.  Constitutive activation of the MAP kinases was obsd. in 50 tumor cell lines (36.2%) in a rather tissue-specific manner: cell lines derived from pancreas, colon, lung, ovary and kidney showed esp. high frequencies with a high degree of MAP kinase activation, while those derived from brain, esophagus, stomach, liver and of hematopoietic origin showed low frequencies with a limited degree of MAP kinase activation.  The authors also detected constitutive activation of the 41-/43-kDa MAP kinases in a relatively large no. of primary human tumors derived from kidney, colon and lung tissues but not from liver tissue.  Many tumor cells, in which point mutations of ras genes were detected, showed constitutive activation of MAP kinases, however, there were also many exceptions to this observation.  In contrast, the activation of the 41-/43-kDa MAP kinases was accompanied by the activation of Raf-1 in the majority of tumor cells and was completely assocd. with the activation of MEK and p90rsk in all the tumor cells examd.  These results suggest that the constitutive activation of 41-/43-kDa MAP kinases in tumor cells is not due to the disorder of MAP kinases themselves, but is due to the disorder of Raf-1, Ras, or some other signaling mols. upstream of Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRICRJXnIoerVg90H21EOLACvtfcHk0lh3GZY4F-NKng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXht1eht70%253D&md5=719a702e589f259a22f53f7a2be0e94a</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1202367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1202367%26sid%3Dliteratum%253Aachs%26aulast%3DHoshino%26aufirst%3DR.%26aulast%3DChatani%26aufirst%3DY.%26aulast%3DYamori%26aufirst%3DT.%26aulast%3DTsuruo%26aufirst%3DT.%26aulast%3DOka%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DO.%26aulast%3DShimada%26aufirst%3DY.%26aulast%3DAri-i%26aufirst%3DS.%26aulast%3DWada%26aufirst%3DH.%26aulast%3DFujimoto%26aufirst%3DJ.%26aulast%3DKohno%26aufirst%3DM.%26atitle%3DConstitutive%2520activation%2520of%2520the%252041-%252F43-kDa%2520mitogen-activated%2520protein%2520kinase%2520signaling%2520pathway%2520in%2520human%2520tumors%26jtitle%3DOncogene%26date%3D1999%26volume%3D18%26spage%3D813%26epage%3D822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dhillon, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolch, W.</span><span> </span><span class="NLM_article-title">MAP kinase signalling pathways in cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3279</span><span class="NLM_x">–</span> <span class="NLM_lpage">3290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1038%2Fsj.onc.1210421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=17496922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3279-3290&author=A.+S.+Dhillonauthor=S.+Haganauthor=W.+Kolch&title=MAP+kinase+signalling+pathways+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">MAP kinase signaling pathways in cancer</span></div><div class="casAuthors">Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3279-3290</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer can be perceived as a disease of communication between and within cells.  The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently.  Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer.  Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway.  Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation.  The balance and integration between these signals may widely vary in different tumors, but are important for the outcome and the sensitivity to drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2AJjwZsw0PbVg90H21EOLACvtfcHk0lh3GZY4F-NKng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D&md5=510709dcee2bbe62c7d48dbd8f270130</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210421%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DA.%2BS.%26aulast%3DHagan%26aufirst%3DS.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMAP%2520kinase%2520signalling%2520pathways%2520in%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3279%26epage%3D3290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nissan, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solid, D. B.</span><span> </span><span class="NLM_article-title">ERK pathway inhibitors: how low should we go?</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">719</span><span class="NLM_x">–</span> <span class="NLM_lpage">721</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=719-721&author=M.+H.+Nissanauthor=N.+Rosenauthor=D.+B.+Solid&title=ERK+pathway+inhibitors%3A+how+low+should+we+go%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNissan%26aufirst%3DM.%2BH.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolid%26aufirst%3DD.%2BB.%26atitle%3DERK%2520pathway%2520inhibitors%253A%2520how%2520low%2520should%2520we%2520go%253F%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D719%26epage%3D721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Yap, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worlikar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKerell, A. D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors of the ERK signaling pathway: towards novel anticancer therapeutics</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=38-48&author=J.+L.+Yapauthor=S.+Worlikarauthor=A.+D.+J.+MacKerellauthor=P.+Shapiroauthor=S.+Fletcher&title=Small-molecule+inhibitors+of+the+ERK+signaling+pathway%3A+towards+novel+anticancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DWorlikar%26aufirst%3DS.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%2BJ.%26aulast%3DShapiro%26aufirst%3DP.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520ERK%2520signaling%2520pathway%253A%2520towards%2520novel%2520anticancer%2520therapeutics%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D38%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of Mutated, Activated BRAF in Metastatic Melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+Mutated%2C+Activated+BRAF+in+Metastatic+Melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0ljOT2nnRgwUPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520Mutated%252C%2520Activated%2520BRAF%2520in%2520Metastatic%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Rheault, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellwagen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjabeng, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornberger, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquerre, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossanese, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnone, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitheman, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane-Carson, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorthy, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehling, D. E.</span><span> </span><span class="NLM_article-title">Discovery of Dabrafenib: a selective inhibitor of Raf kinase with antitumor activity against B-raf-driven tumors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml4000063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Sqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=358-362&author=T.+R.+Rheaultauthor=J.+C.+Stellwagenauthor=G.+M.+Adjabengauthor=K.+R.+Hornbergerauthor=K.+G.+Petrovauthor=A.+G.+Watersonauthor=S.+H.+Dickersonauthor=R.+A.+Mookauthor=S.+G.+Laquerreauthor=A.+J.+Kingauthor=O.+W.+Rossaneseauthor=M.+R.+Arnoneauthor=K.+N.+Smithemanauthor=L.+S.+Kane-Carsonauthor=C.+Hanauthor=G.+S.+Moorthyauthor=K.+G.+Mossauthor=D.+E.+Uehling&title=Discovery+of+Dabrafenib%3A+a+selective+inhibitor+of+Raf+kinase+with+antitumor+activity+against+B-raf-driven+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors</span></div><div class="casAuthors">Rheault, Tara R.; Stellwagen, John C.; Adjabeng, George M.; Hornberger, Keith R.; Petrov, Kimberly G.; Waterson, Alex G.; Dickerson, Scott H.; Mook, Robert A.; Laquerre, Sylvie G.; King, Alastair J.; Rossanese, Olivia W.; Arnone, Marc R.; Smitheman, Kimberly N.; Kane-Carson, Laurie S.; Han, Chao; Moorthy, Ganesh S.; Moss, Katherine G.; Uehling, David E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">358-362</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hyperactive signaling of the MAP kinase pathway resulting from the constitutively active B-RafV600E mutated enzyme has been obsd. in a no. of human tumors, including melanomas.  Herein, we report the discovery and biol. evaluation of GSK2118436 (dabrafenib, I), a selective inhibitor of Raf kinases with potent in vitro activity in oncogenic B-Raf-driven melanoma and colorectal carcinoma cells and robust in vivo antitumor and pharmacodynamic activity in mouse models of B-RafV600E human melanoma.  GSK2118436 was identified as a development candidate, and early clin. results have shown significant activity in patients with B-Raf mutant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq97lPGF-Yb8bVg90H21EOLACvtfcHk0ljOT2nnRgwUPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Sqtr4%253D&md5=4b26187120192c298ca89283e2871fe4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fml4000063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000063%26sid%3Dliteratum%253Aachs%26aulast%3DRheault%26aufirst%3DT.%2BR.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DAdjabeng%26aufirst%3DG.%2BM.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DRossanese%26aufirst%3DO.%2BW.%26aulast%3DArnone%26aufirst%3DM.%2BR.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DKane-Carson%26aufirst%3DL.%2BS.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DMoorthy%26aufirst%3DG.%2BS.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3DDiscovery%2520of%2520Dabrafenib%253A%2520a%2520selective%2520inhibitor%2520of%2520Raf%2520kinase%2520with%2520antitumor%2520activity%2520against%2520B-raf-driven%2520tumors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D358%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milhem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demidov, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassel, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowki, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trefzer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J. M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utikal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyakas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quellet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span> </span><span class="NLM_article-title">Improved survival with MEK inhibition in BRAF-mutated melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1056%2FNEJMoa1203421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=22663011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKjs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=107-114&author=K.+T.+Flahertyauthor=C.+Robertauthor=P.+Herseyauthor=P.+Nathanauthor=C.+Garbeauthor=M.+Milhemauthor=L.+V.+Demidovauthor=J.+C.+Hasselauthor=P.+Rutkowkiauthor=P.+Mohrauthor=R.+Dummerauthor=U.+Trefzerauthor=J.+M.+G.+Larkinauthor=J.+Utikalauthor=B.+Drenoauthor=M.+Nyakasauthor=M.+R.+Middletonauthor=J.+C.+Beckerauthor=M.+Caseyauthor=L.+J.+Shermanauthor=F.+S.+Wuauthor=D.+Quelletauthor=A.+M.+Martinauthor=K.+Patelauthor=D.+Schadendorf&title=Improved+survival+with+MEK+inhibition+in+BRAF-mutated+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with MEK inhibition in BRAF-mutated melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Robert, Caroline; Hersey, Peter; Nathan, Paul; Garbe, Claus; Milhem, Mohammed; Demidov, Lev V.; Hassel, Jessica C.; Rutkowski, Piotr; Mohr, Peter; Dummer, Reinhard; Trefzer, Uwe; Larkin, James M. G.; Utikal, Jochen; Dreno, Brigitte; Nyakas, Marta; Middleton, Mark R.; Becker, Jurgen C.; Casey, Michelle; Sherman, Laurie J.; Wu, Frank S.; Ouellet, Daniele; Martin, Anne-Marie; Schadendorf, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-114</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma.  Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived.  In previous trials, MEK inhibition appeared to be promising in this population.  In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2:1 ratio.  Patients received trametinib (2 mg orally) once daily or i.v. dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 wk.  Patients in the chemotherapy group who had disease progression were permitted to cross over to receive trametinib.  Progression-free survival was the primary end point, and overall survival was a secondary end point.  Median progression-free survival was 4.8 mo in the trametinib group and 1.5 mo in the chemotherapy group (hazard ratio for disease progression or death in the trametinib group, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P < 0.001).  At 6 mo, the rate of overall survival was 81% in the trametinib group and 67% in the chemotherapy group despite crossover (hazard ratio for death, 0.54; 95% CI, 0.32 to 0.92; P = 0.01).  Rash, diarrhea, and peripheral edema were the most common toxic effects in the trametinib group and were managed with dose interruption and dose redn.; asymptomatic and reversible redn. in the cardiac ejection fraction and ocular toxic effects occurred infrequently.  Secondary skin neo- plasms were not obsd.  Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ9lseRU60cLVg90H21EOLACvtfcHk0lgastEJzPoZpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKjs7zN&md5=bf084fd4ac6599e1f023cb732f0678a7</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1203421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1203421%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHersey%26aufirst%3DP.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DMilhem%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DHassel%26aufirst%3DJ.%2BC.%26aulast%3DRutkowki%26aufirst%3DP.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DTrefzer%26aufirst%3DU.%26aulast%3DLarkin%26aufirst%3DJ.%2BM.%2BG.%26aulast%3DUtikal%26aufirst%3DJ.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNyakas%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DBecker%26aufirst%3DJ.%2BC.%26aulast%3DCasey%26aufirst%3DM.%26aulast%3DSherman%26aufirst%3DL.%2BJ.%26aulast%3DWu%26aufirst%3DF.%2BS.%26aulast%3DQuellet%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DSchadendorf%26aufirst%3DD.%26atitle%3DImproved%2520survival%2520with%2520MEK%2520inhibition%2520in%2520BRAF-mutated%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D107%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Botella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span> </span><span class="NLM_article-title">Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1280</span><span class="NLM_x">–</span> <span class="NLM_lpage">1287</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061381f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1280-1287&author=A.+M.+Aronovauthor=G.+Bakerauthor=G.+W.+Bemisauthor=J.+Caoauthor=G.+Chenauthor=P.+J.+Fordauthor=U.+A.+Germannauthor=J.+Greenauthor=M.+R.+Haleauthor=M.+Jacobsauthor=J.+M.+Janetkaauthor=F.+Maltaisauthor=G.+Martinez-Botellaauthor=M.+N.+Namchukauthor=J.+Straubauthor=Q.+Tangauthor=X.+Xie&title=Flipped+out%3A+structure-guided+design+of+selective+pyrazolylpyrrole+ERK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1021%2Fjm061381f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061381f%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DBaker%26aufirst%3DG.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DFord%26aufirst%3DP.%2BJ.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DHale%26aufirst%3DM.%2BR.%26aulast%3DJacobs%26aufirst%3DM.%26aulast%3DJanetka%26aufirst%3DJ.%2BM.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DNamchuk%26aufirst%3DM.%2BN.%26aulast%3DStraub%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DX.%26atitle%3DFlipped%2520out%253A%2520structure-guided%2520design%2520of%2520selective%2520pyrazolylpyrrole%2520ERK%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1280%26epage%3D1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Botella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markland, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanthakumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poondru, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harr, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span> </span><span class="NLM_article-title">Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6362</span><span class="NLM_x">–</span> <span class="NLM_lpage">6368</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900630q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6362-6368&author=A.+M.+Aronovauthor=Q.+Tangauthor=G.+Martinez-Botellaauthor=G.+Bakerauthor=G.+W.+Bemisauthor=J.+Caoauthor=G.+Chenauthor=N.+P.+Ewingauthor=P.+J.+Fordauthor=U.+A.+Germannauthor=J.+Greenauthor=M.+R.+Haleauthor=M.+Jacobsauthor=J.+M.+Janetkaauthor=F.+Maltaisauthor=W.+Marklandauthor=M.+N.+Namchukauthor=S.+Nanthakumarauthor=S.+Poondruauthor=J.+Straubauthor=E.+Harrauthor=X.+Xie&title=Structure-guided+design+of+potent+and+selective+pyrimidylpyrrole+inhibitors+of+extracellular+signal-regulated+kinase+%28ERK%29+using+conformational+control"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1021%2Fjm900630q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900630q%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DBaker%26aufirst%3DG.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DEwing%26aufirst%3DN.%2BP.%26aulast%3DFord%26aufirst%3DP.%2BJ.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DHale%26aufirst%3DM.%2BR.%26aulast%3DJacobs%26aufirst%3DM.%26aulast%3DJanetka%26aufirst%3DJ.%2BM.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DMarkland%26aufirst%3DW.%26aulast%3DNamchuk%26aufirst%3DM.%2BN.%26aulast%3DNanthakumar%26aufirst%3DS.%26aulast%3DPoondru%26aufirst%3DS.%26aulast%3DStraub%26aufirst%3DJ.%26aulast%3DHarr%26aufirst%3DE.%26aulast%3DXie%26aufirst%3DX.%26atitle%3DStructure-guided%2520design%2520of%2520potent%2520and%2520selective%2520pyrimidylpyrrole%2520inhibitors%2520of%2520extracellular%2520signal-regulated%2520kinase%2520%2528ERK%2529%2520using%2520conformational%2520control%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6362%26epage%3D6368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Meloche, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouyssegur, J.</span><span> </span><span class="NLM_article-title">The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3227</span><span class="NLM_x">–</span> <span class="NLM_lpage">3239</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3227-3239&author=S.+Melocheauthor=J.+Pouyssegur&title=The+ERK1%2F2+mitogen-activated+protein+kinase+pathway+as+a+master+regulator+of+the+G1-+to+S-phase+transition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeloche%26aufirst%3DS.%26aulast%3DPouyssegur%26aufirst%3DJ.%26atitle%3DThe%2520ERK1%252F2%2520mitogen-activated%2520protein%2520kinase%2520pathway%2520as%2520a%2520master%2520regulator%2520of%2520the%2520G1-%2520to%2520S-phase%2520transition%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3227%26epage%3D3239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span> </span><span class="NLM_article-title">The hallmarks of cancer</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1016%2FS0092-8674%2800%2981683-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=10647931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=57-70&author=D.+Hanahanauthor=R.+A.+Weinberg&title=The+hallmarks+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">The hallmarks of cancer</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review is given with many refs. on principles governing the transformation of normal human cells into malignant cancers.  The authors suggest that research over the past decades has revealed a small no. of mol., biochem., and cellular traits (acquired capabilities) shared by most and perhaps all types of cancer.  Topics included are the acquired capabilities self-sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis followed by genome instability as an enabling characteristic and alternative pathways to cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooXmGqKjM1C7Vg90H21EOLACvtfcHk0lgastEJzPoZpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D&md5=1d23c4400dad34c7f32d4a0c41890349</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981683-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981683-9%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DThe%2520hallmarks%2520of%2520cancer%26jtitle%3DCell%26date%3D2000%26volume%3D100%26spage%3D57%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span> </span><span class="NLM_article-title">Hallmarks of Cancer: The Next Generation</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+Cancer%3A+The+Next+Generation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0ljh1oGimkb30A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520Cancer%253A%2520The%2520Next%2520Generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Turjanski, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaque, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutkind, J. S.</span><span> </span><span class="NLM_article-title">MAP kinases and the control of nuclear events</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3240</span><span class="NLM_x">–</span> <span class="NLM_lpage">3253</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3240-3253&author=A.+G.+Turjanskiauthor=J.+P.+Vaqueauthor=J.+S.+Gutkind&title=MAP+kinases+and+the+control+of+nuclear+events"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTurjanski%26aufirst%3DA.%2BG.%26aulast%3DVaque%26aufirst%3DJ.%2BP.%26aulast%3DGutkind%26aufirst%3DJ.%2BS.%26atitle%3DMAP%2520kinases%2520and%2520the%2520control%2520of%2520nuclear%2520events%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3240%26epage%3D3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haverty, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heldens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almer, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hampton, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackner, W. R.</span><span> </span><span class="NLM_article-title">ERK inhibition overcomes acquired resistance to MEK inhibitors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1143</span><span class="NLM_x">–</span> <span class="NLM_lpage">1154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1158%2F1535-7163.MCT-11-1010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=22402123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1yrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1143-1154&author=G.+Hatzivassiliouauthor=B.+Liuauthor=C.+O%E2%80%99Brienauthor=J.+M.+Spoerkeauthor=K.+P.+Hoeflichauthor=P.+M.+Havertyauthor=R.+Sorianoauthor=W.+F.+Forrestauthor=S.+Heldensauthor=H.+Chenauthor=K.+Toyauthor=C.+Haauthor=W.+Zhouauthor=K.+Songauthor=L.+S.+Friedmanauthor=L.+C.+Almerauthor=G.+M.+Hamptonauthor=J.+Moffatauthor=M.+Belvinauthor=W.+R.+Lackner&title=ERK+inhibition+overcomes+acquired+resistance+to+MEK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Liu, Bonnie; O'Brien, Carol; Spoerke, Jill M.; Hoeflich, Klaus P.; Haverty, Peter M.; Soriano, Robert; Forrest, William F.; Heldens, Sherry; Chen, Huifen; Toy, Karen; Ha, Connie; Zhou, Wei; Song, Kyung; Friedman, Lori S.; Amler, Lukas C.; Hampton, Garret M.; Moffat, John; Belvin, Marcia; Lackner, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1143-1154</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The RAS/RAF/MEK pathway is activated in more than 30% of human cancers, most commonly via mutation in the K-ras oncogene and also via mutations in BRAF.  Several allosteric mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitors, aimed at treating tumors with RAS/RAF pathway alterations, are in clin. development.  However, acquired resistance to these inhibitors has been documented both in preclin. and clin. samples.  To identify strategies to overcome this resistance, we have derived three independent MEK inhibitor-resistant cell lines.  Resistance to allosteric MEK inhibitors in these cell lines was consistently linked to acquired mutations in the allosteric binding pocket of MEK.  In one cell line, concurrent amplification of mutant K-ras was obsd. in conjunction with MEK allosteric pocket mutations.  Clonal anal. showed that both resistance mechanisms occur in the same cell and contribute to enhanced resistance.  Importantly, in all cases the MEK-resistant cell lines retained their addiction to the mitogen-activated protein kinase (MAPK) pathway, as evidenced by their sensitivity to a selective inhibitor of the ERK1/2 kinases.  These data suggest that tumors with acquired MEK inhibitor resistance remain dependent on the MAPK pathway and are therefore sensitive to inhibitors that act downstream of the mutated MEK target.  Importantly, we show that dual inhibition of MEK and ERK by small mol. inhibitors was synergistic and acted to both inhibit the emergence of resistance, as well as to overcome acquired resistance to MEK inhibitors.  Therefore, our data provide a rationale for cotargeting multiple nodes within the MAPK signaling cascade in K-ras mutant tumors to maximize therapeutic benefit for patients.  Mol Cancer Ther; 11(5); 1143-54.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHIXHjLc1cbbVg90H21EOLACvtfcHk0ljh1oGimkb30A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1yrtLY%253D&md5=79b9ff7fc04c7163f6ebe8f45429651b</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-1010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-1010%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DHaverty%26aufirst%3DP.%2BM.%26aulast%3DSoriano%26aufirst%3DR.%26aulast%3DForrest%26aufirst%3DW.%2BF.%26aulast%3DHeldens%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DToy%26aufirst%3DK.%26aulast%3DHa%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DAlmer%26aufirst%3DL.%2BC.%26aulast%3DHampton%26aufirst%3DG.%2BM.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DLackner%26aufirst%3DW.%2BR.%26atitle%3DERK%2520inhibition%2520overcomes%2520acquired%2520resistance%2520to%2520MEK%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1143%26epage%3D1154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Morris, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Restaino, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayananth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNunzio, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsor, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angagwa, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinheiro, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipps, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hruza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paliwal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babu, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daublain, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelletier, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siliphaivanh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fawell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samatar, A.</span><span> </span><span class="NLM_article-title">Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1158%2F2159-8290.CD-13-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=23614898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=742-750&author=E.+J.+Morrisauthor=S.+Jhaauthor=C.+R.+Restainoauthor=P.+Dayananthauthor=H.+Zhuauthor=A.+Cooperauthor=D.+Carrauthor=Y.+Dengauthor=W.+Jinauthor=S.+Blackauthor=B.+Longauthor=J.+Liuauthor=E.+DiNunzioauthor=W.+Windsorauthor=R.+Zhangauthor=S.+Zhaoauthor=M.+H.+Angagwaauthor=E.+M.+Pinheiroauthor=J.+Desaiauthor=L.+Xiaoauthor=G.+Shippsauthor=A.+Hruzaauthor=J.+Wangauthor=J.+Kellyauthor=S.+Paliwalauthor=X.+Gaoauthor=B.+S.+Babuauthor=L.+Zhuauthor=P.+Daublainauthor=L.+Zhangauthor=B.+A.+Lutterbachauthor=M.+R.+Pelletierauthor=U.+Philipparauthor=P.+Siliphaivanhauthor=D.+Witterauthor=P.+Kirschmeierauthor=W.+R.+Bishopauthor=D.+Hicklinauthor=D.+G.+Gillilandauthor=L.+Jayaramanauthor=L.+Zawelauthor=S.+Fawellauthor=A.+Samatar&title=Discovery+of+a+novel+ERK+inhibitor+with+activity+in+models+of+acquired+resistance+to+BRAF+and+MEK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors</span></div><div class="casAuthors">Morris, Erick J.; Jha, Sharda; Restaino, Clifford R.; Dayananth, Priya; Zhu, Hugh; Cooper, Alan; Carr, Donna; Deng, Yongi; Jin, Weihong; Black, Stuart; Long, Brian; Liu, Jenny; DiNunzio, Edward; Windsor, William; Zhang, Rumin; Zhao, Shuxia; Angagaw, Minilik H.; Pinheiro, Elaine M.; Desai, Jagdish; Xiao, Li; Shipps, Gerald; Hruza, Alan; Wang, James; Kelly, Joe; Paliwal, Sunil; Gao, Xiaolei; Babu, Boga Sobhana; Zhu, Liang; Daublain, Pierre; Zhang, Ling; Lutterbach, Bart A.; Pelletier, Marc R.; Philippar, Ulrike; Siliphaivanh, Phieng; Witter, David; Kirschmeier, Paul; Bishop, W. Robert; Hicklin, Daniel; Gilliland, D. Gary; Jayaraman, Lata; Zawel, Leigh; Fawell, Stephen; Samatar, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway.  Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clin. efficacy in patients with melanoma.  However, the majority of responses are transient, and resistance is often assocd. with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway.  Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors.  SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRA5, or KRAS and induces tumor regressions in xenograft models at tolerated doses.  Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.  These data support the clin. development of ERK inhibitors for tumors refractory to MAPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4HJ4HhYmLL7Vg90H21EOLACvtfcHk0liJlY5NSGjp8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE&md5=1f26a4a5bb1fab64bdd6c38c16b3f4e3</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0070%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DE.%2BJ.%26aulast%3DJha%26aufirst%3DS.%26aulast%3DRestaino%26aufirst%3DC.%2BR.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDiNunzio%26aufirst%3DE.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DAngagwa%26aufirst%3DM.%2BH.%26aulast%3DPinheiro%26aufirst%3DE.%2BM.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DShipps%26aufirst%3DG.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DBabu%26aufirst%3DB.%2BS.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDaublain%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPelletier%26aufirst%3DM.%2BR.%26aulast%3DPhilippar%26aufirst%3DU.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DWitter%26aufirst%3DD.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DHicklin%26aufirst%3DD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DJayaraman%26aufirst%3DL.%26aulast%3DZawel%26aufirst%3DL.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DSamatar%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520ERK%2520inhibitor%2520with%2520activity%2520in%2520models%2520of%2520acquired%2520resistance%2520to%2520BRAF%2520and%2520MEK%2520inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D742%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudino, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Meese, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chicarelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siedem, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolakowski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacheco, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi-Latham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, J. B.</span><span> </span><span class="NLM_article-title">Discovery of 5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidine Inhibitors of Erk2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2635</span><span class="NLM_x">–</span> <span class="NLM_lpage">2639</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1016%2Fj.bmcl.2014.04.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=24813737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvFSntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2635-2639&author=J.+F.+Blakeauthor=J.+J.+Gaudinoauthor=J.+De+Meeseauthor=P.+Mohrauthor=M.+Chicarelliauthor=H.+Tianauthor=R.+Garreyauthor=A.+Thomasauthor=C.+S.+Siedemauthor=M.+B.+Welchauthor=G.+Kolakowskiauthor=R.+Kausauthor=M.+Burkardauthor=M.+Martinsonauthor=H.+Chenauthor=B.+Deanauthor=D.+A.+Dudleyauthor=S.+E.+Gouldauthor=P.+Pachecoauthor=S.+Shahidi-Lathamauthor=W.+Wangauthor=K.+Westauthor=J.+Yinauthor=J.+Moffatauthor=J.+B.+Schwarz&title=Discovery+of+5%2C6%2C7%2C8-tetrahydropyrido%5B3%2C4-d%5Dpyrimidine+Inhibitors+of+Erk2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2</span></div><div class="casAuthors">Blake, James F.; Gaudino, John J.; De Meese, Jason; Mohr, Peter; Chicarelli, Mark; Tian, Hongqi; Garrey, Rustam; Thomas, Allen; Siedem, Christopher S.; Welch, Michael B.; Kolakowski, Gabrielle; Kaus, Robert; Burkard, Michael; Martinson, Matthew; Chen, Huifen; Dean, Brian; Dudley, Danette A.; Gould, Stephen E.; Pacheco, Patricia; Shahidi-Latham, Sheerin; Wang, Weiru; West, Kristina; Yin, Jianping; Moffat, John; Schwarz, Jacob B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2635-2639</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of tetrahydropyridopyrimidine based extracellular signal-regulated kinase (Erks) inhibitors discovered via HTS and structure based drug design is reported.  The compds. demonstrate potent and selective inhibition of Erk2 and knockdown of phospho-RSK levels in HepG2 cells and tumor xenografts.  Proliferation of HCT116 (K-RasG12D) and A375 (BRafV600E) cell lines was inhibited by compd. (I) with EC50s of 0.74 and 0.39 μM, resp.  Pharmacokinetic parameters of I are given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2sLYQY7scc7Vg90H21EOLACvtfcHk0liJlY5NSGjp8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvFSntL4%253D&md5=3fb3eb1f8c127ed45f57664ed4f3cb11</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.068%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DGaudino%26aufirst%3DJ.%2BJ.%26aulast%3DDe%2BMeese%26aufirst%3DJ.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DChicarelli%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DGarrey%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DSiedem%26aufirst%3DC.%2BS.%26aulast%3DWelch%26aufirst%3DM.%2BB.%26aulast%3DKolakowski%26aufirst%3DG.%26aulast%3DKaus%26aufirst%3DR.%26aulast%3DBurkard%26aufirst%3DM.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDean%26aufirst%3DB.%26aulast%3DDudley%26aufirst%3DD.%2BA.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DPacheco%26aufirst%3DP.%26aulast%3DShahidi-Latham%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWest%26aufirst%3DK.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%25205%252C6%252C7%252C8-tetrahydropyrido%255B3%252C4-d%255Dpyrimidine%2520Inhibitors%2520of%2520Erk2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2635%26epage%3D2639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Blake, J. F.; Chicarelli, M. J.; Garrey, R. F.; Gaudino, J. G.; Grina, J.; Moreno, D. A.; Mohr, P. J.; Ren, L.; Schwarz, J.; Chen, H.; Robarge, K.; Zhou, A.</span><span> </span><span class="NLM_article-title">Serine/threonine kinase inhibitors</span>. WO 2013/130976.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Blake%2C+J.+F.%3B+Chicarelli%2C+M.+J.%3B+Garrey%2C+R.+F.%3B+Gaudino%2C+J.+G.%3B+Grina%2C+J.%3B+Moreno%2C+D.+A.%3B+Mohr%2C+P.+J.%3B+Ren%2C+L.%3B+Schwarz%2C+J.%3B+Chen%2C+H.%3B+Robarge%2C+K.%3B+Zhou%2C+A.+Serine%2Fthreonine+kinase+inhibitors.+WO+2013%2F130976."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26atitle%3DSerine%252Fthreonine%2520kinase%2520inhibitors" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Kolb, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanNieuwenhze, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpless, K. B.</span><span> </span><span class="NLM_article-title">Catalytic asymmetric dihydroxylation</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">2483</span><span class="NLM_x">–</span> <span class="NLM_lpage">2547</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr00032a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADyaK2cXntVSitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1994&pages=2483-2547&author=H.+C.+Kolbauthor=M.+S.+VanNieuwenhzeauthor=K.+B.+Sharpless&title=Catalytic+asymmetric+dihydroxylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Asymmetric Dihydroxylation</span></div><div class="casAuthors">Kolb, Hartmuth C.; VanNieuwenhze, Michael S.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2483-547</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">A review with 285 refs. on enantioselective prepn. of chiral 1,2-diols from olefins and synthetic applications of the 1,2-diols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX6vlkXRJjKLVg90H21EOLACvtfcHk0liJlY5NSGjp8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXntVSitrg%253D&md5=71bace539bfee0542d17edcdb889cdd9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fcr00032a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00032a009%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DVanNieuwenhze%26aufirst%3DM.%2BS.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DCatalytic%2520asymmetric%2520dihydroxylation%26jtitle%3DChem.%2520Rev.%26date%3D1994%26volume%3D94%26spage%3D2483%26epage%3D2547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Cheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prusoff, W. H.</span><span> </span><span class="NLM_article-title">Relationship Between the Inhibition Constant (Ki) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (IC50) of an Enzymatic Reaction</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3099</span><span class="NLM_x">–</span> <span class="NLM_lpage">3108</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.+Chengauthor=W.+H.+Prusoff&title=Relationship+Between+the+Inhibition+Constant+%28Ki%29+and+the+Concentration+of+Inhibitor+Which+Causes+50+Per+Cent+Inhibition+%28IC50%29+of+an+Enzymatic+Reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520Between%2520the%2520Inhibition%2520Constant%2520%2528Ki%2529%2520and%2520the%2520Concentration%2520of%2520Inhibitor%2520Which%2520Causes%252050%2520Per%2520Cent%2520Inhibition%2520%2528IC50%2529%2520of%2520an%2520Enzymatic%2520Reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="note"><p class="first last">For example, the enzyme IC<sub>50</sub>s of ERK1 and ERK2 for (<i>S</i>)-<b>14k</b> are 15 and 5 nM, respectively.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span> <span class="citation_source-book">Thin-Layer Chromatography Reagents and Detection Methods, Vol. 1a: Physical and Chemical Detection Methods: Fundamentals, Reagents I</span>; <span class="NLM_contrib-group">Jork, H. H.; Funk, W.; Fischer, W.; Wimmer, H.</span>, Eds.; <span class="NLM_publisher-name">VHC</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">1990</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&author=H.+H.+Jork&author=W.+Funk&author=W.+Fischer&author=H.+Wimmer&title=Thin-Layer+Chromatography+Reagents+and+Detection+Methods%2C+Vol.+1a%3A+Physical+and+Chemical+Detection+Methods%3A+Fundamentals%2C+Reagents+I"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DThin-Layer%2520Chromatography%2520Reagents%2520and%2520Detection%2520Methods%252C%2520Vol.%25201a%253A%2520Physical%2520and%2520Chemical%2520Detection%2520Methods%253A%2520Fundamentals%252C%2520Reagents%2520I%26aulast%3DJork%26aufirst%3DH.%2BH.%26pub%3DVHC%26date%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b','cit2c','cit2d'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b'],'ref7':['cit7a','cit7b','cit7c','cit7d'],'ref8':['cit8a','cit8b'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':[],'ref14':['cit14']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 23 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Xin    Linghu </span><span class="hlFld-ContribAuthor "> Nicholas    Wong </span><span class="hlFld-ContribAuthor "> James F.    Blake </span><span class="hlFld-ContribAuthor "> John J.    Gaudino </span><span class="hlFld-ContribAuthor "> John G.    Moffat </span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of GDC-0994: A Selective and Efficacious Small Molecule Inhibitor of ERK1/2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 1-28. <a href="https://doi.org/10.1021/bk-2018-1307.ch001" title="DOI URL">https://doi.org/10.1021/bk-2018-1307.ch001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2018-1307.ch001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2018-1307.ch001%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BGDC-0994%25253A%252BA%252BSelective%252Band%252BEfficacious%252BSmall%252BMolecule%252BInhibitor%252Bof%252BERK1%25252F2%26aulast%3DLinghu%26aufirst%3DXin%26date%3D2018%26date%3D2018%26spage%3D1%26epage%3D28%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B1%26aulast%3DAbdel-Magid%26aufirst%3DAhmed%2BF.%26date%3D2018%26date%3D2018%26volume%3D1307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Linghu</span>, <span class="hlFld-ContribAuthor ">Nicholas  Wong</span>, <span class="hlFld-ContribAuthor ">Vera  Jost</span>, <span class="hlFld-ContribAuthor ">Serena  Fantasia</span>, <span class="hlFld-ContribAuthor ">C. Gregory  Sowell</span>, and <span class="hlFld-ContribAuthor ">Francis  Gosselin</span>  . </span><span class="cited-content_cbyCitation_article-title">Kumada–Corriu Heteroaryl Cross-Coupling for Synthesis of a Pharmaceutical Intermediate: Comparison of Batch Versus Continuous Reaction Modes. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2017,</strong> <em>21 </em>
                                    (9)
                                     , 1320-1325. <a href="https://doi.org/10.1021/acs.oprd.7b00185" title="DOI URL">https://doi.org/10.1021/acs.oprd.7b00185</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.7b00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.7b00185%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DKumada%2525E2%252580%252593Corriu%252BHeteroaryl%252BCross-Coupling%252Bfor%252BSynthesis%252Bof%252Ba%252BPharmaceutical%252BIntermediate%25253A%252BComparison%252Bof%252BBatch%252BVersus%252BContinuous%252BReaction%252BModes%26aulast%3DLinghu%26aufirst%3DXin%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D23052017%26date%3D18072017%26date%3D15092017%26date%3D28062017%26volume%3D21%26issue%3D9%26spage%3D1320%26epage%3D1325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James  Sipthorp</span>, <span class="hlFld-ContribAuthor ">Honorine  Lebraud</span>, <span class="hlFld-ContribAuthor ">Rebecca  Gilley</span>, <span class="hlFld-ContribAuthor ">Andrew M.  Kidger</span>, <span class="hlFld-ContribAuthor ">Hanneke  Okkenhaug</span>, <span class="hlFld-ContribAuthor ">Marc  Saba-El-Leil</span>, <span class="hlFld-ContribAuthor ">Sylvain  Meloche</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Caunt</span>, <span class="hlFld-ContribAuthor ">Simon J.  Cook</span>, and <span class="hlFld-ContribAuthor ">Tom D.  Heightman</span>  . </span><span class="cited-content_cbyCitation_article-title">Visualization of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent Probe. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2017,</strong> <em>28 </em>
                                    (6)
                                     , 1677-1683. <a href="https://doi.org/10.1021/acs.bioconjchem.7b00152" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.7b00152</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.7b00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.7b00152%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DVisualization%252Bof%252BEndogenous%252BERK1%25252F2%252Bin%252BCells%252Bwith%252Ba%252BBioorthogonal%252BCovalent%252BProbe%26aulast%3DSipthorp%26aufirst%3DJames%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D20032017%26date%3D26042017%26date%3D12052017%26date%3D21062017%26date%3D28042017%26volume%3D28%26issue%3D6%26spage%3D1677%26epage%3D1683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Linghu</span>, <span class="hlFld-ContribAuthor ">Nicholas  Wong</span>, <span class="hlFld-ContribAuthor ">Hans  Iding</span>, <span class="hlFld-ContribAuthor ">Vera  Jost</span>, <span class="hlFld-ContribAuthor ">Haiming  Zhang</span>, <span class="hlFld-ContribAuthor ">Stefan G.  Koenig</span>, <span class="hlFld-ContribAuthor ">C. Gregory  Sowell</span>, and <span class="hlFld-ContribAuthor ">Francis  Gosselin</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of a Practical Synthesis of ERK Inhibitor GDC-0994. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2017,</strong> <em>21 </em>
                                    (3)
                                     , 387-398. <a href="https://doi.org/10.1021/acs.oprd.7b00006" title="DOI URL">https://doi.org/10.1021/acs.oprd.7b00006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.7b00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.7b00006%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ba%252BPractical%252BSynthesis%252Bof%252BERK%252BInhibitor%252BGDC-0994%26aulast%3DLinghu%26aufirst%3DXin%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D09012017%26date%3D08032017%26date%3D17032017%26date%3D23022017%26volume%3D21%26issue%3D3%26spage%3D387%26epage%3D398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Honorine  Lebraud</span>, <span class="hlFld-ContribAuthor ">David J.  Wright</span>, <span class="hlFld-ContribAuthor ">Christopher N.  Johnson</span>, and <span class="hlFld-ContribAuthor ">Tom D.  Heightman</span>  . </span><span class="cited-content_cbyCitation_article-title">Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras. </span><span class="cited-content_cbyCitation_journal-name">ACS Central Science</span><span> <strong>2016,</strong> <em>2 </em>
                                    (12)
                                     , 927-934. <a href="https://doi.org/10.1021/acscentsci.6b00280" title="DOI URL">https://doi.org/10.1021/acscentsci.6b00280</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscentsci.6b00280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscentsci.6b00280%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Central%2520Science%26atitle%3DProtein%252BDegradation%252Bby%252BIn-Cell%252BSelf-Assembly%252Bof%252BProteolysis%252BTargeting%252BChimeras%26aulast%3DLebraud%26aufirst%3DHonorine%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D19092016%26date%3D05122016%26date%3D28122016%26volume%3D2%26issue%3D12%26spage%3D927%26epage%3D934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jongwon  Lim</span>, <span class="hlFld-ContribAuthor ">Elizabeth H.  Kelley</span>, <span class="hlFld-ContribAuthor ">Joey L.  Methot</span>, <span class="hlFld-ContribAuthor ">Hua  Zhou</span>, <span class="hlFld-ContribAuthor ">Alessia  Petrocchi</span>, <span class="hlFld-ContribAuthor ">Hongmin  Chen</span>, <span class="hlFld-ContribAuthor ">Susan E.  Hill</span>, <span class="hlFld-ContribAuthor ">Marlene C.  Hinton</span>, <span class="hlFld-ContribAuthor ">Alan  Hruza</span>, <span class="hlFld-ContribAuthor ">Joon O.  Jung</span>, <span class="hlFld-ContribAuthor ">John K. F.  Maclean</span>, <span class="hlFld-ContribAuthor ">My  Mansueto</span>, <span class="hlFld-ContribAuthor ">George N.  Naumov</span>, <span class="hlFld-ContribAuthor ">Ulrike  Philippar</span>, <span class="hlFld-ContribAuthor ">Shruti  Raut</span>, <span class="hlFld-ContribAuthor ">Peter  Spacciapoli</span>, <span class="hlFld-ContribAuthor ">Dongyu  Sun</span>, and <span class="hlFld-ContribAuthor ">Phieng  Siliphaivanh</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (13)
                                     , 6501-6511. <a href="https://doi.org/10.1021/acs.jmedchem.6b00708" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00708%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B1-%2525281H-Pyrazolo%25255B4%25252C3-c%25255Dpyridin-6-yl%252529urea%252BInhibitors%252Bof%252BExtracellular%252BSignal-Regulated%252BKinase%252B%252528ERK%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BCancers%26aulast%3DLim%26aufirst%3DJongwon%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D09052016%26date%3D01072016%26date%3D14072016%26date%3D22062016%26volume%3D59%26issue%3D13%26spage%3D6501%26epage%3D6511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James F.  Blake</span>, <span class="hlFld-ContribAuthor ">Michael  Burkard</span>, <span class="hlFld-ContribAuthor ">Jocelyn  Chan</span>, <span class="hlFld-ContribAuthor ">Huifen  Chen</span>, <span class="hlFld-ContribAuthor ">Kang-Jye  Chou</span>, <span class="hlFld-ContribAuthor ">Dolores  Diaz</span>, <span class="hlFld-ContribAuthor ">Danette A.  Dudley</span>, <span class="hlFld-ContribAuthor ">John J.  Gaudino</span>, <span class="hlFld-ContribAuthor ">Stephen E.  Gould</span>, <span class="hlFld-ContribAuthor ">Jonas  Grina</span>, <span class="hlFld-ContribAuthor ">Thomas  Hunsaker</span>, <span class="hlFld-ContribAuthor ">Lichuan  Liu</span>, <span class="hlFld-ContribAuthor ">Matthew  Martinson</span>, <span class="hlFld-ContribAuthor ">David  Moreno</span>, <span class="hlFld-ContribAuthor ">Lars  Mueller</span>, <span class="hlFld-ContribAuthor ">Christine  Orr</span>, <span class="hlFld-ContribAuthor ">Patricia  Pacheco</span>, <span class="hlFld-ContribAuthor ">Ann  Qin</span>, <span class="hlFld-ContribAuthor ">Kevin  Rasor</span>, <span class="hlFld-ContribAuthor ">Li  Ren</span>, <span class="hlFld-ContribAuthor ">Kirk  Robarge</span>, <span class="hlFld-ContribAuthor ">Sheerin  Shahidi-Latham</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Stults</span>, <span class="hlFld-ContribAuthor ">Francis  Sullivan</span>, <span class="hlFld-ContribAuthor ">Weiru  Wang</span>, <span class="hlFld-ContribAuthor ">Jianping  Yin</span>, <span class="hlFld-ContribAuthor ">Aihe  Zhou</span>, <span class="hlFld-ContribAuthor ">Marcia  Belvin</span>, <span class="hlFld-ContribAuthor ">Mark  Merchant</span>, <span class="hlFld-ContribAuthor ">John  Moffat</span>, and <span class="hlFld-ContribAuthor ">Jacob B.  Schwarz</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (12)
                                     , 5650-5660. <a href="https://doi.org/10.1021/acs.jmedchem.6b00389" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00389</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00389%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528S%252529-1-%2525281-%2525284-Chloro-3-fluorophenyl%252529-2-hydroxyethyl%252529-4-%2525282-%252528%2525281-methyl-1H-pyrazol-5-yl%252529amino%252529pyrimidin-4-yl%252529pyridin-2%2525281H%252529-one%252B%252528GDC-0994%252529%25252C%252Ban%252BExtracellular%252BSignal-Regulated%252BKinase%252B1%25252F2%252B%252528ERK1%25252F2%252529%252BInhibitor%252Bin%252BEarly%252BClinical%252BDevelopment%26aulast%3DBlake%26aufirst%3DJames%2BF.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D15032016%26date%3D07062016%26date%3D23062016%26date%3D26052016%26volume%3D59%26issue%3D12%26spage%3D5650%26epage%3D5660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dadnover  Vargas-Ibarra</span>, <span class="hlFld-ContribAuthor ">Mariana  Velez-Vasquez</span>, <span class="hlFld-ContribAuthor ">Maria  Bermudez-Munoz</span>. </span><span class="cited-content_cbyCitation_article-title">Regulation of MAPK ERK1/2 Signaling by Phosphorylation: Implications in Physiological and Pathological Contexts. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.5772/intechopen.97061" title="DOI URL">https://doi.org/10.5772/intechopen.97061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5772/intechopen.97061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5772%2Fintechopen.97061%26sid%3Dliteratum%253Aachs%26atitle%3DRegulation%252Bof%252BMAPK%252BERK1%25252F2%252BSignaling%252Bby%252BPhosphorylation%25253A%252BImplications%252Bin%252BPhysiological%252Band%252BPathological%252BContexts%26aulast%3DVargas-Ibarra%26aufirst%3DDadnover%26date%3D2021%26date%3D2021%26pub%3DIntechOpen%26atitle%3DPost-Translational%252BModifications%252Bin%252BCellular%252BFunctions%252Band%252BDiseases%26aulast%3DYing%26aufirst%3DShibo%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan H.  Takahashi</span>, <span class="hlFld-ContribAuthor ">Jessica M.  Grandner</span>, <span class="hlFld-ContribAuthor ">Sudheer  Bobba</span>, <span class="hlFld-ContribAuthor ">Yanzhou  Liu</span>, <span class="hlFld-ContribAuthor ">Paul  Beroza</span>, <span class="hlFld-ContribAuthor ">Donglu  Zhang</span>, <span class="hlFld-ContribAuthor ">Shuguang  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Homodimer Metabolites of GDC-0994 via Cytochrome P450–Catalyzed Radical Coupling. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2020,</strong> <em>48 </em>
                                    (6)
                                     , 521-527. <a href="https://doi.org/10.1124/dmd.119.090019" title="DOI URL">https://doi.org/10.1124/dmd.119.090019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.119.090019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.119.090019%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DNovel%252BHomodimer%252BMetabolites%252Bof%252BGDC-0994%252Bvia%252BCytochrome%252BP450%2525E2%252580%252593Catalyzed%252BRadical%252BCoupling%26aulast%3DTakahashi%26aufirst%3DRyan%2BH.%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D6%26spage%3D521%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shelly  Pathania</span>, <span class="hlFld-ContribAuthor ">Ravindra K  Rawal</span>. </span><span class="cited-content_cbyCitation_article-title">An update on chemical classes targeting ERK1/2 for the management of cancer. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em><a href="https://doi.org/10.4155/fmc-2019-0339" title="DOI URL">https://doi.org/10.4155/fmc-2019-0339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0339%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bupdate%252Bon%252Bchemical%252Bclasses%252Btargeting%252BERK1%25252F2%252Bfor%252Bthe%252Bmanagement%252Bof%252Bcancer%26aulast%3DPathania%26aufirst%3DShelly%26date%3D2020%26date%3D2020%26volume%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Longfei  Miao</span>, <span class="hlFld-ContribAuthor ">Hongqi  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Drug Targeting</span><span> <strong>2020,</strong> <em>28 </em>
                                    (2)
                                     , 154-165. <a href="https://doi.org/10.1080/1061186X.2019.1648477" title="DOI URL">https://doi.org/10.1080/1061186X.2019.1648477</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1061186X.2019.1648477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1061186X.2019.1648477%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Drug%2520Targeting%26atitle%3DDevelopment%252Bof%252BERK1%25252F2%252Binhibitors%252Bas%252Ba%252Btherapeutic%252Bstrategy%252Bfor%252Btumour%252Bwith%252BMAPK%252Bupstream%252Btarget%252Bmutations%26aulast%3DMiao%26aufirst%3DLongfei%26date%3D2020%26date%3D2019%26volume%3D28%26issue%3D2%26spage%3D154%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sheng  Zhou</span>, <span class="hlFld-ContribAuthor ">Huanji  Xu</span>, <span class="hlFld-ContribAuthor ">Qiulin  Tang</span>, <span class="hlFld-ContribAuthor ">Hongwei  Xia</span>, <span class="hlFld-ContribAuthor ">Feng  Bi</span>. </span><span class="cited-content_cbyCitation_article-title">Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (1)
                                     , 135-146. <a href="https://doi.org/10.1158/1535-7163.MCT-19-0413" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-0413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-0413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-0413%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DDipyridamole%252BEnhances%252Bthe%252BCytotoxicities%252Bof%252BTrametinib%252Bagainst%252BColon%252BCancer%252BCells%252Bthrough%252BCombined%252BTargeting%252Bof%252BHMGCS1%252Band%252BMEK%252BPathway%26aulast%3DZhou%26aufirst%3DSheng%26date%3D2020%26date%3D2019%26volume%3D19%26issue%3D1%26spage%3D135%26epage%3D146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashley  Jarvis</span>, <span class="hlFld-ContribAuthor ">Gilles  Ouvry</span>. </span><span class="cited-content_cbyCitation_article-title">Essential ingredients for rational drug design. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (20)
                                     , 126674. <a href="https://doi.org/10.1016/j.bmcl.2019.126674" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126674</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126674%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DEssential%252Bingredients%252Bfor%252Brational%252Bdrug%252Bdesign%26aulast%3DJarvis%26aufirst%3DAshley%26date%3D2019%26volume%3D29%26issue%3D20%26spage%3D126674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhe  Cao</span>, <span class="hlFld-ContribAuthor ">Qianjin  Liao</span>, <span class="hlFld-ContribAuthor ">Min  Su</span>, <span class="hlFld-ContribAuthor ">Kai  Huang</span>, <span class="hlFld-ContribAuthor ">Junfei  Jin</span>, <span class="hlFld-ContribAuthor ">Deliang  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">AKT and ERK dual inhibitors: The way forward?. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2019,</strong> <em>459 </em>, 30-40. <a href="https://doi.org/10.1016/j.canlet.2019.05.025" title="DOI URL">https://doi.org/10.1016/j.canlet.2019.05.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2019.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2019.05.025%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DAKT%252Band%252BERK%252Bdual%252Binhibitors%25253A%252BThe%252Bway%252Bforward%25253F%26aulast%3DCao%26aufirst%3DZhe%26date%3D2019%26volume%3D459%26spage%3D30%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feifei  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaotong  Yang</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Min  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2018,</strong> <em>8 </em>
                                    (4)
                                     , 552-562. <a href="https://doi.org/10.1016/j.apsb.2018.01.008" title="DOI URL">https://doi.org/10.1016/j.apsb.2018.01.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2018.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2018.01.008%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DTargeting%252BERK%25252C%252Ban%252BAchilles%252527%252BHeel%252Bof%252Bthe%252BMAPK%252Bpathway%25252C%252Bin%252Bcancer%252Btherapy%26aulast%3DLiu%26aufirst%3DFeifei%26date%3D2018%26volume%3D8%26issue%3D4%26spage%3D552%26epage%3D562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew M.  Kidger</span>, <span class="hlFld-ContribAuthor ">James  Sipthorp</span>, <span class="hlFld-ContribAuthor ">Simon J.  Cook</span>. </span><span class="cited-content_cbyCitation_article-title">ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2018,</strong> <em>187 </em>, 45-60. <a href="https://doi.org/10.1016/j.pharmthera.2018.02.007" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2018.02.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2018.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2018.02.007%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DERK1%25252F2%252Binhibitors%25253A%252BNew%252Bweapons%252Bto%252Binhibit%252Bthe%252BRAS-regulated%252BRAF-MEK1%25252F2-ERK1%25252F2%252Bpathway%26aulast%3DKidger%26aufirst%3DAndrew%2BM.%26date%3D2018%26volume%3D187%26spage%3D45%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">RONALDO A.  PILLI</span>, <span class="hlFld-ContribAuthor ">FRANCISCO F. DE  ASSIS</span>. </span><span class="cited-content_cbyCitation_article-title">Organic Synthesis: New Vistas in the Brazilian Landscape. </span><span class="cited-content_cbyCitation_journal-name">Anais da Academia Brasileira de Ciências</span><span> <strong>2018,</strong> <em>90 </em>
                                    (1 suppl 1)
                                     , 895-941. <a href="https://doi.org/10.1590/0001-3765201820170564" title="DOI URL">https://doi.org/10.1590/0001-3765201820170564</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1590/0001-3765201820170564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1590%2F0001-3765201820170564%26sid%3Dliteratum%253Aachs%26jtitle%3DAnais%2520da%2520Academia%2520Brasileira%2520de%2520Ci%25C3%25AAncias%26atitle%3DOrganic%252BSynthesis%25253A%252BNew%252BVistas%252Bin%252Bthe%252BBrazilian%252BLandscape%26aulast%3DPILLI%26aufirst%3DRONALDO%2BA.%26date%3D2018%26date%3D2018%26volume%3D90%26issue%3D1%2520suppl%25201%26spage%3D895%26epage%3D941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrey S.  Marchev</span>, <span class="hlFld-ContribAuthor ">Petya  Dimitrova</span>, <span class="hlFld-ContribAuthor ">Ivanka K.  Koycheva</span>, <span class="hlFld-ContribAuthor ">Milen I.  Georgiev</span>. </span><span class="cited-content_cbyCitation_article-title">Altered expression of TRAIL on mouse T cells via ERK phosphorylation by Rhodiola rosea L. and its marker compounds. </span><span class="cited-content_cbyCitation_journal-name">Food and Chemical Toxicology</span><span> <strong>2017,</strong> <em>108 </em>, 419-428. <a href="https://doi.org/10.1016/j.fct.2017.02.009" title="DOI URL">https://doi.org/10.1016/j.fct.2017.02.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.fct.2017.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.fct.2017.02.009%26sid%3Dliteratum%253Aachs%26jtitle%3DFood%2520and%2520Chemical%2520Toxicology%26atitle%3DAltered%252Bexpression%252Bof%252BTRAIL%252Bon%252Bmouse%252BT%252Bcells%252Bvia%252BERK%252Bphosphorylation%252Bby%252BRhodiola%252Brosea%252BL.%252Band%252Bits%252Bmarker%252Bcompounds%26aulast%3DMarchev%26aufirst%3DAndrey%2BS.%26date%3D2017%26volume%3D108%26spage%3D419%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuan-Xuan  Du</span>, <span class="hlFld-ContribAuthor ">Rong  Huang</span>, <span class="hlFld-ContribAuthor ">Chang-Long  Yang</span>, <span class="hlFld-ContribAuthor ">Jun  Lin</span>, <span class="hlFld-ContribAuthor ">Sheng-Jiao  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of the antitumor activity of highly functionalised pyridin-2-ones and pyrimidin-4-ones. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2017,</strong> <em>7 </em>
                                    (64)
                                     , 40067-40073. <a href="https://doi.org/10.1039/C7RA06466G" title="DOI URL">https://doi.org/10.1039/C7RA06466G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7RA06466G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7RA06466G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252Bthe%252Bantitumor%252Bactivity%252Bof%252Bhighly%252Bfunctionalised%252Bpyridin-2-ones%252Band%252Bpyrimidin-4-ones%26aulast%3DDu%26aufirst%3DXuan-Xuan%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D64%26spage%3D40067%26epage%3D40073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qifei  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaoding  Jiang</span>, <span class="hlFld-ContribAuthor ">Weixing  Zhu</span>, <span class="hlFld-ContribAuthor ">Chuo  Chen</span>, <span class="hlFld-ContribAuthor ">Gaoyun  Hu</span>, <span class="hlFld-ContribAuthor ">Qianbin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, preliminary biological evaluation and 3D-QSAR study of novel 1,5-disubstituted-2(1H)-pyridone derivatives as potential anti-lung cancer agents. </span><span class="cited-content_cbyCitation_journal-name">Arabian Journal of Chemistry</span><span> <strong>2016,</strong> <em>9 </em>
                                    (5)
                                     , 721-735. <a href="https://doi.org/10.1016/j.arabjc.2015.08.001" title="DOI URL">https://doi.org/10.1016/j.arabjc.2015.08.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.arabjc.2015.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.arabjc.2015.08.001%26sid%3Dliteratum%253Aachs%26jtitle%3DArabian%2520Journal%2520of%2520Chemistry%26atitle%3DSynthesis%25252C%252Bpreliminary%252Bbiological%252Bevaluation%252Band%252B3D-QSAR%252Bstudy%252Bof%252Bnovel%252B1%25252C5-disubstituted-2%2525281H%252529-pyridone%252Bderivatives%252Bas%252Bpotential%252Banti-lung%252Bcancer%252Bagents%26aulast%3DXu%26aufirst%3DQifei%26date%3D2016%26volume%3D9%26issue%3D5%26spage%3D721%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Honorine  Lebraud</span>, <span class="hlFld-ContribAuthor ">David J.  Wright</span>, <span class="hlFld-ContribAuthor ">Charlotte E.  East</span>, <span class="hlFld-ContribAuthor ">Finn P.  Holding</span>, <span class="hlFld-ContribAuthor ">Marc  O'Reilly</span>, <span class="hlFld-ContribAuthor ">Tom D.  Heightman</span>. </span><span class="cited-content_cbyCitation_article-title">In-gel activity-based protein profiling of a clickable covalent ERK1/2 inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Molecular BioSystems</span><span> <strong>2016,</strong> <em>12 </em>
                                    (9)
                                     , 2867-2874. <a href="https://doi.org/10.1039/C6MB00367B" title="DOI URL">https://doi.org/10.1039/C6MB00367B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6MB00367B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6MB00367B%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520BioSystems%26atitle%3DIn-gel%252Bactivity-based%252Bprotein%252Bprofiling%252Bof%252Ba%252Bclickable%252Bcovalent%252BERK1%25252F2%252Binhibitor%26aulast%3DLebraud%26aufirst%3DHonorine%26date%3D2016%26date%3D2016%26volume%3D12%26issue%3D9%26spage%3D2867%26epage%3D2874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jin  Liu</span>, <span class="hlFld-ContribAuthor ">Sheng-Jiao  Yan</span>, <span class="hlFld-ContribAuthor ">Zheng-Mao  Cao</span>, <span class="hlFld-ContribAuthor ">Shi-Sheng  Cui</span>, <span class="hlFld-ContribAuthor ">Jun  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of bicyclic 2-pyridones by regioselective annulations of heterocyclic ketene aminals with anhydrides. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (105)
                                     , 103057-103064. <a href="https://doi.org/10.1039/C6RA23451H" title="DOI URL">https://doi.org/10.1039/C6RA23451H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA23451H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA23451H%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSynthesis%252Bof%252Bbicyclic%252B2-pyridones%252Bby%252Bregioselective%252Bannulations%252Bof%252Bheterocyclic%252Bketene%252Baminals%252Bwith%252Banhydrides%26aulast%3DLiu%26aufirst%3DJin%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D105%26spage%3D103057%26epage%3D103064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David E.  Uehling</span>, <span class="hlFld-ContribAuthor ">Philip A.  Harris</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress on MAP kinase pathway inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (19)
                                     , 4047-4056. <a href="https://doi.org/10.1016/j.bmcl.2015.07.093" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.07.093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.07.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.07.093%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRecent%252Bprogress%252Bon%252BMAP%252Bkinase%252Bpathway%252Binhibitors%26aulast%3DUehling%26aufirst%3DDavid%2BE.%26date%3D2015%26volume%3D25%26issue%3D19%26spage%3D4047%26epage%3D4056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0019.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Stuctures of <b>1a</b> and <b>1b</b> from the piperidinopyrimidine urea series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Structure-Based Design: From Piperidinopyrimidine Ureas to Pyridones</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Pyridone <b>6a</b> (orange) docked into the X-ray structure of <b>1b</b> (green) with ERK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O6E">4O6E</a>, solved at 1.95 Å resolution). Hydrogen-bonding interactions are illustrated with red dashed lines. (B) Same model as in (A), rotated to illustrate key water mediated H-bond interactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>6a</b>–<b>6f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reaction conditions: (a) 5% Pd(dppf)Cl<sub>2</sub>(DCM), Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O (4:1), 80 °C, 3 h, 96%; (b) tetrahydro-2<i>H</i>-pyran-4-amine, <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine, 2-butanol, 100 °C, 16 h, 49%; (c) 2 N HCl, 100 °C, 16 h, 94%; (d) benzyl bromide, K<sub>2</sub>CO<sub>3</sub>, DMF, 25 °C, 65%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Compounds <b>14a</b>–<b>14o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reaction conditions: (a) 5% Pd(dppf)Cl<sub>2</sub>(DCM), Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O (4:1), 80 °C, 2 h, 90%; (b) 2 N HCl, 100 °C, 2 h, 50%; (c) THF, 0 °C, 1 h, 93%; (d) MsCl, NEt<sub>3</sub>, DCM, 0 °C, 1 h, 96%; (e) KHMDS, THF, 65 °C, 30 h, 65%; (f) <i>m</i>CPBA, DCM, 0 °C, 2 h, 89%; (g) tetrahydro-2<i>H</i>-pyran-4-amine, 2-butanol, 120 °C, 4 h, 90%; (h) TBAF, THF, 25 °C, 16 h, 90%.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0011.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Compounds (<i>S</i>)-<b>14k</b> and <b>22a</b>–<b>22i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reaction conditions: (a) NaH, methyltriphenylphosphonium bromide, THF, 25 °C, 16 h, 47%; (b) AD-mix-β, <i>t</i>-BuOH/H<sub>2</sub>O (1:1), 25 °C, 16 h, 64%; (c) TBSCl, imidazole, DCM, 0 °C, 1 h, 58%; (d) MsCl, NEt<sub>3</sub>, DCM, 0 °C, 1 h, 96%; (e) KHMDS, THF, 65 °C, 30 h, 65%; (f) <i>m</i>CPBA, DCM, 0 °C, 2 h, 89%; (g) R<sub>4</sub>NH<sub>2</sub>, 120 °C, 4 h, 90%; (h) TBAF, THF, 25 °C, 16 h, 90%.</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) X-ray structure of (<i>S</i>)-<b>14k</b> (green) bound to ERK2, solved at 2.58 Å resolution (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XJ0">4XJ0</a>). Hydrogen-bonding interactions are illustrated with red dashed lines. (B) X-ray structure rotated to illustrate key water mediated H-bond interactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Dose-escalation of (<i>S</i>)-<b>14k</b> in nude mice. Three nude mice were dosed orally with (<i>S</i>)-<b>14k</b> at doses of 30, 100, and 150 mg/kg in 10%HP-<i>b</i>-CD/PEG400 suspension. At different time intervals, a blood sample was taken from each animal and plasma concentration was determined. Reported values were the average of three animals. The free fraction adjusted cellular IC<sub>50</sub> was calculated by dividing the cellular IC<sub>50</sub> by the unbound fraction in mouse.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PK/PD in HCT116 xenograft tumors for compound (<i>S</i>)-<b>14k</b> at 2, 4, 8, and 12 h time points dosed orally at 75 mg/kg QD. Mean and sd for <i>n</i> = 3 animals are plotted. Green triangles represent total plasma concentration, red squares represent total tumor concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/medium/jm-2014-01921k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. HCT116 colorectal tumor xenograft treated with compound (<i>S</i>)-<b>14k</b> orally at 75 mg/kg BID for 21 days. Cubic spline fitted tumor volume curves are shown for each group in red. Individual tumor volume traces are shown in gray, traces terminating in an X indicate animals sacrificed when tumors reached maximum permissible volume. The cubic spline fit for the vehicle group is shown in the (<i>S</i>)-<b>14k</b> treated group for comparison (green dashed line).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm501921k/20150220/images/large/jm-2014-01921k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501921k&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i78">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43461" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43461" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 14 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Robert, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3291</span><span class="NLM_x">–</span> <span class="NLM_lpage">3310</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1038%2Fsj.onc.1210422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=17496923" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3291-3310&author=P.+J.+Robertauthor=C.+J.+Der&title=Targeting+the+Raf-MEK-ERK+mitogen-activated+protein+kinase+cascade+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210422%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DP.%2BJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520the%2520Raf-MEK-ERK%2520mitogen-activated%2520protein%2520kinase%2520cascade%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3291%26epage%3D3310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hoshino, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ari-i, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohno, M.</span><span> </span><span class="NLM_article-title">Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">–</span> <span class="NLM_lpage">822</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1038%2Fsj.onc.1202367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=9989833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADyaK1MXht1eht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=813-822&author=R.+Hoshinoauthor=Y.+Chataniauthor=T.+Yamoriauthor=T.+Tsuruoauthor=H.+Okaauthor=O.+Yoshidaauthor=Y.+Shimadaauthor=S.+Ari-iauthor=H.+Wadaauthor=J.+Fujimotoauthor=M.+Kohno&title=Constitutive+activation+of+the+41-%2F43-kDa+mitogen-activated+protein+kinase+signaling+pathway+in+human+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors</span></div><div class="casAuthors">Hoshino, Rika; Chatani, Yuji; Yamori, Takao; Tsuruo, Takashi; Oka, Hiroya; Yoshida, Osamu; Shimada, Yutaka; Ari-i, Shigeki; Wada, Hiromi; Fujimoto, Jiro; Kohno, Michiaki</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">813-822</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">The 41-kDa and 43-kDa mitogen-activated protein (MAP) kinases play a pivotal role in the mitogenic signal transduction pathway and are essential components of the MAP kinase cascade, which includes MAP kinase kinase (MEK) and Raf-1.  As aberrant activation of signal transducing mols. such as Ras and Raf-1 has been linked with cancer, the authors examd. whether constitutive activation of the 41-/43-kDa MAP kinases is assocd. with the neoplastic phenotype of 138 tumor cell lines and 102 primary tumors derived from various human organs.  Constitutive activation of the MAP kinases was obsd. in 50 tumor cell lines (36.2%) in a rather tissue-specific manner: cell lines derived from pancreas, colon, lung, ovary and kidney showed esp. high frequencies with a high degree of MAP kinase activation, while those derived from brain, esophagus, stomach, liver and of hematopoietic origin showed low frequencies with a limited degree of MAP kinase activation.  The authors also detected constitutive activation of the 41-/43-kDa MAP kinases in a relatively large no. of primary human tumors derived from kidney, colon and lung tissues but not from liver tissue.  Many tumor cells, in which point mutations of ras genes were detected, showed constitutive activation of MAP kinases, however, there were also many exceptions to this observation.  In contrast, the activation of the 41-/43-kDa MAP kinases was accompanied by the activation of Raf-1 in the majority of tumor cells and was completely assocd. with the activation of MEK and p90rsk in all the tumor cells examd.  These results suggest that the constitutive activation of 41-/43-kDa MAP kinases in tumor cells is not due to the disorder of MAP kinases themselves, but is due to the disorder of Raf-1, Ras, or some other signaling mols. upstream of Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRICRJXnIoerVg90H21EOLACvtfcHk0liAirP_WlyiaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXht1eht70%253D&md5=719a702e589f259a22f53f7a2be0e94a</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1202367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1202367%26sid%3Dliteratum%253Aachs%26aulast%3DHoshino%26aufirst%3DR.%26aulast%3DChatani%26aufirst%3DY.%26aulast%3DYamori%26aufirst%3DT.%26aulast%3DTsuruo%26aufirst%3DT.%26aulast%3DOka%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DO.%26aulast%3DShimada%26aufirst%3DY.%26aulast%3DAri-i%26aufirst%3DS.%26aulast%3DWada%26aufirst%3DH.%26aulast%3DFujimoto%26aufirst%3DJ.%26aulast%3DKohno%26aufirst%3DM.%26atitle%3DConstitutive%2520activation%2520of%2520the%252041-%252F43-kDa%2520mitogen-activated%2520protein%2520kinase%2520signaling%2520pathway%2520in%2520human%2520tumors%26jtitle%3DOncogene%26date%3D1999%26volume%3D18%26spage%3D813%26epage%3D822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dhillon, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolch, W.</span><span> </span><span class="NLM_article-title">MAP kinase signalling pathways in cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3279</span><span class="NLM_x">–</span> <span class="NLM_lpage">3290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1038%2Fsj.onc.1210421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=17496922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3279-3290&author=A.+S.+Dhillonauthor=S.+Haganauthor=W.+Kolch&title=MAP+kinase+signalling+pathways+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">MAP kinase signaling pathways in cancer</span></div><div class="casAuthors">Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3279-3290</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer can be perceived as a disease of communication between and within cells.  The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently.  Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer.  Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway.  Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation.  The balance and integration between these signals may widely vary in different tumors, but are important for the outcome and the sensitivity to drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2AJjwZsw0PbVg90H21EOLACvtfcHk0lgbGgsubhGyGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D&md5=510709dcee2bbe62c7d48dbd8f270130</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210421%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DA.%2BS.%26aulast%3DHagan%26aufirst%3DS.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMAP%2520kinase%2520signalling%2520pathways%2520in%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3279%26epage%3D3290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nissan, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solid, D. B.</span><span> </span><span class="NLM_article-title">ERK pathway inhibitors: how low should we go?</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">719</span><span class="NLM_x">–</span> <span class="NLM_lpage">721</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=719-721&author=M.+H.+Nissanauthor=N.+Rosenauthor=D.+B.+Solid&title=ERK+pathway+inhibitors%3A+how+low+should+we+go%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNissan%26aufirst%3DM.%2BH.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolid%26aufirst%3DD.%2BB.%26atitle%3DERK%2520pathway%2520inhibitors%253A%2520how%2520low%2520should%2520we%2520go%253F%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D719%26epage%3D721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Yap, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worlikar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKerell, A. D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors of the ERK signaling pathway: towards novel anticancer therapeutics</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=38-48&author=J.+L.+Yapauthor=S.+Worlikarauthor=A.+D.+J.+MacKerellauthor=P.+Shapiroauthor=S.+Fletcher&title=Small-molecule+inhibitors+of+the+ERK+signaling+pathway%3A+towards+novel+anticancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DWorlikar%26aufirst%3DS.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%2BJ.%26aulast%3DShapiro%26aufirst%3DP.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520ERK%2520signaling%2520pathway%253A%2520towards%2520novel%2520anticancer%2520therapeutics%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D38%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of Mutated, Activated BRAF in Metastatic Melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+Mutated%2C+Activated+BRAF+in+Metastatic+Melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0lgbGgsubhGyGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520Mutated%252C%2520Activated%2520BRAF%2520in%2520Metastatic%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Rheault, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellwagen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjabeng, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornberger, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquerre, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossanese, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnone, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitheman, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane-Carson, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorthy, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehling, D. E.</span><span> </span><span class="NLM_article-title">Discovery of Dabrafenib: a selective inhibitor of Raf kinase with antitumor activity against B-raf-driven tumors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml4000063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Sqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=358-362&author=T.+R.+Rheaultauthor=J.+C.+Stellwagenauthor=G.+M.+Adjabengauthor=K.+R.+Hornbergerauthor=K.+G.+Petrovauthor=A.+G.+Watersonauthor=S.+H.+Dickersonauthor=R.+A.+Mookauthor=S.+G.+Laquerreauthor=A.+J.+Kingauthor=O.+W.+Rossaneseauthor=M.+R.+Arnoneauthor=K.+N.+Smithemanauthor=L.+S.+Kane-Carsonauthor=C.+Hanauthor=G.+S.+Moorthyauthor=K.+G.+Mossauthor=D.+E.+Uehling&title=Discovery+of+Dabrafenib%3A+a+selective+inhibitor+of+Raf+kinase+with+antitumor+activity+against+B-raf-driven+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors</span></div><div class="casAuthors">Rheault, Tara R.; Stellwagen, John C.; Adjabeng, George M.; Hornberger, Keith R.; Petrov, Kimberly G.; Waterson, Alex G.; Dickerson, Scott H.; Mook, Robert A.; Laquerre, Sylvie G.; King, Alastair J.; Rossanese, Olivia W.; Arnone, Marc R.; Smitheman, Kimberly N.; Kane-Carson, Laurie S.; Han, Chao; Moorthy, Ganesh S.; Moss, Katherine G.; Uehling, David E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">358-362</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hyperactive signaling of the MAP kinase pathway resulting from the constitutively active B-RafV600E mutated enzyme has been obsd. in a no. of human tumors, including melanomas.  Herein, we report the discovery and biol. evaluation of GSK2118436 (dabrafenib, I), a selective inhibitor of Raf kinases with potent in vitro activity in oncogenic B-Raf-driven melanoma and colorectal carcinoma cells and robust in vivo antitumor and pharmacodynamic activity in mouse models of B-RafV600E human melanoma.  GSK2118436 was identified as a development candidate, and early clin. results have shown significant activity in patients with B-Raf mutant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq97lPGF-Yb8bVg90H21EOLACvtfcHk0lgbGgsubhGyGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Sqtr4%253D&md5=4b26187120192c298ca89283e2871fe4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fml4000063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000063%26sid%3Dliteratum%253Aachs%26aulast%3DRheault%26aufirst%3DT.%2BR.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DAdjabeng%26aufirst%3DG.%2BM.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DRossanese%26aufirst%3DO.%2BW.%26aulast%3DArnone%26aufirst%3DM.%2BR.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DKane-Carson%26aufirst%3DL.%2BS.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DMoorthy%26aufirst%3DG.%2BS.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3DDiscovery%2520of%2520Dabrafenib%253A%2520a%2520selective%2520inhibitor%2520of%2520Raf%2520kinase%2520with%2520antitumor%2520activity%2520against%2520B-raf-driven%2520tumors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D358%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milhem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demidov, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassel, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowki, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trefzer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J. M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utikal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyakas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quellet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span> </span><span class="NLM_article-title">Improved survival with MEK inhibition in BRAF-mutated melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1056%2FNEJMoa1203421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=22663011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKjs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=107-114&author=K.+T.+Flahertyauthor=C.+Robertauthor=P.+Herseyauthor=P.+Nathanauthor=C.+Garbeauthor=M.+Milhemauthor=L.+V.+Demidovauthor=J.+C.+Hasselauthor=P.+Rutkowkiauthor=P.+Mohrauthor=R.+Dummerauthor=U.+Trefzerauthor=J.+M.+G.+Larkinauthor=J.+Utikalauthor=B.+Drenoauthor=M.+Nyakasauthor=M.+R.+Middletonauthor=J.+C.+Beckerauthor=M.+Caseyauthor=L.+J.+Shermanauthor=F.+S.+Wuauthor=D.+Quelletauthor=A.+M.+Martinauthor=K.+Patelauthor=D.+Schadendorf&title=Improved+survival+with+MEK+inhibition+in+BRAF-mutated+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with MEK inhibition in BRAF-mutated melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Robert, Caroline; Hersey, Peter; Nathan, Paul; Garbe, Claus; Milhem, Mohammed; Demidov, Lev V.; Hassel, Jessica C.; Rutkowski, Piotr; Mohr, Peter; Dummer, Reinhard; Trefzer, Uwe; Larkin, James M. G.; Utikal, Jochen; Dreno, Brigitte; Nyakas, Marta; Middleton, Mark R.; Becker, Jurgen C.; Casey, Michelle; Sherman, Laurie J.; Wu, Frank S.; Ouellet, Daniele; Martin, Anne-Marie; Schadendorf, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-114</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma.  Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived.  In previous trials, MEK inhibition appeared to be promising in this population.  In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2:1 ratio.  Patients received trametinib (2 mg orally) once daily or i.v. dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 wk.  Patients in the chemotherapy group who had disease progression were permitted to cross over to receive trametinib.  Progression-free survival was the primary end point, and overall survival was a secondary end point.  Median progression-free survival was 4.8 mo in the trametinib group and 1.5 mo in the chemotherapy group (hazard ratio for disease progression or death in the trametinib group, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P < 0.001).  At 6 mo, the rate of overall survival was 81% in the trametinib group and 67% in the chemotherapy group despite crossover (hazard ratio for death, 0.54; 95% CI, 0.32 to 0.92; P = 0.01).  Rash, diarrhea, and peripheral edema were the most common toxic effects in the trametinib group and were managed with dose interruption and dose redn.; asymptomatic and reversible redn. in the cardiac ejection fraction and ocular toxic effects occurred infrequently.  Secondary skin neo- plasms were not obsd.  Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ9lseRU60cLVg90H21EOLACvtfcHk0lgKOCRXJcB6Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKjs7zN&md5=bf084fd4ac6599e1f023cb732f0678a7</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1203421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1203421%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHersey%26aufirst%3DP.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DMilhem%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DHassel%26aufirst%3DJ.%2BC.%26aulast%3DRutkowki%26aufirst%3DP.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DTrefzer%26aufirst%3DU.%26aulast%3DLarkin%26aufirst%3DJ.%2BM.%2BG.%26aulast%3DUtikal%26aufirst%3DJ.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNyakas%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DBecker%26aufirst%3DJ.%2BC.%26aulast%3DCasey%26aufirst%3DM.%26aulast%3DSherman%26aufirst%3DL.%2BJ.%26aulast%3DWu%26aufirst%3DF.%2BS.%26aulast%3DQuellet%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DSchadendorf%26aufirst%3DD.%26atitle%3DImproved%2520survival%2520with%2520MEK%2520inhibition%2520in%2520BRAF-mutated%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D107%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Botella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span> </span><span class="NLM_article-title">Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1280</span><span class="NLM_x">–</span> <span class="NLM_lpage">1287</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061381f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1280-1287&author=A.+M.+Aronovauthor=G.+Bakerauthor=G.+W.+Bemisauthor=J.+Caoauthor=G.+Chenauthor=P.+J.+Fordauthor=U.+A.+Germannauthor=J.+Greenauthor=M.+R.+Haleauthor=M.+Jacobsauthor=J.+M.+Janetkaauthor=F.+Maltaisauthor=G.+Martinez-Botellaauthor=M.+N.+Namchukauthor=J.+Straubauthor=Q.+Tangauthor=X.+Xie&title=Flipped+out%3A+structure-guided+design+of+selective+pyrazolylpyrrole+ERK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1021%2Fjm061381f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061381f%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DBaker%26aufirst%3DG.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DFord%26aufirst%3DP.%2BJ.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DHale%26aufirst%3DM.%2BR.%26aulast%3DJacobs%26aufirst%3DM.%26aulast%3DJanetka%26aufirst%3DJ.%2BM.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DNamchuk%26aufirst%3DM.%2BN.%26aulast%3DStraub%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DX.%26atitle%3DFlipped%2520out%253A%2520structure-guided%2520design%2520of%2520selective%2520pyrazolylpyrrole%2520ERK%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1280%26epage%3D1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Botella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markland, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanthakumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poondru, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harr, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span> </span><span class="NLM_article-title">Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6362</span><span class="NLM_x">–</span> <span class="NLM_lpage">6368</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900630q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6362-6368&author=A.+M.+Aronovauthor=Q.+Tangauthor=G.+Martinez-Botellaauthor=G.+Bakerauthor=G.+W.+Bemisauthor=J.+Caoauthor=G.+Chenauthor=N.+P.+Ewingauthor=P.+J.+Fordauthor=U.+A.+Germannauthor=J.+Greenauthor=M.+R.+Haleauthor=M.+Jacobsauthor=J.+M.+Janetkaauthor=F.+Maltaisauthor=W.+Marklandauthor=M.+N.+Namchukauthor=S.+Nanthakumarauthor=S.+Poondruauthor=J.+Straubauthor=E.+Harrauthor=X.+Xie&title=Structure-guided+design+of+potent+and+selective+pyrimidylpyrrole+inhibitors+of+extracellular+signal-regulated+kinase+%28ERK%29+using+conformational+control"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1021%2Fjm900630q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900630q%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DBaker%26aufirst%3DG.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DEwing%26aufirst%3DN.%2BP.%26aulast%3DFord%26aufirst%3DP.%2BJ.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DHale%26aufirst%3DM.%2BR.%26aulast%3DJacobs%26aufirst%3DM.%26aulast%3DJanetka%26aufirst%3DJ.%2BM.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DMarkland%26aufirst%3DW.%26aulast%3DNamchuk%26aufirst%3DM.%2BN.%26aulast%3DNanthakumar%26aufirst%3DS.%26aulast%3DPoondru%26aufirst%3DS.%26aulast%3DStraub%26aufirst%3DJ.%26aulast%3DHarr%26aufirst%3DE.%26aulast%3DXie%26aufirst%3DX.%26atitle%3DStructure-guided%2520design%2520of%2520potent%2520and%2520selective%2520pyrimidylpyrrole%2520inhibitors%2520of%2520extracellular%2520signal-regulated%2520kinase%2520%2528ERK%2529%2520using%2520conformational%2520control%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6362%26epage%3D6368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Meloche, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouyssegur, J.</span><span> </span><span class="NLM_article-title">The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3227</span><span class="NLM_x">–</span> <span class="NLM_lpage">3239</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3227-3239&author=S.+Melocheauthor=J.+Pouyssegur&title=The+ERK1%2F2+mitogen-activated+protein+kinase+pathway+as+a+master+regulator+of+the+G1-+to+S-phase+transition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeloche%26aufirst%3DS.%26aulast%3DPouyssegur%26aufirst%3DJ.%26atitle%3DThe%2520ERK1%252F2%2520mitogen-activated%2520protein%2520kinase%2520pathway%2520as%2520a%2520master%2520regulator%2520of%2520the%2520G1-%2520to%2520S-phase%2520transition%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3227%26epage%3D3239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span> </span><span class="NLM_article-title">The hallmarks of cancer</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1016%2FS0092-8674%2800%2981683-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=10647931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=57-70&author=D.+Hanahanauthor=R.+A.+Weinberg&title=The+hallmarks+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">The hallmarks of cancer</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review is given with many refs. on principles governing the transformation of normal human cells into malignant cancers.  The authors suggest that research over the past decades has revealed a small no. of mol., biochem., and cellular traits (acquired capabilities) shared by most and perhaps all types of cancer.  Topics included are the acquired capabilities self-sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis followed by genome instability as an enabling characteristic and alternative pathways to cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooXmGqKjM1C7Vg90H21EOLACvtfcHk0lhqAtkwh_m2Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D&md5=1d23c4400dad34c7f32d4a0c41890349</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981683-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981683-9%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DThe%2520hallmarks%2520of%2520cancer%26jtitle%3DCell%26date%3D2000%26volume%3D100%26spage%3D57%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span> </span><span class="NLM_article-title">Hallmarks of Cancer: The Next Generation</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+Cancer%3A+The+Next+Generation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0lhqAtkwh_m2Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520Cancer%253A%2520The%2520Next%2520Generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Turjanski, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaque, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutkind, J. S.</span><span> </span><span class="NLM_article-title">MAP kinases and the control of nuclear events</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3240</span><span class="NLM_x">–</span> <span class="NLM_lpage">3253</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3240-3253&author=A.+G.+Turjanskiauthor=J.+P.+Vaqueauthor=J.+S.+Gutkind&title=MAP+kinases+and+the+control+of+nuclear+events"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTurjanski%26aufirst%3DA.%2BG.%26aulast%3DVaque%26aufirst%3DJ.%2BP.%26aulast%3DGutkind%26aufirst%3DJ.%2BS.%26atitle%3DMAP%2520kinases%2520and%2520the%2520control%2520of%2520nuclear%2520events%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3240%26epage%3D3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haverty, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heldens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almer, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hampton, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackner, W. R.</span><span> </span><span class="NLM_article-title">ERK inhibition overcomes acquired resistance to MEK inhibitors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1143</span><span class="NLM_x">–</span> <span class="NLM_lpage">1154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1158%2F1535-7163.MCT-11-1010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=22402123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1yrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1143-1154&author=G.+Hatzivassiliouauthor=B.+Liuauthor=C.+O%E2%80%99Brienauthor=J.+M.+Spoerkeauthor=K.+P.+Hoeflichauthor=P.+M.+Havertyauthor=R.+Sorianoauthor=W.+F.+Forrestauthor=S.+Heldensauthor=H.+Chenauthor=K.+Toyauthor=C.+Haauthor=W.+Zhouauthor=K.+Songauthor=L.+S.+Friedmanauthor=L.+C.+Almerauthor=G.+M.+Hamptonauthor=J.+Moffatauthor=M.+Belvinauthor=W.+R.+Lackner&title=ERK+inhibition+overcomes+acquired+resistance+to+MEK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Liu, Bonnie; O'Brien, Carol; Spoerke, Jill M.; Hoeflich, Klaus P.; Haverty, Peter M.; Soriano, Robert; Forrest, William F.; Heldens, Sherry; Chen, Huifen; Toy, Karen; Ha, Connie; Zhou, Wei; Song, Kyung; Friedman, Lori S.; Amler, Lukas C.; Hampton, Garret M.; Moffat, John; Belvin, Marcia; Lackner, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1143-1154</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The RAS/RAF/MEK pathway is activated in more than 30% of human cancers, most commonly via mutation in the K-ras oncogene and also via mutations in BRAF.  Several allosteric mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitors, aimed at treating tumors with RAS/RAF pathway alterations, are in clin. development.  However, acquired resistance to these inhibitors has been documented both in preclin. and clin. samples.  To identify strategies to overcome this resistance, we have derived three independent MEK inhibitor-resistant cell lines.  Resistance to allosteric MEK inhibitors in these cell lines was consistently linked to acquired mutations in the allosteric binding pocket of MEK.  In one cell line, concurrent amplification of mutant K-ras was obsd. in conjunction with MEK allosteric pocket mutations.  Clonal anal. showed that both resistance mechanisms occur in the same cell and contribute to enhanced resistance.  Importantly, in all cases the MEK-resistant cell lines retained their addiction to the mitogen-activated protein kinase (MAPK) pathway, as evidenced by their sensitivity to a selective inhibitor of the ERK1/2 kinases.  These data suggest that tumors with acquired MEK inhibitor resistance remain dependent on the MAPK pathway and are therefore sensitive to inhibitors that act downstream of the mutated MEK target.  Importantly, we show that dual inhibition of MEK and ERK by small mol. inhibitors was synergistic and acted to both inhibit the emergence of resistance, as well as to overcome acquired resistance to MEK inhibitors.  Therefore, our data provide a rationale for cotargeting multiple nodes within the MAPK signaling cascade in K-ras mutant tumors to maximize therapeutic benefit for patients.  Mol Cancer Ther; 11(5); 1143-54.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHIXHjLc1cbbVg90H21EOLACvtfcHk0lhqAtkwh_m2Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1yrtLY%253D&md5=79b9ff7fc04c7163f6ebe8f45429651b</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-1010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-1010%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DHaverty%26aufirst%3DP.%2BM.%26aulast%3DSoriano%26aufirst%3DR.%26aulast%3DForrest%26aufirst%3DW.%2BF.%26aulast%3DHeldens%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DToy%26aufirst%3DK.%26aulast%3DHa%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DAlmer%26aufirst%3DL.%2BC.%26aulast%3DHampton%26aufirst%3DG.%2BM.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DLackner%26aufirst%3DW.%2BR.%26atitle%3DERK%2520inhibition%2520overcomes%2520acquired%2520resistance%2520to%2520MEK%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1143%26epage%3D1154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Morris, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Restaino, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayananth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNunzio, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsor, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angagwa, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinheiro, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipps, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hruza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paliwal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babu, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daublain, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelletier, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siliphaivanh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fawell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samatar, A.</span><span> </span><span class="NLM_article-title">Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1158%2F2159-8290.CD-13-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=23614898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=742-750&author=E.+J.+Morrisauthor=S.+Jhaauthor=C.+R.+Restainoauthor=P.+Dayananthauthor=H.+Zhuauthor=A.+Cooperauthor=D.+Carrauthor=Y.+Dengauthor=W.+Jinauthor=S.+Blackauthor=B.+Longauthor=J.+Liuauthor=E.+DiNunzioauthor=W.+Windsorauthor=R.+Zhangauthor=S.+Zhaoauthor=M.+H.+Angagwaauthor=E.+M.+Pinheiroauthor=J.+Desaiauthor=L.+Xiaoauthor=G.+Shippsauthor=A.+Hruzaauthor=J.+Wangauthor=J.+Kellyauthor=S.+Paliwalauthor=X.+Gaoauthor=B.+S.+Babuauthor=L.+Zhuauthor=P.+Daublainauthor=L.+Zhangauthor=B.+A.+Lutterbachauthor=M.+R.+Pelletierauthor=U.+Philipparauthor=P.+Siliphaivanhauthor=D.+Witterauthor=P.+Kirschmeierauthor=W.+R.+Bishopauthor=D.+Hicklinauthor=D.+G.+Gillilandauthor=L.+Jayaramanauthor=L.+Zawelauthor=S.+Fawellauthor=A.+Samatar&title=Discovery+of+a+novel+ERK+inhibitor+with+activity+in+models+of+acquired+resistance+to+BRAF+and+MEK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors</span></div><div class="casAuthors">Morris, Erick J.; Jha, Sharda; Restaino, Clifford R.; Dayananth, Priya; Zhu, Hugh; Cooper, Alan; Carr, Donna; Deng, Yongi; Jin, Weihong; Black, Stuart; Long, Brian; Liu, Jenny; DiNunzio, Edward; Windsor, William; Zhang, Rumin; Zhao, Shuxia; Angagaw, Minilik H.; Pinheiro, Elaine M.; Desai, Jagdish; Xiao, Li; Shipps, Gerald; Hruza, Alan; Wang, James; Kelly, Joe; Paliwal, Sunil; Gao, Xiaolei; Babu, Boga Sobhana; Zhu, Liang; Daublain, Pierre; Zhang, Ling; Lutterbach, Bart A.; Pelletier, Marc R.; Philippar, Ulrike; Siliphaivanh, Phieng; Witter, David; Kirschmeier, Paul; Bishop, W. Robert; Hicklin, Daniel; Gilliland, D. Gary; Jayaraman, Lata; Zawel, Leigh; Fawell, Stephen; Samatar, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway.  Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clin. efficacy in patients with melanoma.  However, the majority of responses are transient, and resistance is often assocd. with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway.  Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors.  SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRA5, or KRAS and induces tumor regressions in xenograft models at tolerated doses.  Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.  These data support the clin. development of ERK inhibitors for tumors refractory to MAPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4HJ4HhYmLL7Vg90H21EOLACvtfcHk0liLt6mopJdqRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE&md5=1f26a4a5bb1fab64bdd6c38c16b3f4e3</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0070%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DE.%2BJ.%26aulast%3DJha%26aufirst%3DS.%26aulast%3DRestaino%26aufirst%3DC.%2BR.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDiNunzio%26aufirst%3DE.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DAngagwa%26aufirst%3DM.%2BH.%26aulast%3DPinheiro%26aufirst%3DE.%2BM.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DShipps%26aufirst%3DG.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DBabu%26aufirst%3DB.%2BS.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDaublain%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPelletier%26aufirst%3DM.%2BR.%26aulast%3DPhilippar%26aufirst%3DU.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DWitter%26aufirst%3DD.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DHicklin%26aufirst%3DD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DJayaraman%26aufirst%3DL.%26aulast%3DZawel%26aufirst%3DL.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DSamatar%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520ERK%2520inhibitor%2520with%2520activity%2520in%2520models%2520of%2520acquired%2520resistance%2520to%2520BRAF%2520and%2520MEK%2520inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D742%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudino, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Meese, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chicarelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siedem, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolakowski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacheco, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi-Latham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, J. B.</span><span> </span><span class="NLM_article-title">Discovery of 5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidine Inhibitors of Erk2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2635</span><span class="NLM_x">–</span> <span class="NLM_lpage">2639</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm501921k&amp;key=10.1016%2Fj.bmcl.2014.04.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm501921k&amp;key=24813737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvFSntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2635-2639&author=J.+F.+Blakeauthor=J.+J.+Gaudinoauthor=J.+De+Meeseauthor=P.+Mohrauthor=M.+Chicarelliauthor=H.+Tianauthor=R.+Garreyauthor=A.+Thomasauthor=C.+S.+Siedemauthor=M.+B.+Welchauthor=G.+Kolakowskiauthor=R.+Kausauthor=M.+Burkardauthor=M.+Martinsonauthor=H.+Chenauthor=B.+Deanauthor=D.+A.+Dudleyauthor=S.+E.+Gouldauthor=P.+Pachecoauthor=S.+Shahidi-Lathamauthor=W.+Wangauthor=K.+Westauthor=J.+Yinauthor=J.+Moffatauthor=J.+B.+Schwarz&title=Discovery+of+5%2C6%2C7%2C8-tetrahydropyrido%5B3%2C4-d%5Dpyrimidine+Inhibitors+of+Erk2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2</span></div><div class="casAuthors">Blake, James F.; Gaudino, John J.; De Meese, Jason; Mohr, Peter; Chicarelli, Mark; Tian, Hongqi; Garrey, Rustam; Thomas, Allen; Siedem, Christopher S.; Welch, Michael B.; Kolakowski, Gabrielle; Kaus, Robert; Burkard, Michael; Martinson, Matthew; Chen, Huifen; Dean, Brian; Dudley, Danette A.; Gould, Stephen E.; Pacheco, Patricia; Shahidi-Latham, Sheerin; Wang, Weiru; West, Kristina; Yin, Jianping; Moffat, John; Schwarz, Jacob B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2635-2639</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of tetrahydropyridopyrimidine based extracellular signal-regulated kinase (Erks) inhibitors discovered via HTS and structure based drug design is reported.  The compds. demonstrate potent and selective inhibition of Erk2 and knockdown of phospho-RSK levels in HepG2 cells and tumor xenografts.  Proliferation of HCT116 (K-RasG12D) and A375 (BRafV600E) cell lines was inhibited by compd. (I) with EC50s of 0.74 and 0.39 μM, resp.  Pharmacokinetic parameters of I are given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2sLYQY7scc7Vg90H21EOLACvtfcHk0liLt6mopJdqRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvFSntL4%253D&md5=3fb3eb1f8c127ed45f57664ed4f3cb11</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.068%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DGaudino%26aufirst%3DJ.%2BJ.%26aulast%3DDe%2BMeese%26aufirst%3DJ.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DChicarelli%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DGarrey%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DSiedem%26aufirst%3DC.%2BS.%26aulast%3DWelch%26aufirst%3DM.%2BB.%26aulast%3DKolakowski%26aufirst%3DG.%26aulast%3DKaus%26aufirst%3DR.%26aulast%3DBurkard%26aufirst%3DM.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDean%26aufirst%3DB.%26aulast%3DDudley%26aufirst%3DD.%2BA.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DPacheco%26aufirst%3DP.%26aulast%3DShahidi-Latham%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWest%26aufirst%3DK.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%25205%252C6%252C7%252C8-tetrahydropyrido%255B3%252C4-d%255Dpyrimidine%2520Inhibitors%2520of%2520Erk2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2635%26epage%3D2639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Blake, J. F.; Chicarelli, M. J.; Garrey, R. F.; Gaudino, J. G.; Grina, J.; Moreno, D. A.; Mohr, P. J.; Ren, L.; Schwarz, J.; Chen, H.; Robarge, K.; Zhou, A.</span><span> </span><span class="NLM_article-title">Serine/threonine kinase inhibitors</span>. WO 2013/130976.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Blake%2C+J.+F.%3B+Chicarelli%2C+M.+J.%3B+Garrey%2C+R.+F.%3B+Gaudino%2C+J.+G.%3B+Grina%2C+J.%3B+Moreno%2C+D.+A.%3B+Mohr%2C+P.+J.%3B+Ren%2C+L.%3B+Schwarz%2C+J.%3B+Chen%2C+H.%3B+Robarge%2C+K.%3B+Zhou%2C+A.+Serine%2Fthreonine+kinase+inhibitors.+WO+2013%2F130976."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26atitle%3DSerine%252Fthreonine%2520kinase%2520inhibitors" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Kolb, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanNieuwenhze, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpless, K. B.</span><span> </span><span class="NLM_article-title">Catalytic asymmetric dihydroxylation</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">2483</span><span class="NLM_x">–</span> <span class="NLM_lpage">2547</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr00032a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm501921k&amp;key=1%3ACAS%3A528%3ADyaK2cXntVSitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1994&pages=2483-2547&author=H.+C.+Kolbauthor=M.+S.+VanNieuwenhzeauthor=K.+B.+Sharpless&title=Catalytic+asymmetric+dihydroxylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Asymmetric Dihydroxylation</span></div><div class="casAuthors">Kolb, Hartmuth C.; VanNieuwenhze, Michael S.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2483-547</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">A review with 285 refs. on enantioselective prepn. of chiral 1,2-diols from olefins and synthetic applications of the 1,2-diols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX6vlkXRJjKLVg90H21EOLACvtfcHk0liqFQ2v6wg2CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXntVSitrg%253D&md5=71bace539bfee0542d17edcdb889cdd9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fcr00032a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00032a009%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DVanNieuwenhze%26aufirst%3DM.%2BS.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DCatalytic%2520asymmetric%2520dihydroxylation%26jtitle%3DChem.%2520Rev.%26date%3D1994%26volume%3D94%26spage%3D2483%26epage%3D2547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Cheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prusoff, W. H.</span><span> </span><span class="NLM_article-title">Relationship Between the Inhibition Constant (Ki) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (IC50) of an Enzymatic Reaction</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3099</span><span class="NLM_x">–</span> <span class="NLM_lpage">3108</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.+Chengauthor=W.+H.+Prusoff&title=Relationship+Between+the+Inhibition+Constant+%28Ki%29+and+the+Concentration+of+Inhibitor+Which+Causes+50+Per+Cent+Inhibition+%28IC50%29+of+an+Enzymatic+Reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520Between%2520the%2520Inhibition%2520Constant%2520%2528Ki%2529%2520and%2520the%2520Concentration%2520of%2520Inhibitor%2520Which%2520Causes%252050%2520Per%2520Cent%2520Inhibition%2520%2528IC50%2529%2520of%2520an%2520Enzymatic%2520Reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="note"><p class="first last">For example, the enzyme IC<sub>50</sub>s of ERK1 and ERK2 for (<i>S</i>)-<b>14k</b> are 15 and 5 nM, respectively.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span> <span class="citation_source-book">Thin-Layer Chromatography Reagents and Detection Methods, Vol. 1a: Physical and Chemical Detection Methods: Fundamentals, Reagents I</span>; <span class="NLM_contrib-group">Jork, H. H.; Funk, W.; Fischer, W.; Wimmer, H.</span>, Eds.; <span class="NLM_publisher-name">VHC</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">1990</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&author=H.+H.+Jork&author=W.+Funk&author=W.+Fischer&author=H.+Wimmer&title=Thin-Layer+Chromatography+Reagents+and+Detection+Methods%2C+Vol.+1a%3A+Physical+and+Chemical+Detection+Methods%3A+Fundamentals%2C+Reagents+I"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DThin-Layer%2520Chromatography%2520Reagents%2520and%2520Detection%2520Methods%252C%2520Vol.%25201a%253A%2520Physical%2520and%2520Chemical%2520Detection%2520Methods%253A%2520Fundamentals%252C%2520Reagents%2520I%26aulast%3DJork%26aufirst%3DH.%2BH.%26pub%3DVHC%26date%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O6E" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O6E','PDB','4O6E'); return false;">PDB: 4O6E</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XJ0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XJ0','PDB','4XJ0'); return false;">PDB: 4XJ0</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i75"><a href="/doi/suppl/10.1021/jm501921k">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_06485"></div></div></div></div></div><hr /></hr><p class="last">Experimental procedures for the synthesis of <b>6f</b>, <b>23a</b>–<b>23f</b>, and <b>24a</b>–<b>24e</b>, biological assay information, kinase selectivity of (<i>S</i>)-<b>14k</b>, Cerep panel of receptor selectivity of (<i>S</i>)-<b>14k</b>, protein expression and purification of ERK2 protein constructs for crystallography, crystal structure determination of ERK2 complex with (<i>S</i>)-<b>14k</b>.  This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm501921k/suppl_file/jm501921k_si_001.pdf">jm501921k_si_001.pdf (647.12 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm501921k&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-4%3Barticle%3Aarticle%3A10.1021%2Fjm501921k" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm501921k" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679953227e343d18","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
